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ABSTRACT
Coronary heart disease is one of the major causes of death and morbidity in the U.K population 
and many other industrialised countries. An atherogenic lipoprotein phenotype may represent the 
most common source of lipid-mediated coronary heart disease risk in the ‘free-living’ population, 
and the structural heterogeneity of triacylglycerol-rich lipoproteins (TGRL) may be of relevance 
to this. However, few methods have been able to accurately distinguish between very low 
density lipoproteins (VLDL) and chylomicrons (CM), and to differentiate between the 
methodologically defined ‘light’-VLDL and ‘dense’-VLDL (Bjorkegren etal., 1997).
The inability to quickly resolve structural heterogeneity in the TGRL by conventional salt density 
gradients, led to the development of a rapid method for the separation of TGRL from an original 
iodixanol self-forming gradient method Graham (unpublished) which produced TGRL-TAG 
profiles. After centrifugation the gradient was fractionated on the basis of the TAG profile into 
three pools; ‘light’-TGRL, ‘light’-VLDL and ‘dense’-VLDL. These pools could then be further 
characterised by the analysis for apo B-48. The iodixanol gradient was validated by comparison 
with TGRL separated by cumulative flotation i.e. light-VLDL (VLDLJ and dense-VLDL 
(VLDL2) which were isolated by cumulative flotation and then co-isolated on the iodixanol 
gradient. The iodixanol gradient was used to investigate the role of the TGRL subclasses in the 
generation of postprandial lipaemia produced by 1) an acute effect of ethanol; 2) carbohydrate 
loading 3) attenuation of postprandial lipaemia by unsaturated fatty acids; monounsaturated fatty 
acid (MUFA) and n-3 polyunsaturated fatty acids (PUFA).
The acute effects of ethanol (0.6 g/kg), after a 51 g fat meal produced a significant increase in 
postprandial plasma TAG compared to control in the late phases of lipaemia at 360 min (33%, 
/?<0.05), in TRL-apo B-48 (8 %, /?<0.05) and retinyl esters (RE) as a marker for CM (20 %, 
^<0.05),‘light’-TGRL (>33 %) and ‘light’-VLDL (>48 %, p<0.05). This effect was associated 
with a decreases in lipoprotein (LPL) and hepatic lipase-(HL) activity of 12 % and 25 % 
respectively. Acute CHO supplementation (30 % of total energy as sucrose for 4 days) produced 
a significant increase (36 % p<0.05) in fasting plasma TAG contributed to by a significantly 
increased ‘light’-TGRL(>97 %, /?<0.00i;, ‘light’-VLDL (58 % j?<0.05), ‘dense’-VLDL -TAG 
(26 %,/><0.05) and reduced HDL-C (12 %, jp<0.05). Conversely studies with dietary unsaturated
fatty acids produced the opposite effects. A MUFA enriched diet (18 % of energy intake) 
produced a significant reduction (21 %,/?<0.05) in postprandial lipaemia in response to a 82.7 g 
test meal; whereas long chain n-3 PUFA supplementation (3.01 g of EPA and DHA/d) produced 
a significant reduction (28 %, p<0.001) in fasting plasma TAG. Both responses were 
accompanied by a reduction in ‘dense’ and ‘light’ TGRL and the MUFA diet also caused an 
increase in the activity of LPL.
Overall, the study results shown that dietary constituents which either raise or lower TAG do so 
by exerting differential effects in plasma TGRL. Of the constituents that raise plasma TAG 
(ethanol/CHO), ethanol affects the larger TGRL ‘light’-TGRL and ‘light’-VLDL, whilst CHO 
appears to have an affect on all TGRL. Of the constituents which lower plasma TAG, MUFA 
affected the larger TGRL in the CM range, whilst n-3 PUFA appears to affect both the larger 
TGRL in the CM range and smaller TGRL ‘dense’- VLDL. Although differences in study 
design make it difficult to directly compare these dietary interventions, these findings provide 
further insight into the mechanisms by which diet influences lipid mediated cardiovascular risk.
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CHAPTER 1:
GENERAL INTRODUCTION
Coronary heart disease (CHD) continues to remain one of the major causes of death in the 
Western Hemisphere, accounting for over 135,000 deaths in the U.K. in 1998 (Petersen et a l, 
2000). There is strong evidence to suggest that adverse dietary habits are a major contributing 
factor in the development to CHD (Department of Health 1994), with unhealthy diets accounting 
for an estimated 30 % of deaths from CHD (European Heart Network, 1998). The first research 
to provide evidence for a relationship between nutrition and atherosclerosis was undertaken on 
the island of Java by Delangen (1916) described by Beisiegel (1998). Javanese fed traditional 
diets had minimal atherosclerosis until they switched from their low-fat/high-fresh fruit and 
vegetable diet, to a European diet rich in animal fat. For the majority of the non-smoking 
population today, the food that they consume is the largest controllable factor determining their 
long term health (Fields, 1998). The diet-heart disease hypothesis states that dietary fat, 
specifically high intakes of saturated fatty acids (SFA), raise plasma triacylglycerol (TAG), very 
low density lipoprotein (VLDL)-TAG, cholesterol and low density lipoprotein cholesterol (LDL- 
C), all of which have been associated with increased risk of CHD (Patsch et a l, 1992; Griffin, 
1999). While the cause of CHD is multi-factorial, one highly studied and dynamic mechanism in 
the disease process is the complex involvement of lipid and its carrier lipoproteins. Much of the 
epidemiological evidence has been determined from lipoprotein concentrations in the fasting 
state, yet the majority of individuals of the developed world, spend most of their time in the 
postprandial state. Evidence suggests that the extent and magnitude of postprandial lipaemia 
(PPL) is influenced by diet and governs the remodelling of lipoproteins to potentially atherogenic 
remnant particles (Sethi et a l, 1993). Zilversmit (1979) was one of the first to hypothesise that 
such remnant particles were implicated in the pathogenesis of CHD, and since then further 
research has demonstrated a significant association between the triacylglycerol-rich lipoproteins 
(TGRL) and the progression of CHD (Hodis et a l, 1997; Bjorkengren et a l, 1998).
1.1 P ostprandial LIPAEMIA
PPL is a state in which the metabolic capacity to clear TGRL from the circulation is under 
challenge, and lipid metabolism is at maximum capacity (Demacker, 1995). The majority of the 
Western world spends 80 % of its time in this state (Patsch et a l, 1987). After eating a meal
there is a rise in plasma TAG due to increased synthesis and secretion of the TGRL, with PPL 
occurring in two stages. Stage one involves the release of TAG from the intestine in the form of 
chylomicron (CM), their subsequent metabolism by LPL to form chylomicron remnants (CM-R), 
which are taken-up by the liver. This stage lasts approximately 6-8 hours after the meal (Patsch 
et a l , 1987). Stage two of PPL involves the release of TAG from the liver in the form of VLDL. 
This stage lasts approximately 8 - 2 4  hours after the meal (Cohn et a l, 1989). It was not until 
1979 that postprandial TAG metabolism was recognised to be a significant factor in the 
progression of CHD (Zilversmit, 1979). The original ‘Zilversmit hypothesis’ suggested that 
cholesterol-rich CM-R may be as atherogenic as LDL. This hypothesis has since been extended 
to include enhanced PPL, which is believed to be a better indicator of coronary heart disease 
(CHD) than fasting TAG levels (Patsch et a l, 1992). As a result of marked variation in PPL 
between normotriacylglycerolaemic (NTG) and hypertriacylglycerolaemic (HTG) individuals, 
and plasma TAG in the late phases of PPL, these measures have proved more discriminatory of 
CHD risk than the concentration of other fasting lipoproteins.
1.2 ATHEROGEMC LIPOPROTEIN PHENOTYPE
In recent years the description of the atherogenic lipoprotein phenotype (ALP) has assisted our 
understanding of lipoprotein metabolism and CHD (Austin et a l, 1990). Central to the high risk 
of developing the ALP, is a moderately raised plasma TAG level above 1.5 mmol/1, marginally 
raised total cholesterol, and a HDL-C level below 1.0 mmol/1 (Packard, 1996), as illustrated in 
Figure 1. Whereas those with a low risk of developing the ALP have a TAG of less than 1.5 
mmol/1, normal total cholesterol levels and a HDL-C level above 1.0 mmol/1. Those predisposed 
to a high risk of developing the ALP are also associated with a preponderance of small dense 
LDL (Griffin, 1999), an increase in small HDL (HDLg) and in large VLDL (VLDLJ. HDL and 
LDL have been well studied but less data is available on VLDL subclasses and their involvement 
in the formation of the ALP. In order to further understanding, of the metabolic basis of an ALP, 
it is necessary to acquire further information on the relationship between TGRL and LDL and 
HDL.
Atherogenic Lipoprotein Phenotype (ALP)
plasma TAG > 1.5 mmol/l 
HDL< 1 mmol/l
High Risk
1. Small, d en se  LDL
2. Small non- 
protectfve HDL
3. A djerogenic VLDL 
and chylom icron  
remnants
plasma TAG <1.5 mmol/l 
HDL> 1 mmol/l
Low Risk
1. Large light LDL
2. Large 
protective HDL
3. Normal VLDL 
and chylom icron  
remnants
Figure 1: The atherogenic lipoprotein phenotype (ALP) (Austin et al., 1990).
1.3 Lipoprotein metabolism
Lipoproteins enable the transport and metabolism of insoluble, lipid molecules throughout the 
body. Lipoprotein particles consist of a hydrophobic lipid core, containing TAG and cholesterol 
esters (CE) surrounded by a polar outer layer consisting of phospholipids, apolipoproteins (apo), 
and cholesterol
Several different types of lipoproteins can be isolated and have been classified by various 
systems, according to differences in their origin, function, composition and physical properties. 
The discovery of a milky appearance in the blood of diabetics was first reported in 1771 by 
Hewson cited in Alaupovic (1972). This was soon followed by the finding that ‘fat’ was present 
in fasting serum (Christison, 1830) quoted in Beisiegel (1998). While the theory that plasma 
lipids were chemically bound to proteins was first postulated by Nerking (1901) quoted in 
Alaupovic (1972). The first isolation of such a lipoprotein was not achieved until 1929, in horse 
plasma by (Machebouef 1929) quoted in Beisiegel (1998), who established by precipitation, the 
existence of a separate group of macro-molecular complexes for the transport of lipids 
(McFarlane et al., 1935) quoted in Beisiegel (1998). The development of electrophoretic 
techniques, showed that plasma lipids were combined with specific proteins to form two major 
groups of lipoproteins. Blix (1941) quoted in Alaupovic (1972) was one of the first to isolate a -  
and P-globulin fractions enabling the separation of two major groups of lipoproteins. The
identification of two more bands (CM and VLDL) did not take place until the development of 
zonal electrophoresis, when it was noticed that one band remained at the origin (CM) and the 
other migrated to the pre-P position (VLDL). The association of proteins with lipids also 
provides a low hydrated density, a physical property that can be used for their isolation and 
characterisation. Gofman (1949), quoted in Beisiegel (1998), undertook major isolation work, 
using fractional ultracentrifugation, and salt solutions of increasing density. From these results 
lipoproteins were classified into five classes, which corresponded to the bands obtained by 
electrophoresis (Nobel 1968, Rapp e ta l, 1968) in Greenspan et a l (1995), at the origin, pre-P-, 
p-, and a-positions respectively: CM, VLDL, intermediate density lipoproteins (ÏDL), low 
density lipoproteins (LDL) and high density lipoproteins (HDL), which can be further 
distinguished on the basis of differences in hydrated density, lipid and apolipoprotein 
composition (Figure 2). More recently the development of techniques, such as cumulative 
flotation, have given rise to a further nomenclature which describes the lipoprotein classes with 
respect to their flotation coefficients. The flotation coefficient is defined by a Svedberg flotation 
units (Sf). Each lipoprotein class covers a range o f ‘S/ values, vnth the largest TGRL having the 
highest Sf rate as follows; Sf>400 (CM), Sf 60-400 (VLDLJ, Sf 20-60 (VLDL^), Sf 12-20 (DDL) 
and Sf 0-12 (LDL). As with sequential flotation density ranges, Sf ranges are an operational 
definition used for separating the endogenous and exogenous lipoproteins. However, there is 
much evidence that endogenous VLDLj and exogenous CM and CM-R may have overlapping or 
‘paucidisperse’ distributions in terms of their‘S/ rates and density (Lindgren e ta l, 1971).
Lipoproteins vary greatly in composition and function, with the liver and intestine providing the 
primary sites of lipoprotein synthesis. The TGRL transport TAG from the intestine (CM) and 
liver (VLDL) to sites of storage or utilisation. Cholesterol rich lipoproteins, primarily LDL, 
transport cholesterol for incorporation into membrane tissues, whilst HDL, transports cholesterol 
from the peripheral tissues to the liver for catabolism in a process known as reverse cholesterol 
transport. Lipid transport can be divided into exogenous (CM and CM-R) and endogenous 
(VLDL, IDL, LDL and HDL) pathways. Although the metabolism of individual lipoproteins can 
be described separately their metabolic pathways are inter-linked as illustrated in Figure 3.
Figure 2: The physiochemical properties of lipoproteins (source: Durrington, 1989)
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Digestion and absorption of dietary fats
The average western adult consumes approximately 50-100 g/day of dietary fat. This fat is 
predominantly TAG with phospholipid (PL) contributing 4-8 g and cholesterol 0.5 g/d. 
Hydrolysis of TAG begins in the mouth with the action of lingual lipase, primarily acting on 
medium and short-chain TAG, with longer-chain fatty acids (FA) being released in the lumen 
and mucosa of the upper small intestine. Once in the duodenum and jejunum; bile salts from the 
pancreas facilitate the formation of micelles which solubilise dietary fat. Phospholipase and 
pancreatic lipase then break down phospholipids and di- and triacylglycerols to 2- 
monoacylglycerols and FA, which are then absorbed into the enterocyte. Pancreatic cholesterol 
esterase in the intestinal lumen hydrolyses cholesterol esters to yield cholesterol and fatty acids.
1.3,1 CM metabolism
CM synthesis and secretion
The main function of CM is to transport TAG of exogenous origin around the body. CM are 
formed in the enterocyte of the small intestine during the digestion and absorption of a fat- 
containing meal. Postprandial FA and 2-monoacylglycerol are produced in the lumen of the 
intestine by the action of pancreatic lipase on dietary lipids. Medium and short-chain fatty acids 
(<12 C atoms) are absorbed into the enterocyte and pass into the hepatic portal vein without 
being esterified, they bind to albumin and are transported to the liver and other tissues, via the 
hepatic portal system as non-esterified fatty acids (NEFA). Long chain fatty acids (>12 C atoms) 
are absorbed into the enterocyte and used in the re-esterifîcation of 2-monoacylglycerol to form 
TAG, CE and PL. The absorption of FA is facilitated by the maintenance of an inward diffusion 
gradient. A fatty acid binding protein (FABP) in the brush border membrane enables the F As to 
enter the cell where they are re-esterified in the smooth endoplasmic reticulum (SER) by 
enzymes of the monoacylglycerol or glycerol-3-phosphate pathway to form TAG. FABP is 
believed to preferentially bind to long chain unsaturated fatty acids rather than to SFA. 
Cholesterol is absorbed more slowly than TAG and is re-esterified by the enzyme acyl 
CoA;cholesterol acyltransferase (ACAT). Both CE and free cholesterol are present on the CM. 
Apo B-48, A-I, A-II and A-IV are synthesised in ribosomes associated with the rough 
endoplasmic reticulum (RER) of the enterocyte. Apo B-48 is involved in establishing the 
structure of the CM, and is essential for the assembly and secretion of this lipoprotein (Brewer et
al, 1988). Apo B-48 is joined to the TAG and PL at the junction of the SER and RER to form 
nascent CM which are transported to the Golgi apparatus (Gotto et a l, 1986), where the apo B- 
48 is glycosylated (Durrington, 1995). Golgi vesicles containing CM migrate to the lateral 
membrane of the enterocyte, the CM particles are released into the intercellular space via 
exocytosis, and secreted into the lymph. CM enter the bloodstream via the thoracic duct causing 
postprandial lipaemia. While in the circulation apo C-I, C-II and C-III and apo E are transferred 
to the CM from HDL in exchange for some of the apo A components of the CM (Patsch et a l, 
1987). Only one apo B-48 molecule is present on each CM (Phillips et a l, 1993) and it is unique 
to CM and CM-R in humans.
Chylomicron catabolism
CM usually first appear in the plasma within 15-30 min of ingesting a fatty meal, and continue to 
be formed and removed for approximately 5-8 hours after the meal. Once CM enter the plasma 
they are catabolised; through the activity of LPL and by receptor mediated removal of CM-R via 
specific receptors in the liver. LPL is found in high levels in the endothelial lining of capillaries 
of peripheral tissues with a high requirement for TAG, such as adipose tissue, muscle and the 
mammary gland. The enzyme is produced in parenchymal cells and secreted onto the 
endothelium where it is bound by heparin sulphate proteoglycans (Eckel, 1989). LPL hydrolyses 
ester bonds in positions 1 and 3 of CM core TAG to produce FA and monoacylglycerol. The FA 
are taken-up by cells and monoacylglycerol are further hydrolysed to produce FA and glycerol 
which are then taken-up by the tissues. Apo C-II on the CM surface is known to be a co-factor 
for LPL, increasing the LPL-CM interaction by binding and activating the enzyme (Nestel, 
1987). LPL is the rate limiting step in TAG hydrolysis and therefore determines the extent and 
duration of postprandial lipaemia (Eckel, 1989). Insulin has an important effect on LPL activity, 
inhibiting LPL activity in skeletal muscle, whilst stimulating activity in adipose tissue (Sethi et 
a l, 1993). Insulin activity is also modified postprandially. After a meal insulin levels rise, 
activating adipose tissue LPL, whilst suppressing muscle LPL activity. Conversely, in the fasted 
state muscle LPL is activated whilst adipose tissue LPL activity is suppressed.
CM-R uptake/removal
During the catabolism of CM, surface components are released by the activity of LPL; apo A, 
apo c  n , apo C-III and PL are transferred to HDL, whilst the FA produced are rapidly
transported across the endothelium to parenchymal cells where they are oxidised in the muscle or 
re-esterified for storage in adipose tissue. CM-R are formed when a large proportion of TAG is 
removed, such remodelling to CM-R of CM is also believed to enhance hepatic uptake. CM-R 
are taken into the liver by apo E interacting with at least two receptors on the hepatocyte surface; 
CM-R and LDL receptors, which bind CM-R, IDL and HDL. The presence of apo C-III also 
prevents the premature uptake of CM before sufficient TAG has been hydrolysed. Apo C-III is 
removed from the CM, prior to it being converted to CM-R (Sethi et a l, 1993). Apo E has been 
suggested to be responsible for the rapid clearance of CM-R by the liver. The apo E gene is 
polymorphic, giving rise to three isoforms of apo E denoted E2, E3, E4. Carriers of the latter 
show the most rapid clearance of TGRL followed by E3 and E2 (Weintraub et a l, 1987). There 
is also strong evidence to suggest that LPL and hepatic lipase (HL) act as ligands mediating the 
binding and uptake of lipoproteins into cells (Zambon et a l, 1995). It is possible that LPL may 
remain associated with the CM-R once most of the TAG has been hydrolysed and the remnant is 
released into the circulation.
1.3.2 VLDL metabolism 
VLDL synthesis and secretion
VLDL show structural and metabolic heterogeneity; varying in TAG and apolipoprotein 
composition (Packard and Shepherd, 1997). Endogenous fat transport is accomplished via the 
synthesis, secretion and catabolism of VLDL. The liver produces and secretes TGRL-VLDL 
particles, which are operationally defined by cumulative flotation as; a larger, less dense TAG- 
rich VLDLi, and a smaller denser, CE rich VLDLg (Millar and Packard, 1998). The two 
particles can also be differentiated by density, using Svedberg units (Sf), which measure the rate 
at which lipoprotein particles float in an ultracentrifuge; VLDLf ranging from (Sf) 60-400; 
VLDL2 ranges from (S  ^20-60 (Fisher et a l, 1993). The size of the VLDL particle is important 
as kinetic studies indicate that the size of the particle determines its metabolic fate (Packard, 
Munro et al., 1984). There is evidence to show that VLDLj contain more apo C-II and C-III than 
VLDLg and are the precursor of IDL (Fisher et a l,  1993), and VLDLg the precursor of IDL then 
LDL (Stalenhoef et a l, 1984). The HTG state has been characterised, by a predominance of 
large TAG-rich VLDL^ (Griffin, 1997) and a higher concentration of small dense LDL (Karpe et 
al, 1993).
VLDL possesses apo B-lOO which is secreted by the endoplasmic reticulum, in hepatocytes. 
Newly synthesised VLDL acquire apo E, apo C-II, apo C-III from HDL particles (Tall, 1990) 
which are incorporated into VLDL and prove essential for their further metabolism. Apo C-II is 
a co-factor for LPL, whereas apo C-III is inhibitory to LPL action (Durrington, 1992). Apo E 
may also be necessary for the conversion of VLDL to LDL. The liver is a major producer of 
VLDL although a small amount has been suggested to be synthesised and secreted by the gut 
(Havel, 1997). VLDL transports TAG of endogenous origin to ensure a supply of TAG to 
peripheral tissues for storage (adipose tissue) or oxidation (muscle) in the fasting and 
postprandial states. The formation of VLDL in hepatocytes resembles that of CM in intestinal 
cells, with the main difference being that cholesterol for transport in VLDL is not usually 
esterified before its secretion (Durrington, 1995). VLDL therefore contain free cholesterol which 
is transferred to HDL for estérification in the circulation. VLDL also contain most of their 
complement of apo C when they are released into the circulation and also contain varying 
amounts of apo E (Lewis et a l, 1990). While VLDL provides a pathway for the transport of 
TAG from the liver to the peripheral tissues, in post-absorptive plasma it is quantitatively the 
more important carrier of TAG, and through the ‘common lipolytic pathway’ has its TAG 
degraded less efficiently than CM (Karpe and Hultin, 1995; Bjorkengren et a l, 1996). This leads 
to a prolonged residence time for VLDL after a meal (Havel, 1997), allowing increased exchange 
of TAG between LDL and HDL (Griffin and Packard, 1994). Such a preferential clearance of 
TAG from apo B-48 containing particles over VLDL (due to size rather than possession of apo 
B-48 (Van Beek et a l, 1998) may provide a buffering mechanism to prevent excessively 
prolonged TAG levels, known as HTG (Gibbons, 1990).
The hydrolysis of VLDL-TAG by LPL is controlled by insulin which plays a key role in 
promoting the synthesis and temporary storage of hepatic TAG during periods of food intake 
(Gibbons, 1990). FA for VLDL synthesis comes from four possible sources; (1) de novo 
lipogenesis (stimulated by CHO feeding, excess energy intake), (2) recycled TAG (derived from 
lipoproteins taken-up directly by the liver), (3) plasma NEFA (derived from adipose tissue TAG 
stores or from LPL lipolysis of circulating lipoproteins) and (4) hepatic cytoplasmic TAG stores 
(Lewis, 1997). During the postprandial period, some long chain FA in TAG from the most 
recent meal are liberated from the CM by LPL, and do not enter adipocytes, in which case they 
are delivered to the liver bound to albumin. Dietary short chain FA are delivered directly to the
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hepatic portal vein bound to albumin. In the fasting state FA are mobilised from the adipose 
tissue and transported to the liver as NEFA for re-esterification (Gotto et a l, 1986).
The VLDL particle exhibits a high degree of heterogeneity in relation to its size and composition 
(Gotto et a l, 1986), vyhich may alter the resultant metabolic fate of a VLDL particle (Nestel, 
1987). Hormonal influences on VLDL, in vitro (Lewis, 1997) and in vivo (Steiner, 1991; Lewis 
et a l, 1993), have provided evidence to show that acute hyperinsulineamia suppresses VLDL- 
TAG and apo B production in humans. However, on removal of insulin, VLDL secretion 
increases, suggesting that insulin suppresses the secretion of VLDL, possibly by reducing the 
supply of NEFA. Failure of insulin to perform its normal function of suppressing HL and 
consequent release of NEFA into the circulation during the late postprandial phase would lead to 
increased synthesis and secretion of VLDL. This is most apparent in insulin resistant states such 
as the ALP, obesity and non-insulin dependent diabetes mellitus (NEDDM).
VLDL catabolism
Once secreted, VLDL particles undergo the same changes as CM as their core TAG is hydrolysed 
by LPL to produce remnant particles which are removed by a receptor-mediated process. VLDL 
removal is suggested to be delayed due to preferential degradation of CM, first demonstrated by 
Potts et a l (1991 and Berry et a l (1992). It has also been suggested that, as with CM, the 
presence of apo C-III prevents the premature uptake of larger particles. In vitt'o studies have 
shown that larger particles such as CM and VLDLj are the preferred substrates of LPL, whereas 
HL prefers smaller particles VLDL^ and IDL (Janus et a l, 1980). While, early studies suggested 
that all VLDL moved through the delipidation cascade to IDL before becoming LDL through the 
progressive loss of TAG via the action of LPL (Packard, 1994), more recent evidence suggests 
that a broad spectrum of particles are produced which do not necessarily all become LDL. 
VLDL composition actually determines what proportion is converted to LDL (Janus et a l, 1980). 
The metabolism of VLDL is more complex than CM due to VLDL heterogeneity (Shepherd,
1987), which is apparent not just in hyperlipidaemic states but also in normal individuals. If LPL 
functions normally then the residence time of VLDL^ is short, minimising CE exchange with 
HDL (Demant et a l, 1988). However if LPL activity is reduced, the residence time of VLDLj, 
is increased along with CE exchange. Karpe et a l (1993) confirmed that HTG individuals have 
lower postheparin LPL activity, elevated levels of VLDL^ (Bjorkengren et a l, 2000; Packard et 
al, 2000), and a reduced clearance of VLDL due to increased competition through the common
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lipolytic pathway (Bjorkegren et a l, 1996). Evidence from metabolic studies has shown that in 
HTG individuals VLDLi catabolism into remnants in the VLDL^ range is unimpaired, unlike the 
conversion of VLDL2 to IDL and LDL (Demant et a l, 1988). After 90 % of the VLDL-TAG 
has been hydrolysed, and apo A, C and PL and some cholesterol have been transferred to HDL, 
only apo B-lOO, apo E and C remain. This remnant particle is known as IDL, which can either 
be metabolised further to produce LDL or can be taken-up directly by the liver. Packard et a l 
(1984) suggested that the original size may determine their metabolic fate, in that the larger 
VLDL, give rise to IDL and the smaller VLDL^ produce LDL (Stalenhoef et a l, 1984). There 
also appears to be a relationship between VLDL subclass and plasma TAG level, in that as post- 
absorptive plasma TAG increases between 1-3 mmol/l, ‘metabolic channelling’ occurs, with 
VLDL, predominating in HTG individuals whereas in normolipidaemic individuals VLDLo 
predominates (Redgrave and Carlson, 1979; Eisenberg, 1987; Karpe e ta l,  1995) as illustrated in 
Figure 4.
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Figure 4: Effect of fasting plasma TAG concentration on VLDL heterogeneity (source; Tan et ai ,  1995)
In the HTG state, the greater proportion of VLDL, reduces the formation of LDL (Havel et al. 
1994), since VLDL, possesses more core TAG, and are hydrolysed at a much slower rate than 
VLDLo (Karpe et al, 1993). In normolipidaemic plasma, approximately 80-100 % of VLDL 
becomes LDL, whilst in the HTG individual, approximately only 20-40 % of VLDL was 
converted to LDL (Eisenberg, 1987). Quantitatively also, VLDL, accepts more CE than VLDL^ 
(Lassel et a l, 1998), despite VLDL^ having a greater relative capacity to accept CE. CM and 
CM-R impede degradation of VLDL by competing with VLDL for LPL and TAG breakdown, 
thereby causing a build up of VLDL, (Bjorkengren et a l, 1996). The abnormal distribution of 
VLDL particles can be normalised by lowering serum TAG. There is evidence to show that
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TAG-lowering drugs such as fibrates (Eisenberg et al, 1984) or long chain n-3 polyunsaturated 
fatty acids (PUFA) modify the distribution of VLDL subclasses, primarily by reducing the 
production of TAG-rich VLDL, in the liver (Goldstein and Brown, 1977).
1.3.3 LDL metabolism
The final catabolism of DDL to form LDL occurs with the progressive transfer of cholesterol, PL, 
apo E and C to HDL (Lewis et a l, 1990). This leaves a particle with a cholesterol ester-enriched 
core and an apolipoprotein content which is predominately apo B-100. The LDL is then taken- 
up by LDL receptors in both the liver and extra-hepatic tissues by interaction of the apo B-100 
with the receptor (Gotto et a l, 1986). After internalisation, CE is hydrolysed and the protein 
degraded in lysosomes. Thus, LDL particles transfer cholesterol to the extra-hepatic tissues for 
use in membrane biosynthesis and repair. The release of free cholesterol inhibits the enzyme 
HMG-CoA reductase, reducing the synthesis of any new cholesterol and down regulating the 
LDL receptor at the DNA level, restricting the influx of LDL with more cholesterol, as illustrated 
in Figure 5.
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LDL heterogeneity
LDL can be separated by density gradient ultracentrifugation (DGUC) into three subclasses of 
varying size and density LDL-I, LDL-II and LDL-III (Griffin, 1995). When larger LDL-I and 
LDL-II predominate pattern ‘A’ is displayed, whereas a higher concentration of the smaller 
denser LDL-III, constitutes pattern ‘B’. It has been recognised for some time that TAG 
metabolism can influence the structure and metabolic function of LDL (Packard et a l, 1984). 
Austin et a l (1990) have shown that individuals with a plasma TAG above 1.1 mmol/l were 
more likely to express the pattern B phenotype for LDL, whereas at lower plasma TAG 
concentrations the pattern A LDL phenotype was expressed. This was supported by Griffin and 
Packard (1994) who found that small dense LDL demonstrated a positive correlation with plasma 
TAG, at levels above 1.5 mmol/l, as illustrated in Figure 6 .
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Figure 6: Relationship of triacylglycerol with HDL (source; GrifGn et ai,  1990)
Further evidence suggested a relationship between the TGRL and LDL (Karpe et a l, 1993). 
Karpe et a l (1993) who investigated the postprandial TGRL in men with premature coronary 
atherosclerosis and found that HTG patients had enhanced PPL, lower post-heparin LPL activity 
(PH-LPL) and higher levels of small dense LDL. They suggested that approximately 50 % of the 
variability in the distribution of LDL particles between the class A and B subclasses was due to 
the combined effect of LPL activity and magnitude of the postprandial TGRL response. They 
also proposed that in normal individuals with a high LPL activity, there was a rapid conversion 
of VLDL through to LDL via neutral lipid exchange, and that the lower levels of VLDL-TAG 
reduce the possibility for LDL modulation. Further evidence by Griffin and Packard (1994),
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who investigated the relationship between plasma TAG and LDL in patients with and without 
coronary artery disease (CAD), postulated that at TAG levels >1.5 mmol/l, more VLDL^ is 
produced giving rise to more slowly removed LDL. VLDLj also stayed in the circulation longer 
and therefore promotes the hetero-exchange of TAG for CE in LDL which suggests that VLDL^ 
may be an appropriate marker of PPL (Griffin, 1997).
1.3.4 HDL metabolism
HDL concentrations have consistently been negatively associated with CHD mortality and 
morbidity (Gordon and Rifkind, 1989). HDL removes unesterifed cholesterol from the 
peripheral tissues and transports it in its esterified form to the liver where it is either degraded or 
used for the synthesis of bile acids. HDL are synthesised directly by the liver and intestine 
(Brewer e ta l,  1988). Nascent HDL are secreted as a discoidal bilayer of PL, apolipoprotein and 
unesterifed cholesterol with no core lipid. Upon entering the circulation the nascent HDL take- 
up free cholesterol from peripheral cells and circulating TGRL, other apo A-IV, C-II, C-III & E, 
PL and TAG. Free cholesterol is esterified by lecithin-cholesterol acyltransferase (LCAT), a rate 
limiting enzyme located on HDL which requires apo A-I as a co-factor. The initial formation of 
CE by nascent HDL generates small HDLj, but as CE accumulates, CE appear to be transferred 
into less dense HDL^g. On acquiring TAG in exchange for CE from cholesteryl ester transfer 
protein (CETP) HDL^ becomes converted to smaller denser HDLg. Most tissues, including the 
liver, appear to possess different binding sites other than CM or LDL receptors, which bind 
HDL. After binding to these receptors, either the entire HDL particle can be internalised and 
degraded or the CE can be transferred to the cell leaving the particle intact (Silver et a l, 2001).
Reverse cholesterol transport
HDL plays a central role in regulating the flux of lipid and protein constituents between the 
different lipoproteins. The rate of transport of LDL-C to peripheral cells generally exceeds the 
tissue cholesterol requirements. Most cells are unable to oxidise cholesterol and so cholesterol 
must be returned to the liver for elimination in the bile. The return of cholesterol from tissues to 
the liver is known as reverse cholesterol transport (Eisenberg, 1984), involves the uptake of CE 
into both TGRL and HDL for its use or catabolism Figure 7. The reciprocal enrichment of HDL 
particles with TAG, and TGRL with CE is undertaken by CETP. Some cholesterol is taken-up 
directly by the liver from HDL^ but most is transferred onto CM and VLDL. In humans at least 
80 % of the CE formed initially in HDL is transported to other lipoproteins, and estimates
15
suggest that at least 1500 mg of CE is metabolised daily via this route (Durrington, 1995). It is 
clear that perturbations which lead to increased transfer of CE onto CM and VLDL or result in 
impaired removal of these lipoproteins will result in accumulation of cholesterol enriched 
remnants.
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LCAT = Lecithin:cholesterylacyltransferase 
CETP = Cholesteryl ester transfer protein 
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CETP
Figure 7: Reverse cholesterol transport (HDL pathway)
Neutral lipid exchange (involvement of HDL in TGRL metabolism)
Neutral lipid exchange. Figure 8, and the remodelling of HDL/LDL involves LPL, HL and 
CETP. The concentration of the TGRL and LPL activity determines the CE direction of transfer 
between the lipoproteins (Griffin, 1997). CETP functions to redistribute CE, derived from 
LCAT activity, from its site of synthesis in HDL, to less dense TGRL (Hayek et a l, 1993). 
Increased CETP activity is seen with a high SFA diet and may also occur due to increased 
concentrations of VLDL and CM. Under normal physiological conditions, as long as the 
synthesis and removal of TGRL is unaltered, CETP levels are not raised and rapid TAG 
enrichment of HDL/LDL is suppressed (Tall, 1986). Tall (1993) demonstrated that CETP 
activity is enhanced in the presence of NEFA released upon hydrolysis of TGRL, thus 
underlining the relevance and importance of CETP in the postprandial state. It has also been 
demonstrated that CE transfer to VLDL is three times faster in HTG than normal individuals 
(Mann et a l, 1991; Tall et a l, 1987), whilst CETP activity was similar in both groups.
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1.4 TGRL
TGRL are a heterogeneous population of lipoproteins particles, distinguished by differences in 
their origin, apolipoprotein, size, density and lipid composition. They consist of VLDL, secreted 
by the liver, containing apolipoprotein B-100, and CM secreted by the intestine containing apo 
B-48, both originate from the same gene, but apo B-48 is approximately half the size of apo B- 
100 (Kane et a l, 1980). Apo B functions as an essential part of the assembly and secretion of 
VLDL and CM, maintaining the structure of lipoprotein particles, and can act as a ligand for the 
uptake of LDL by the receptor (Young, 1990). The unique possession of either apo B-48 or apo 
B-100 has also proven essential to techniques for the investigation of VLDL or CM.
1.4.1 Relationship of TGRL and atherosclerosis
In 1956 Buzina and Keys observed that elevated TAG concentrations accelerated blood clotting. 
Shortly after, Albrink and Man (1959) reported that the incidence of clinical atherosclerosis was 
more strongly linked to fasting serum TAG than cholesterol. However, this was discounted in 
1963 by Keys and Blackburn who questioned the ‘TAG theory’ due to problems with study 
design and analytical errors, a view that has been upheld until recent years. Evidence has 
accumulated in the intervening period for the involvement of TGRL in the atherogenic process 
(Zilversmit, 1979). Zilversmit et al, (1979) proposed that LPL may act on TGRL on the 
endothelium of artery walls. TGRL remnants would therefore be produced in close proximity to 
possible sites of injury and if enriched in CE, would have the potential to cause cholesterol 
deposition in the artery wall. Zilversmit (1979) also provided initial evidence to demonstrate that 
TGRL can be taken-up into the artery wall of cholesterol-fed rabbits. Apo B and C, found in
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VLDL have also been recovered in human arterial lesions (Zilversmit, 1979). Direct in vitro 
evidence that CM-R can gain access to human arterial smooth muscle cells during endothelial 
injury was provided by Floren et a l (1981). Chung et a l (1998) demonstrated that TGRL-R can 
cause both foam cell formation and death of endothelial cells. Evidence for the direct uptake of 
TGRL into atherosclerotic plaques was provided by Rapp et a t (1994) who isolated intact TGRL 
from human atherosclerotic plaques, and demonstrated the presence of apo B-48 free fractions. 
Many recent studies have also confirmed that remnants of TGRL may be directly incorporated 
into the plaque (Karpe and Hamsten, 1994; Uiterwaal et a l, 1994; Weintraub et a l, 1996). 
Current opinions, favour a role of impaired TAG transport and TGRL remnants rather than a 
direct effect of CM and cholesterol. As originally proposed by Miesenbock and Patsch (1992), 
the postprandial state provided a challenge to TAG transport in that a low capacity to catabolise 
TGRL might lead to an increased susceptibility to CAD. Bjorkegren et a l (1997) demonstrated 
recently that postprandial VLDL in normolipidaemic healthy males was very similar to the 
TGRL changes found in patients with CAD. Subjects who had a high TAG had a high fasting 
HDLj level which invoked an increase in HL activity to form an HDLg particle (Patsch et a l, 
1984). Such subjects also had a lower level of LPL activity and a higher level of PPL. 
Furthermore, Groot et a l (1991) showed, that the clearance of postprandial lipoproteins was 
delayed in normolipidaemic men with CHD as compared to a control group of healthy men. In 
view of the strong relationships between HDL-C, HDLg-C, CM , VLDL and CAD, it became 
evident that either a decrease in production or efficient clearance of TGRL decreased the amount 
of transfer by CETP of TAG to HDL in exchange for CE to TGRL, thereby decreasing CAD 
risk. The TAG level in the late postprandial phase, 6-8 hr after a fat-containing meal, has been 
identified as a major risk factor for CHD (Patsch et a l, 1992; Nikkilâ et a l, 1994). Karpe and 
Hamsten (1994) also found that the presence of apo B-48 in the particles in Sf 20-60 range was 
significantly correlated with levels of small dense LDL, and went on further to conclude that 
repeated episodes of perturbed postprandial lipaemia are linked to disturbances in lipoprotein 
metabolism, that increase the risk of CAD. The relevance of these findings is that the 
predominance of small dense LDL is associated with a four-fold increase in risk of CAD and a 
six- fold increase in risk of myocardial infarction (Griffin and Packard, 1994). De Graaf et a l 
(1991) have shown that small dense LDL are more susceptible to oxidation, a critical step in the 
initiation and progression of atherosclerotic lesion development.
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1.4.2 Methods for analysing TGRL (RE- vitamin A. apo B-48. ultracentrifugation!
TGRL in the form of CM can be analysed by measurement of RE, a marker of CM which 
remains in the CM-R until its uptake by the liver, or by direct measurement of apo B-48 and 
isolation of VLDL using ultracentrifugation, including the self-forming iodixanol gradient.
1.4.2.1 RE
Vitamin A is a fat soluble vitamin which is involved in a number of biological processes 
including differentiation of epithelial cells and visual processes. In 1935, Drummond, Bell and 
Palmer, quoted in Hazzard and Bierman (1976), reported that the structure of vitamin A 
resembled that of cholesterol and was incorporated into the core of the CM along with 
cholesterol esters. However, unlike cholesterol, RE were not re-secreted by the liver (Goodman 
e ta l, 1966). In 1976 Hazzard and Bierman introduced a method of indirect labelling of CM and 
their remnants using vitamin A, a method that has been used subsequently in postprandial 
studies. The method is based on the assumption that RE is selectively incorporated into the core 
of CM prior to its secretion from the enterocyte, and that there is negligible intravascular 
hydrolysis of the RE or extrahepatic removal of the labelled CM remnants or transfer of RE to 
other particles such as VLDL in the late phase. However, recent studies have placed doubt on 
the accuracy of the RE method, in that RE is taken-up by other tissues after 9-10 hours (Berr and 
Kem, 1984) and that there is also a delay in the postprandial RE response in comparison with the 
apo B-48 response in the TRL fraction (Krasinski e ta l,  1990; Lovegrove e ta l,  1999).
1.4.2.2 Apo B-48
Apo B-48 provides a specific, and thus more direct measurement of CM metabolism than RE. 
Only one apo B-48 molecule is found in each CM particle and it is not transferred to other 
lipoproteins in the circulation, remaining in the CM-R until it is taken-up by the liver. The most 
popular method involves the measurement of apo B-48 levels following consumption of a test 
meal by applying lipoproteins isolated by sequential ultracentrifugation onto SDS-PAGE (Karpe 
and Hamsten, 1994). The separated bands are then visualised using Coomassie Blue and the two 
apo B containing lipoproteins are determined by densitometric scanning of the gels. Recently, in 
the University of Surrey, a polyclonal antiserum has been raised against apo B-48 following 
injection of New Zealand rabbits with a synthetic peptide consisting of the six C-terminal amino 
acid residues of apo B-48 attached to an N-terminal cysteine residue. This has been used in the 
quantification of apo B-48 following separation on a SDS-PAGE gel and immunoblotting of the
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nitrocellulose filter (Peel et a l, 1993), A semi-quantitative apo B-48 ELISA has also been 
reported by Brasaemle et a l (1993) using a nonspecific antiserum to apo B-100 with affinity 
purified antibodies against apo B-48. Lovegrove e ta l  (1996) have used the antiserum developed 
by Peel et a l (1993) in the development of a specific apo B-48 ELISA. This enables the 
measurement of apo B-48 containing lipoproteins in TGRL samples which is not easily 
performed using SDS-PAGE due to the low concentrations of apo B-48. Sources of error are 
suggested to be reduced in the ELISA format, with no prior preparation of samples before hand. 
In conclusion, apo B-48 is currently recognised as a specific marker for CM and their remnants, 
it provides a sensitive specific alternative to the use of vitamin A-loading studies the limitations 
of which are now recognised.
1.4.2.3 VLDL
The isolation of VLDL, in the past, has largely been based on sequential ultracentrifugation using 
the methods of Havel et a l (1955) and Lindgren et a l (1971). Alternative procedures include 
zonal and density gradient ultracentrifugation, chromatography and gel electrophoresis. 
However, these are beset with problems of separating VLDL from CM and are also unable to 
resolve VLDL heterogeneity, whilst direct methods of VLDL measurement, such as apo B-100 
require specific antibodies, equipment and expertise. The recent development of a self-forming 
iodixanol gradient Graham (unpublished) to replace the NaBr salt gradient has meant a dramatic 
reduction in labour and centrifugation run time. The iodixanol gradient, with the addition of a 
preparatory CM spin (to remove larger CM) enabled the separation of Tight’-TGRL, ‘ dense’- 
VLDL and Tight’ VLDL. This method provides a quick and reproducible method of VLDL 
isolation, and is described in Section 3.6.
1.4.3 Methods for studying TGRL
Postprandial lipaemia is known to be influenced by meal composition, and many confounding 
factors exist that make comparison between studies very difficult including; total fat and other 
nutrient contents of the meal, frequency of meals, solid versus liquid meals, route of 
administration; oral versus intravenous, and also the habitual diet. A commonly used method of 
studying postprandial lipaemia, is an oral fat tolerance test as described by Patsch et a l (1983). 
The test involves feeding subjects a high fat (50-80 g) meal after a 10-12 hr fast, then taking 
sequential blood samples up to 10 hours after the meal. This enables the demonstration of the 
variability of postprandial TAG in NTG and HTG individuals. Smaller fat loads tend to under
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challenge, whilst larger loads tend to exceed the body’s metabolic clearance capacity. Although 
Shishehbor et a l (1999) suggested that fat intakes as low as 10-15 g can elicit a postprandial 
response. The simplest way to measure the extent and duration of change in postprandial 
lipaemia is to measure plasma TAG levels and to calculate the AUC under the time-response 
curve as a measure of the metabolic capacity to clear TAG.
1.4.4 Factors affecting postprandial lipaemia
The magnitude and duration of postprandial lipaemia is determined by several factors including 
the lipolytic enzymes; LPL, HL, LCAT and CETP.
1.4.4.1 LPL
LPL, originally described as the ‘clearing factor’, is the key enzyme responsible for the 
hydrolysis of TAG from the TGRL (Eckel, 1989). One of the first researchers to investigate the 
effect of LPL activity was Hahn (1943) who found a more rapid clearance of plasma turbidity by 
injecting an animal with heparin. LPL is primarily synthesised in the ER and Golgi of adipose 
tissue and muscle, where it is bound to capillary endothelial cells by heparan-sulphate 
proteoglycan molecules. LPL demonstrates a strong specificity for TAG, preferentially acting on 
the larger TGRL (Levy et a l, 1991), and it is responsible for the removal of 70-90 % of TAG 
from CM to form CM-R (Eckel, 1989). Apo C-II is required for the its activation, and apo C-III 
for the inactivation of LPL (McConathy et a l, 1992). The composition of the lipid substrate, 
core structure of the TGRL as well as the FA chain length has also been shown to influence the 
LPL catalytic rate (Demel and Jackson, 1985). The enzymatic action of LPL on TGRL results in 
the generation of mono- and di-acylglycerols as well as FA which are used for energy or re- 
esterified for storage in peripheral cells. The key role of LPL in lipoprotein metabolism was 
determined by Havel and Gordon (1960) who demonstrated that the slow clearance of CM in 
LPL deficiency was restored after an injection of heparin, which released LPL. LPL activity is 
known to be regulated by the accumulation of FA. Peterson et a l (1990) found a positive 
correlation between plasma LPL activity and plasma free fatty acid (FFA) levels, in humans 
during infusion of a TAG emulsion. The reciprocal effects of fasting, in adipose tissue and 
cardiac muscle, where LPL activity is reduced and increased respectively represents an example 
of tissue specific regulation of LPL.
The measurement of LPL activity has produced very varied results, largely because of problems
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associated with post-heparin procedures. LPL levels are known to be regulated by levels of 
circulating insulin (Doolittle et al., 1990). LPL activity in AT correlates well with plasma 
insulin levels (Berr and Kem, 1984), particularly in insulin deficiency states such as insulin 
dependent diabetes mellitus (IDDM) (Taskinen and Nikkila, 1979).
1.4.4.2 HL
HL is found on the endothelial cells of the liver and is bound by a heparan sulphate like ligand, 
like LPL. Previous research has suggested that HL preferentially acts on smaller lipoproteins; 
VLDL2, IDL and HDL (Daggy and Bensadoun, 1986), and this substrate affinity is illustrated in 
Figure 9. In addition, recent evidence has implicated HL in the clearance of CM-R (Brasaemle et 
a l, 1993). HL is also involved in altering the particle size distribution of HDL particles, and in 
the conversion of HDL2 to the smaller HDL3 (Barrans et a l, 1994). Therefore it is suggested that 
reduced LPL activity contributes to enhanced postprandial lipaemia through the action of CETP 
which transfers high loads of TAG from TGRL to LDL and HDL, resulting in an increased 
concentration of cholesterol rich small dense LDL and HDL3.
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Figure 9: LPL and HL lipoprotein substrate affinity
1.4.4.3 LCAT
LCAT is secreted by the liver and attaches to HDL in the plasma where it acts preferentially on 
HDL3. It requires apo A-I and apo A-IV for optimal activity. LCAT is responsible for the 
formation of CE in plasma by transferring an acyl group from lecithin to cholesterol (Nilsson- 
Ehle, 1980). Once synthesised, CE moves into HDL, some is exchanged for TAG from the 
TGRL by the action of CETP, whilst CE that accumulates is transferred to LDL.
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1.4.4.4 CETP
CETP is responsible for the transfer of TAG and CE among other lipoproteins (Tall, 1993), and 
for the maintenance of dynamic equilibrium between VLDL and other lipoproteins (Main et a l, 
1998). CETP is responsible for most of the neutral lipid transfer activity \n vivo (Hesler et a l,
1988).
1.4.5 TGRL and PPL
One of the major problems inherent in the study of postprandial lipaemia, has been the accurate 
determination of not just exogenous but also endogenous lipoproteins (VLDL). The inability to 
accurately differentiate between VLDL and CM has complicated the interpretation of many 
studies. One major problem is the fact that VLDL and CM density ranges overlap, which has 
presented numerous difficulties in their physical separation by ultracentrifugation. Few 
researchers have been able to raise both apo-B48 and apo B-100 antibodies, as markers of CM 
and VLDL respectively. The postprandial rise in TAG after a fat containing meal has been 
shown to consist of lipoproteins of both exogenous and endogenous origin as indicated by the 
concentrations of both apo B-48 and apo B-100 particles respectively (Cohn e ta l,  1988; Cohn et 
a l, 1993; Karpe e ta l,  1993; Schneeman et a l, 1993). Schneeman et a l (1993) found that after 
a fat-containing meal, 80 % of the postprandial increase in number of lipoprotein particles was 
accounted for by apo B-100, whilst only 20 % of the TAG was carried in these particles, with 80 
% of TAG being carried by CM and CM-R. Cohn et a l (1993) suggested that postprandially 
there was a 50 % increase in the apo B-100 concentration but only a 5-6 % increase in apo B-48. 
Possible mechanisms to explain this could be through a reduced clearance of VLDL or through a 
combination of both increased secretion and reduced clearance (Cohn et a l, 1989; Cohn et a l, 
1993; Karpe e ta l,  1993; Bjorkegren e ta l,  1996). Enhanced secretion of VLDL might occur as 
a result of increased hepatic uptake of FA derived from CM-R, through NEFA levels do not 
usually increase after the ingestion of mixed meals (Lewis et a l, 1990) due to insulin inhibition 
of HSL in adipose tissue (AT). Associations between the increase in apo B-48 and apo B-100 (Sf 
60-400) together with the reduced plasma concentrations of apo B-100 (Sf 12-60 fraction) 
supports the theory that the delayed clearance of VLDL induces enhanced postprandial lipaemia 
(Karpe et a l, 1993; Bjorkegren et a l, 1996; Mero et a l, 2000). The postprandial increase in 
VLDL may be due to increased competition for LPL in the common lipolytic pathway (Hazzard 
and Bierman, 1976), with LPL preferentially acting on CM over VLDL, leading to an increased 
concentration of VLDL in the plasma. This was further supported by Van Beek et a l (1998)
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who showed that at low levels of LPL activity (< 120mU/ml) only apo B-48 containing particles 
disappeared from the plasma, but at higher LPL concentrations, there was a similar rate of 
removal of both types of apo B-containing particles. Potts et a l (1991) showed that following a 
fat-rich meal in humans, CM clearance as opposed to VLDL was enhanced.
1.4.6 TGRL AND CHD
A classic example of disordered lipoprotein metabolism can be found in CHD (Gurr and 
Harwood, 1991). The ratio of apo B-100 to apo B-48, postprandially at 4 hours, in the Sf> 60 
fraction, was found to be a significant predictor of CAD (Simons et a l, 1987; Uiterwaal et a l,
1994). There is much debate as to the involvement of VLDL and the different VLDL fractions 
in the development of atherosclerosis and CHD. Formation of the fatty streak is thought to occur 
when the arterial endothelium becomes excessively permeable allowing increased entry of 
lipoproteins and other blood components into the arterial sub-intima. Such lipoproteins are 
taken-up by macrophages which form the fatty streak. Atheroma formation occurs if there is a 
proliferation of smooth muscle cells which then behave like fibroblasts laying down collagen 
which traps macrophages. Repetition of this process leads to the development of mature 
atheroma with layers of fibrous tissue and cholesterol. The final event is when the plaque 
ruptures releasing pro-coaguable material leading to the formation of a thrombus. The coronary 
circulation system then fails to meet the oxygen demands of the heart, leading to a myocardial 
infarction. The suggestion has been made that VLDLj is more adhesive to cellular surfaces and is 
therefore more prone to cellular uptake than LDL, which has implications for atherosclerosis and 
thrombosis (Bjorkengren et a l, 1997). Chung and Segrest (1990) have also shown that TGRL 
remnants can cause both foam cell formation and cell death in endothelial cells, whilst large 
VLDL particles were isolated from the vascular wall (Rapp, Lespine et a l,  1994). Increased 
plasma TAG and VLDL may also be connected with disorders of the coagulation system, 
including an increase in plasminogen activator inhibitor 1 (PAI-1) which inhibits fibrinolysis and 
increased levels of Factor VII which contributes to a procoagulant state. There is also an 
increase in the concentration of apo C-III in VLDL and HDL in HTG patients which, through 
inhibition of LPL, leads to impaired clearance of atherogenic lipoproteins and an increase in the 
angiographic progression of CHD (Krauss, 1998).
During lipid metabolism, after a fat-containing meal, excess TAG leads to the formation of larger 
VLDLi particles (Karpe et a l, 1994) which, it has been postulated, will inevitably lead to TAG-
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rich small dense LDL (Durrington, 1995; Millar and Packard, 1998). Principally in CHD, 
individuals secrete larger TAG enriched VLDL^ particles (Redgrave et a l, 1975; Eisenberg, 
1984) which increases competition for LPL between larger VLDLj and CM (Karpe et al., 1993). 
Otliers have suggested that an increase in VLDL^ inhibits LDL binding to LDL receptors 
(Bjorkengren et a l , 1997). There is also evidence for the involvement of VLDLj which has been 
shown to be the strongest independent predictor of progression of CHD, and IDL which may be 
even more directly involved in atherosclerosis progression than LDL (Krauss, 1998). Hodis et 
al (1997), have suggested that TGRL and CE rich lipoproteins (LDL) exert different effects in 
CHD; TGRL being responsible for the mild to moderate progression of lesions which are 
predominantly responsible for clinical coronary events, whilst CE-rich lipoproteins are 
responsible for severe coronary artery lesions.
1.5 Dietary  factors affecting  tgrl metabolism
Diet has long been suspected of being a major factor in the development and prevention of CHD. 
Diets of the Western world tend to have a high content of total fats especially SFA, and ethanol. 
Some of the strongest evidence to implicate dietary factors in CHD came from the Seven 
Countries study undertaken by Keys (1970). Although other factors such as obesity, age, gender, 
level of exercise, smoking of cigarettes and genetics are important, dietary SFA and TAG appear 
to be a major determinant of TAG levels and therefore of TGRL. After a fat containing meal; 
older, male, inactive obese subjects show a greater postprandial-triacylglycerolaemia than 
younger, active, female subjects. Changing a subject’s dietary composition provides a useful tool 
to investigate the CHD risk mediated through this phenomenon; in the following sections the 
influence of various dietary factors on postprandial lipid metabolism including, ethanol, CHO, 
MUFA and PUFA on the TGRL metabolism will be discussed.
1.5.1 Effects of ethanol
In the U.K. the annual consumption of ethanol exceeds 1.6 litres per capita (Porkka and 
Ehnholm, 1996), it is well known that the higher per capita consumption of ethanol the greater 
the amount of damage to health caused in the population. Ethanol, however, may also be 
beneficial in protecting against cardiovascular diseases. Recent studies have suggested that a 
moderate consumption of ethanol is beneficial by reducing CHD risk (Klatsky e ta l,  1974). A
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moderate consumption of ethanol has been suggested to explain the ‘French paradox’ , in that the 
French population consumes a high level of SFA but have a low incidence of CHD. Up to 50 % 
of the anti-atherogenic effects of moderate ethanol consumption are believed to be mediated 
through its effects on lipoprotein metabolism (Gaziano et a l, 1993) and more specifically 
through the well documented fall in HDL-C (Taskinen et a l, 1985; Taskinen et a l, 1987; Criqui, 
1998), and its anti-oxidant properties which may reduce the incidence of LDL oxidation, 
(Baraona and Lieber, 1979) and decreased LDL-C levels (Masarei et a l, 1986; Van Toi et al,
1998). Conversely, ethanol has been shown to increase TAG in pre- and post-prandial plasma 
(Ishmitsu et a l, 1997; Van Toi et a l, 1998), increasing VLDL and CM levels (Nestel, 1964; 
Wilson et a l, 1970; Barboriak and Hogan, 1976; Taskinen et a l, 1987), and reducing LPL 
activity (Hansson and Nilsson-Ehle, 1983). Acute and chronic ethanol consumption may also 
reduce LPL activity (Wilson e ta l,  1970; Baraona and Lieber, 1979).
1.5.1.1 Ethanol metabolism
Ethanol, (ethyl alcohol, C2H5OH), once consumed, is immediately absorbed at the stomach and 
metabolised by alcohol dehydrogenase in the liver. The rate of this process is variable, and 
dependent on such factors as gender and ethnic background. There are four routes of catabolism 
(Figure 10). The principal route is via alcohol dehydrogenase in the liver, generating 
acetaldehyde and NADH. Acetaldehyde is toxic and is normally converted to acetyl CoA prior to 
oxidation. In some tissues ethanol also stimulates the proliferation of microsomal membranes, 
inducing a specific cytochrome P-450 and a microsomal ethanol oxidising system (MEOS) which 
stimulates oxidative phosphorylation and generates heat in the process.
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Figure 10: Outline of ethanol metabolism (source James 1994 in Garrow and James (1994)
1.5.1.2 Ethanol and TGRL
The enhanced and prolonged postprandial TAG produced in response to a fat containing meal 
with ethanol has been suggested to arise from either the increased secretion, reduced catabolism 
or both, of VLDL and CM. An increase in plasma VLDL in response to acute ethanol intake has 
been demonstrated by Baraona and Lieber (1979). The increase in postprandial TAG has been 
proposed to be predominantly due to an increase in the residence time of VLDL in the 
circulation. Through reduced clearance (Schaefer e ta l,  1978; Crouse and Grundy, 1984). While 
kinetic studies on the effects of chronic ethanol ingestion have suggested that the production rate 
of VLDL is increased (Sane et a l, 1984). Crouse and Grundy (1984) and Barona et al, (1973), 
propose a threshold effect, so that increased synthesis of VLDL only occurs after consumption of 
60-80 g of ethanol.
An increase in the concentration of CM has also been reported after ethanol consumption, as 
shown by an increase in plasma retinyl palmitate (RP) following a test meal containing an RP 
load (Schneider e ta l, 1985; West et a l, 1996). Impaired CM hydrolysis due to an inhibition of 
lipase activities was suggested to underlie this effect. Pownall (1994) postulated that the 
postprandial rise in TAG after ethanol was due to an increase in plasma NEFA, implicating
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lipoproteins of exogenous origin, whilst Krasinski et a l (1990) suggested that the increases in 
TAG in the early and late phases were due to CM and VLDL respectively.
1.5.2 Effects of high-CHO/low-fat diets
In the average adult in the West, the majority of calories come from CHO, approximately 40 % of 
total energy (200-400 g/d). This value is higher in underdeveloped countries which have a high 
intake of complex CHO and a low intake of refined sugars. A key factor in the U.K. Government 
guidelines has been the recommendation of the consumption of a low-fat/high-CHO diet, the 
main reason being, to reduce cholesterol levels and promote of weight loss. However, the 
accurate measurement of CHO, and therefore assessment of related health benefits, has been 
hindered by the variation in the type of CHO, which possibly accounts for the discrepancy in the 
literature. The nutrition literature categorises CHO into two forms, simple and complex, whilst 
more recent studies have utilised the glycaemic index classification (Frost et a l, 1999). The 
latter is the plasma glucose response of a particular food expressed as a percentage of the glucose 
response to a reference food such as white bread (Riccardi and Rivellese, 2000).
The effects of dietary carbohydrate on lipoprotein metabolism has been recently reviewed by 
Parks and Hellerstein (2000). A consistent finding was that low-fat/high-CHO diets have the 
benefit of lowering total cholesterol and LDL-C, in addition to the potentially adverse effects of 
raising plasma TAG, VLDL-TAG and lowering HDL-C (Grundy, 1986; Ullmann et a l, 1991; 
Howard et a l, 1995). The effect of dietary CHO on TAG is modulated by the type of CHO 
administered. CHOs with a high glycaemic index have a greater HTG effect, as compared to 
CHO with a lower glycaemic index which may in NTG and HTG subjects have a 
hypotriacylglycerolaemic effect (Kuo and Bassett, 1965; Grande et a l, 1974; Chicco et a l,
1999). CHO-induced increases in VLDL-TAG as a result of de novo lipogenesis may also be 
dependent on whether the CHO is simple or complex. Hudgins et a l (1996), Frost et a l (1996) 
found lesser increases in FA synthesis in response to complex dietary CHO, whilst others suggest 
no difference in effect on TAG of starch and sucrose (Bantle et a l, 1993). Both CHO and 
MUFA enriched diets (Grundy, 1986) have been suggested to reduce LDL-C through a different 
mechanism. CHO stimulates hepatic secretion of larger TAG-rich VLDLi, which is less likely 
to delipidate to LDL (McNamara, 1992) and also reduces the cholesterol content of the LDL 
particles (Dreon e ta l, 1994). Furthermore, there is evidence to show that high-CHO diets >40 % 
of total energy convert the LDL subclass phenotype from pattern ‘A’ (predominantly large LDL) 
to pattern ‘B’ (predominantly small dense LDL), implying a detrimental effect for those subjects
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with an ALP at baseline (Dreon et al, 1994). Low-fat/high-CHO diets also lower total 
cholesterol levels due to the fall in HDL-C. A meta-analysis of data from 27 studies found that 
HDL-C fell by 0.01 mmol/1 for every 1 % fall in energy from SFA (Katan, 1997). While others 
such as West et a l (1990), have suggested that this fall in HDL-C is transient, but there is also 
epidemiological evidence to show that lower HDL-C levels exist in populations that consume 
low-fat/high-CHO diets. Mayes (1993) proposed that the increase in VLDL secretion is due to 
the direct actions of fructose in the liver due to the fact that NEFA and insulin levels are not 
affected by this monosaccharide. The impact of CHO on insulin production has produced varied 
results. A high-CHO diet was found to moderately increase glucose, but greatly increase insulin 
levels (Reaven and Olefsky, 1974; Lithell et a l, 1982), whilst others have suggested that a high- 
CHO diet, especially if it is high in complex CHO (low glycaemic index), results in either an 
improvement in insulin sensitivity (Zavaroni et a l, 1982; Smith, 1994; Aitman et a l, 1997), or 
no effect on insulin levels if the supplementation involved high levels of fructose (Jeppesen et a l,
1995). With regard to effects on glucose metabolism, early studies, giving CHO at 63-75 % of 
total energy, found an improvement in glucose tolerance on a high-CHO/low-fat diet 
(Himsworth, 1935). This finding is supported by more recent evidence (Fox et a l, 1985; Daly et 
a l, 1997) who found no detrimental effect on blood glucose after a high-CHO diet, in subjects 
that were healthy and not overweight. A high-sucrose diet may also increase uric acid levels 
which has been suggested to be a risk factor associated with CHD (Reiser et a l, 1989). In 
contrast, others have found no effect on uric acid levels (Crapo and Kolterman, 1984).
1.5.2.1 CHO metabolism
Most meals are a mixture of monosaccharides, such as fructose in fruit, disaccharides such as 
sucrose in sugar cane and polysaccharides such as starch in fruit and vegetables. The metabolism 
of CHO begins in the mouth and continues in the intestine through the action of a-amylase, 
known as Tuminal’ digestion. Membrane digestion of CHO takes place at or on the surface of 
the epithelium, with specific enzymes being localised in the brush border of the cells lining the 
small intestine. This brush border contains disaccharidases which hydrolyse the end products of 
intestinal digestion, maltase acting on maltose and maltotriose liberating glucose; sucrase acting 
on sucrose liberating glucose and fructose; and lactase acting on lactose liberating glucose and 
galactose. Both sucrase and maltase will be induced by feeding sucrose or maltose over a period 
of 2-3 days but not glucose. The absorption of monosaccharides occurs at a varying rate without 
the involvement of insulin. The remnants of glucose and galactose are finally absorbed by Na+ 
dependent active transport, whilst fructose is absorbed separately by facilitated diffusion. The
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monosaccharides glucose, fructose and galactose are then transported across the epithelial cells 
and enter the portal vein for delivery to the liver.
Sucrose/fructose metabolism
Sucrose consists of glucose and fructose monosaccharides. Fructose appears to be primarily a 
hepatic precursor of lipogenesis or gluconeogenesis rather than an energy substrate like glucose, 
disappearing from the circulation twice as fast as glucose (Sith et a l, 1953) and by-passing the 
major regulatory step in glycolysis involving the action of phosphofructokinase (Mayes, 1993). 
It then enters the glycolytic pathway at the triose phosphate level and increases acetyl CoA 
production which can be used for the synthesis of FA. Fructose entry and phosphorylation by 
fructokinase leads to a decrease in phosphate and in the amount of ATP produced. This 
decreased ATP-ADP ratio activates pyruvate dehydrogenase allowing the conversion of pyruvate 
to acetyl CoA. The resultant shift in the balance from oxidation to estérification of NEFA results 
in an increased secretion of VLDL (Grant et a l, 1994). Fructose fed to rats for a short period of 
time has been found to increase the activity of enzymes such as glucose-6-phosphate 
dehydrogenase and ATP-citrate lyases which produce NADPH needed in FA synthesis (Little et 
al, 1979). Long term studies have shown a decrease in hepatic lipogenesis, suggesting that some 
adaptation has taken place.
1.5.2.2 CHO and TGRL
The HTG effect of a high-CHO diet is well documented (Parks and Hellerstein, 2000), and leads 
to an increase in VLDL-TAG (Hagenfeldt et a l, 1974). Vessby and Carlson (1975) proposed 
that since the intestine could not produce CM on the fat free-high CHO diets, the increased TAG 
was due to an increased flow of hepatic VLDL particles rich in TAG (Taghibigiou et a l, 2000). 
Schonfeld et al (1976) fed 16 young normolipidaemic adults a high-CHO diet for 4 days. The 
VLDL-TAG, VLDL-C and VLDL-protein rose by 2.4, 1.67 and 1.88 mmol/1 respectively, 
indicating also that VLDL became TAG-rich. The effect of CHO supplementation on CM levels 
was analysed by Abbasi et a l (2000) who found that when 60 % of total energy was provided as 
CHO, CM-TAG was increased by 60 %. Increases in CM were also found (Mancini et a l, 1973; 
Jeppesen et a l, 1995; Parks et a l, 1999). In these studies, there was no change in apo B levels 
after CHO supplementation, implying that there was no increase in the number of VLDL or CM 
particles and thus the increase in TGRL possibly resulted from reduced clearance rather than 
increased synthesis (Melish et a l, 1980; Ullmann et a l, 1991 Baum and Brown, 2000). Nestel 
and Hirsch (1965) and Reaven et al (1965) reported the fractional turnover rate of TGRL to be
30
decreased after CHO supplementation. Grundy and Mok (1976), Parks et a l (1999) and Baum 
and Brown (2000) also demonstrated that VLDL particles were removed more slowly in HTG 
subjects. This effect on catabolism was explained by Hirano et a l (1988) who showed LPL 
activity was inversely correlated with the increase in plasma TAG in rats. Kasim et a l (1993) 
reported LPL activity to be inversely correlated with fasting plasma TAG in subjects fed a high- 
CHO diet.
1.5.3 The effects of dietary fattv acids: SFA. MÜFA and fn-3 and n-61 PUFA
The Seven Countries Study (Keys, 1970) was a longitudinal prospective study of middle aged 
men which examined the relationship of diet to CHD. The 15 year mortality data showed a direct 
relationship between the percentage of energy as SFA and CHD mortality (Keys et a l, 1986). 
Epidemiological data strongly suggests that CHD mortality and dietary fat are intimately related 
(Mensink and Katan, 1992). The percentage of food energy derived from total fat in the British 
diet has fallen only gradually, from 42% in the mid 1970s to just under 39 % in 1998. However, 
the type of fat eaten in the U.K. has changed more dramatically, with SFA intake falling from 20 
to 15 %. Based on the household food survey, in 1998 the average household consumed 15.2 % 
SFA, 7 % PUFA and 13.8 % MUFA as % of total energy from fat (Petersen et a l, 2000).
1.5.3.1 SFA
The principal dietary SFAs are lauric acid (C12:0), myristic (C14:0), palmitic acid (C l6:0) and 
stearic acid (C l8:0), mainly found in animal products; meat and diary produce. Government 
recommendations indicate the consumption of no more than 10 % of total energy as SFA. In the 
1960s several investigators (Keys et al, 1965; Hegsted et al, 1965), observed how serum 
cholesterol levels were affected by macro-nutrients in the diet. The authors concluded that 
MUFA and CHO had neutral effects on total cholesterol levels, as compared to SFA which 
resulted in raised serum cholesterol levels. The hypercholesterolaemic effect of SFA does not 
extend to all FA, medium chain fatty acids C8:0-<C12:0, are absorbed directly into the portal 
vein and are not involved in lipoprotein metabolism (McNamara, 1992). Long chain lauric acid 
(C12:0 and myristic acid (C14;0) and palmitic acid (C16:0) all raise total and LDL-C whereas 
stearic acid (C l8:0) does not. This could possibly be associated with the in vivo conversion of 
stearic to oleic acid (Grundy and Denke, 1990), Most investigators agree that the lipoprotein 
fraction most affected by SFA is the LDL-C level. SFA may exert direct effects on LDL 
receptors through an influence on membrane fluidity, and indirect effects through the modulation 
of levels of intracellular free cholesterol, SFA are poor substrates for AC AT estérification which
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reduces LDL receptor activity (Daumerie et a t, 1992). In general SFA produce smaller VLDL 
than PUFA, vyhich are precursors of small dense LDL (Norum, 1992), contributing to the ALP, 
whilst beneficially, raising HDL (Grundy, 1986).
1.5.3.2 Unsaturated fattv acids (TJFAI
UFA consists of PUFA and MUFA, the former of which is subdivided into n-3 PUFA and n-6 
PUFA. n-3 PUFA possess one of their double bonds between carbon atom 3 and 4, and n-6 
between carbons 6 and 7. The main species of n-3 PUFA which occur naturally in appreciable 
amounts, are a-linoleic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
found predominantly in fish oils. Whilst the main species of n-6 PUFA occur predominantly in 
fats of plant origin. Those occurring naturally in appreciable amounts are linoleic and 
arachidonic acid. Both linoleic and a-linolenic acid are essential fatty acids which cannot be 
produced by the body and must be taken in the diet. MUFA have one double bond in their FA 
carbon chain, the most common is oleic acid, whose main sources are olive oil, rapeseed oil and 
peanut oil. Government recommendations state an ideal consumption of n-3 and n-6 PUFA to be
6.5 %, up to a maximum of 10 %, and MUFA of 12 % of total energy intake (COMA 1994).
JJFA metaholism
Fat digestion begins in the small intestine, with the action of pancreatic lipase breaking down fat 
globules of TAG to fatty acids and 2-monoacylglycerols (an emulsfying agent which aids the 
action of bile salts). Bile salts produced by the gall bladder, enable the further formation of 
smaller groups of molecules known as mixed micelles. Micelles permit absorption through brush 
border membrane of the small intestine, for later re-esterification and eventual formation of CM. 
The later metabolic transformation of the three major unsaturated fatty acid families, which occur 
by desaturation and elongation, in the SER, is shown in Figure 11.
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Figure 11: Outline of UFA metabolism (source Gurr 1994, in Garrow and James, 1994)
1.5.3.3 MUFA
Fewer studies have examined the effects of MUFA supplementation on plasma TAG. Initially it 
was suggested that MUFA, like n-6 PUFA, was a fat with a neutral effect on plasma TAG, but 
recent evidence suggests that unlike high-CHO/low-fat diets, MUFA reduces plasma TAG, total 
cholesterol and LDL-C, whilst preserving HDL-C levels. In the Seven Countries Study (Keys, 
1970), populations consuming a Mediterranean diet, principally in Greece and Southern Italy 
were found to have a lower incidence of CHD, yet their diets contained 40 % of total calories as 
fat, but mostly in the form of MUFA.
Studies looking at the impact of a high-MUFA diet have found varied results but overall, total 
cholesterol has been found to be reduced (Mattson and Grundy, 1985; Mensink and Katan, 1989). 
The hypocholesterolaemic effect of MUFA (Grundy and Vega, 1987) may be specifically 
mediated through effects on the LDL receptor, oleic acid being the preferred substrate for ACAT,
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thereby increasing the synthesis of storage CE. HDL-C levels have either been unaltered or 
increased following a high-MUFA diet, the latter of which has been ascribed to reduced CETP 
activity (Mattson and Grundy, 1985; Jansen et a l, 2000; Tsihilas et a l, 2000). In addition, 
insulin resistance was found to be improved after a high-MUFA diet (Storlien et a l, 1997; 
Riccardi and Rivellese, 2000). An additional anti-atherogenic effect of MUFA may be its ability 
to reduce the susceptibility of lipids to peroxidation and thus the oxidative modification of LDL 
(Berry e ta l, 1991).
There has been much debate as to the differential effects of dietary MUFA and PUFA on serum 
lipids (Mattson and Grundy, 1985; Dreon e ta l,  1990; Berry et a l, 1991). In a meta-analysis of 
15 studies Gardner and Kraemer (1995) found no significant differences between the effects of 
MUFA and PUFA on plasma TAG, total cholesterol, LDL-C, or HDL-C. Conversely, Berry et 
a l (1991) found that a high-PUFA diet lowered total cholesterol more than the MUFA diet. This 
was later corroborated by Howard et a l (1995) who compared MUFA and PUFA in a dose- 
dependent fashion and also found that total cholesterol was significantly lower on the high-PUFA 
diet compared to the highest MUFA diet, with no significant change in HDL-C on both diets. 
Whilst Mensink and Katan (1992) reported no differences, except that LDL-C and HDL-C were 
found to be slightly lower on a MUFA compared to a PUFA diet.
1.5.3.4 n-3 PUFA
There is extensive research on the impact of long chain n-3 PUFA on lipoprotein metabolism, n- 
3 PUFA are essential fatty acids obtained from both marine sources, primarily EPA and DHA and 
plant sources, such as a-linolenic acid, the precursor of EPA and DHA (Harris et a l, 1997). The 
relationship between n-3 PUFA and human health has been highlighted by the association of fish 
oil with reduced CHD mortality and morbidity. Initial evidence in the 1970s (Bang et a l, 1971; 
Dyerberg et a l, 1975), suggested that the low incidence of CHD in Greenland Eskimos was due 
to their increased intakes of marine oils consisting of long chain n-3 PUFA. The Multiple Risk 
Factor Intervention Trial (MRFIT) found that n-3 PUFA consumption correlated inversely with 
coronary mortality (Dolecek and Grandits, 1991) though a protective effect of fish was only 
found when the habitual fish consumption was low (Shekelle et a l, 1985; Kromhout et a l, 1985). 
In a long term prospective study the Diet and Reinfarction Trial (DART) (Burr et al, 1989) in 
which 2000 men were randomly given 0.9 g/d of EPA/DHA and fish eating advice for 2 years, 
was associated with a 29 % reduction in death from CHD. Such findings are consistent with the 
largest n-3 PUFA fish oil trial conducted to date, the GISSI trial, (GISSI-Prevenzione
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Investigators, 1999) which took place over a period of two years and involved supplementing 
11,324 myocardial infarction patients with 1 g/d of PUFA resulting in a reduced CHD mortality. 
In contrast, the studies in which no protective effect was found, had high habitual intakes, with 
few subjects rarely or never eating fish (Curb and Reed, 1985; Vollset et a l, 1985), and it is 
therefore possible that moderate amounts of fish consumption are protective but larger amounts 
convey no additional protection, a view supported by Ascherio et a l (1995). Numerous studies 
have demonstrated that the intake of long chain n-3 PUFA has a significant hypolipidaemic 
effect, with the major response being a reduction in plasma TAG (Harris, 1989). Long chain n-3 
PUFA has also been shown to produce favourable effects on eicosanoid metabolism, affecting 
platelet and endothelial cell wall interactions (McNamara, 1992). n-3 PUFA increases membrane 
fluidity, allowing membrane proteins to move more readily thus potentially changing rates of 
signal transduction, hormone receptor interaction and substrate transport. The primary effect of 
n-3 fatty acids is to reduce VLDL levels, in both normolipidaemic and HTG subjects, which 
appears to be a dose-dependent response, those HTG subjects with a higher level of fasting TAG 
having a greater percentage reduction than NTG subjects (Harris, 1989). Their effects on 
cholesterol metabolism are minimal with either no change or a modest increases in LDL-C, HDL- 
C and total cholesterol. Long term studies have suggested that the observed increase in LDL-C 
may be transient with levels returning to normal when n-3 PUFA supplementation was continued 
beyond 9 months (Eritsland et a l, 1995; Saynor and Gillbott, 1992). Increased FA oxidation 
(Frenkel et a l, 1994; Nenseter and Drevon, 1995) has also been reported with n-3 PUFA 
supplementation, but not when PUFA intake is less than 10 % of total energy (Eritsland, 2000). 
Reports on the effects of n-3 PUFA on HDL-C seems to be less consistent. Harris (1989) 
reported that HDL-C increased with n-3 PUFA supplementation in both normal and HTG 
individuals, whereas Kasim-Karakas (1995) reported that long term intakes of moderate and large 
amounts of n-3 PUFA lowered HDL-C. n-3 PUFA supplementation has been found to produce 
both hypotriacylglycerolaemic effects both after acute (Demacker et a l, 1991; Zampelas et a l,
1994), and chronic intakes (Harris et a l, 1988; Weintraub et a l, 1988; Williams et a l, 1992), 
though some studies have found only minimal effects (Harris et a l, 1988; Bordin et a l, 1998; 
Fisher et a l, 1998). Harris et a l (1988) subtracted the habitual n-3 intake and found that n-3 
PUFA still produced a hypotriacylglycerolaemic effect, which could be due to a reduced rate of 
absorption of n-3 PUFA, altered formation of CM, enhanced LPL-mediated TGRL catabolism 
(Arrol et a l, 2000), with both CM and VLDL competing for clearance by LPL (Brunzell et al, 
1973).or reduced VLDL production (Harris e ta l, 1990).
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1.5.3.4.1 n-3 PUFA and TGRL
n-3 PUFA has consistently produced reductions in plasma TAG, by up to 25 % in normal and 20- 
50 % in HTG groups (Harris, 1989). This could be due to reduced synthesis and secretion of 
VLDL or increased VLDL removal. Gibney and Daly (1994) investigated the effect of a fish oil 
test meal on the postprandial incorporation of n-3 PUFA into plasma CM and VLDL fractions. 
The study demonstrated that n-3 PUFA were incorporated into both TGRL fractions with EPA 
being found in both CM and VLDL. Most studies have been consistent in showing reduced 
levels of VLDL-TAG in normal and HTG individuals following a n-3 PUFA rich diet (Nestel et 
a l, 1984; Sanders e ta l ,  1985; Nestel, 2000). Harris et a l (1990) investigated VLDL kinetics 
and found a 72 % decrease in the VLDL-TAG pool, a 45 % reduction in synthesis and a 65 % 
increase in the FCR of VLDL-TAG. A strong positive correlation between change in VLDL- 
TAG and VLDL synthetic rates, in this and other studies (Blades and Gorg, 1995) suggested 
suppression of synthesis as the primary mechanism. These findings are further supported by 
stable isotope research (Bordin et al, 1998) which showed a reduction in the VLDL apo B-lOO 
pool size and production rate after n-3 PUFA supplementation. The VLDL lowering effect is due 
to reduced hepatic synthesis by inhibiting acyl-CoA; 1,2-diacylgycerol acyltransferase, the last 
step in the synthesis of TAG (McNamara, 1992). n-3 PUFA supplementation also increased 
VLDL-TAG catabolism to a greater extent in the subjects with lower plasma TAG rather than 
those with higher TAG levels. Harris et a l (1990) concluded this was due to increased 
supplementation and was abolished when n-3 supplementation was removed. Several studies 
support the view that increased VLDL fractional catabolic rate results from a reduction in VLDL 
size (VLDL2) (Sullivan et a l, 1986) which results in a more efficient conversion into LDL than 
with large VLDL (Sanders, 1993). n-3 PUFA have also been suggested to both reduce CM more 
so than CM-R (Westphal et a l, 2000), and CM-R more so than CM (Lambert et a l, 2000). It is 
postulated that improved CM clearance results from reduced competition between CM and 
VLDL due to reduced VLDL (Eckel, 1989) since LPL preferentially hydrolyses larger particles 
(Karpe e/fl/., 1997).
1.5.3.5 n-6 PUFA
The literature on n-6 PUFA generally concludes that after acute or chronic supplementation, n-6 
PUFA has little effect on plasma TAG and is generally regarded as a fat with a neutral effect. 
However, in recent years the n3:n6 ratio has become increasingly more important, due to the 
greater abundance of n-6 PUFA in the diet preventing transformation of n-3 a-hnolenic acid to 
EPA and DHA (Figure 11). Weintraub et a l (1988) demonstrated that individuals consuming a
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SFA-rich diet had an equivalent postprandial lipaemia to those who consumed a n-6 PUFA diet. 
The predominant n-6 PUFA is linoleic acid, which has well established cholesterol lowering 
effects on VLDL, LDL, HDL, (Grundy, 1997). However, it is generally accepted that when n-6 
PUFA are in excess of 10 % of total calories there is a decrease in HDL-C (Griffin and Zampelas,
1995). The majority of findings indicate that PUFA exert their hypocholesterolaemic effects by 
modifying both the synthesis and catabolism of lipoproteins and have only minimal effects on 
endogenous cholesterol metabolism (Grundy and Denke, 1990). Combined kinetic data from 
Shepherd et a l (1980) and Turner et a l (1981), concluded that the exchange of PUFA for SFA 
resulted in a significant increase in the FCR of LDL and a decrease in LDL-apo B synthetic rate.
1.6 Aim s aisd objectives of current research
CHD remains the most important cause of premature death in the U.K. today (Petersen et a l,
2000). A major modulating factor to CHD is through the manipulation of the diet, primarily the 
modification of fasting plasma TAG levels, more specifically TGRL metabolism. This research 
project set out to establish the importance of such TGRL subspecies in relation to the ALP and to 
evaluate the influence of dietary factors on this relationship. This was first examined by 
developing a means of rapid separation of TGRL subclasses, which has lead to the further 
development of a self-forming iodixanol gradient. Once modified, the method was applied to 
examine further the influence of dietary factors with an established effect on postprandial lipid 
metabolism. These included an acute dose of ethanol and CHO supplementation, both known to 
increase PPL; and MUFA and n-3 PUFA dietary interventions known to reduce PPL, to address 
the relationship between these dietary components to lipid mediated CHD risk.
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CHAPTER!:
MATERIALS AND GENERAL METHODS
2.1 Isolation o fblo o b  samples I
2.1.2 Materials
■ Butterfly needles gauge no. 21 were supplied by Abbot laboratories (Sligo, Republic of 
Ireland).
■ 0.8 X 40 mm gauge no. 2 needles were supplied by Terumo (Leuven, Belgium).
■ Potassium ethylenediaminetetraacetic acid (Kz EDTA) blood tubes (10 ml) lithium heparin 
blood tubes (5 ml) and LP4 and LP3 polystyrene tubes were supplied by LIP (Shipley, West 
Yorkshire).
2.1.3 Procedure
Venous blood samples were drawn from a forearm vein (see individual Chapter protocols for 
further details on blood sampling times). Blood was collected in lithium heparin tubes for LDL- 
C and HDL-C analysis and into Kg EDTA tubes for all other analyses, then centrifuged at 3,000 
rpm for 10 minutes (2.56 x lO'^  g.min) to separate plasma from red blood cells. Plasma was 
removed and aliquots were placed into LP4 and LP3 tubes for each analysis. Samples were then 
stored at -20‘^ C, but due to the instability of TGRL, iodixanol pool fractions, were analysed from 
fresh plasma (as described in Section 3.6).
2.2 Automated analysis on the cobas m ira  plus
The analysis of TAG, total cholesterol, HDL-C, NEFA, glucose, total protein and apo B was 
carried out using an automated COBAS Mira plus analyser (ABX Diagnostics Ltd., Hitchin, 
Bedford). TAG, glucose, paracetomol, total cholesterol, HLD-C, NEFA were measured by a 
sequence of enzymatic reactions, total protein was measured by the biuret reaction and apo B was 
measured by immunoturbidimetry.
For each analyte, all samples for each subject were measured in the same sequence. External 
quality controls (QC) were measured at regular intervals within each run to ensure that conditions
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throughout the assay did not vary beyond the acceptable QC range defined by the manufactures 
guidelines.
2.2.1 Analysis of triacvlglvcerol (TAG)
The working reagent (Unimate 5 TRIG), calibrator (calibrator H) and QC (control serum normal
- CSN) were supplied in kit form from ABX Diagnostics Ltd., (Hitchin, Bedford).
Principle
The method used was an enzymatic colorimetric method based on the following reactions:
TAG + H2O  LPL__^  Glycerol + Fatty acids
Glycerol + ATP Glycerol kinase ^  Glycerol-3-P + ADP
Glycerol-3-P +O2 Glycerol-P-oxidase ^  Dihydroxyacetone phosphate + %02
2H2O2 + 4-chlorophenol Peroxidase ^  Quinoneimine + HgO 
+ 4-aminophenazone
The intensity of the quinoneimine dye produced is proportional to the TAG concentration when 
measured at 500 nm and the assay is linear up to 8 mmol/1.
The assigned value for CSN was 1.05 mmol/1, (0.95- 1.15 mmol/1 range). The mean intra-assay 
coefficient of variation on a mean value of 0.98 mmol/1 was 0.68 % (n = 12) and inter-assay 
coefficient of variation on a mean value of 0.98 was 1.59 % (n = 12).
2.2.2 Analysis of total cholesterol
The working reagent (Unimate 7 CHOL), calibrator (calibrator H) and QC (control serum normal
- CSN) were supplied in kit form from ABX Diagnostics Ltd., (Hitchin, Bedford).
Principle
The method used was an enzymatic colorimetric method based on the following reactions: 
Cholesterol ester + H^ O Cholesterol esterase ^  Cholesterol + Fatty acids
Cholesterol + Og_______Cholesterol oxidase ^ Cholest-4-en-3-one + HgOg
H2O2 + 4-chlorophenol Peroxidase ^  Quinoneimine pigment 
+ 4-aminophenazone
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The intensity of the quinoneimine dye produced is proportional to the cholesterol concentration 
when measured at 500 nm and the assay is linear up to 6.2 mmol/1.
The assigned value for CSN was 5.31 mmol/1, (4.78 - 5.44 mmol/1 range). The mean intra-assay 
coefficient of variation on a mean value of 5.30 mmol/1 was 1.87 % (n = 12) and inter-assay 
coefficient of variation on a mean value of 5.38 mmol/1 was 2.03 % (n = 10).
2.2.3 Analysis of HPL-choIesterol
The working reagent (Direct HDL-C), calibrator (Direct LDL/HDL-C calibrator) and QC (Lipid 
level Ir LLl) were supplied in kit form from Randox Laboratories Ltd., (Crumlin, Co. Antrim).
Principle
The method used was an enzymatic colorimetric method based on two distinct steps:
In the first reaction CM, VLDL-C and LDL-C are eliminated by cholesterol esterase, 
cholesterol oxidase and subsequently catalase.
Cholesterol ester + 0 cholesterol esterase  ^ Cholesterol + Fatty acids
Cholesterol +  Cholesterol oxidase ^  Cholestenone + H2Q2
H202 p  H20 +02
In the second reaction the specific measurement of HDL-C occurs after release of 
HDL-C by detergents in a second reagent (containing sodiumazide which inhibits 
catalase activity).
Cholesterol ester + H 2O cholestei-ol esterase  ^ Cholesterol + Fatty acids
Cholesterol oxidaseCholesterol + Og---------------------------- ► Cholestenone
Peroxidase2H2O2 + 4-AA + HD AOS __________ p. Quinonepigment + 4H2O
4-AA = 4-Ainmoantipyrine
HD AOS = N-(2-hydro3gr-3-sulphopropyl)-3,5-dimethoxyanilme
The intensity of the quinoneimine dye is directly proportional to the cholesterol concentration 
when measured at 600 nm. The assay is linear up to 2.8 mmol/1. The assigned value for LLl 
was 0.805 mmol/1, (0.644 - 0.966 mmol/1 range). The mean intra-assay coefficient of variation 
on a mean value of 0,77 mmol/1 was 2,60 % (n = 6) and inter-assay coefficient of variation on a 
mean value of 0.77 mmol/1 was 3.10 % (n = 6).
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2.2.4 Analysis of non-esteritled fattv acids (NEFA)
The working reagent (NEFA C) was supplied from Wako Chemicals, (Neuss, Germany), 
calibrator (calibrator level 1) and QC (Multi-serum normal level 1- MSNl) were supplied in kit 
form from Randox Laboratories Ltd., (Crumlin, Co. Antrim).
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
NEFA + ATP + CoA Acetyl-CoA synlhetase ^ Acyl-CoA + AMP + Pyrophosphate 
Acyl-CoA + O2 Acetyl-CoA oxidase ^ 2,3-trans-enoyl-CoA + H2O2 
H2O2 +
+ 3-methyl-N-ethyl-(B-hydroxyethyl)-amline + 4 aminoantipyrene
Peroxidase ^ purple coloured 
adduct
The intensity of purple coloured formed is proportional to the NEFA concentration when 
measured at 550 nm and the assay is linear up to 2 mmol/1.
The assigned value for MSNl was 1.11 mmol/1, (0.994 - 1.28 mmol/1 range). The mean intra­
assay coefficient of variation on a mean value of 1.02 mmol/1 was 4.9 % (n = 9) and inter-assay 
coefficient of variation on a mean value of 1.04 mmol/1 was 5.3 % (n = 9).
2.2.5 Analysis of glucose
The working reagent (Glucose GOD/PAP), calibrator (calibrator level 1) and QC (Multi-serum 
normal level 1- MSNl) were supplied in kit form from Randox Laboratories Ltd., (Crumlin, Co. 
Antrim).
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
Glucose +O2 + HgO_____________ Glucose oxidase^ Gluconic acid + H2O2
H 2 O2  +  4-aminophenazone + phenol Peroxidase Quinoneimine
The intensity of purple coloured adduct is proportional to the glucose concentration when 
measured at 550 nm and the assay is linear up to 22.2 mmol/1.
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The assigned value for MSNl was 6.08 mmol/1, (5.17 - 6.99 mmol/1 range). The mean intra­
assay coefficient of variation on a value of 6.24 mmol/1 was 0.71 % (n = 12) and inter-assay 
coefficient of variation on a mean value of 6.28 mmol/1 was 0.86 % (n = 6).
2.2.6 Analysis of total protein
The working reagent (Total protein - biuret method), calibrator (calibrator level 1) and QC 
(Multi-serum normal level 1- MSNl) were supplied in kit form from Randox Laboratories Ltd., 
(Crumlin, Co. Antrim).
Principle
The analysis is a biuret reaction based on cupric ions which, in an alkaline medium, interact with 
peptide bonds in proteins resulting in the formation of a coloured complex.
Protein + OiW Alkaline media ^  Vinlef coloured
complex
The intensity of colour is proportional to the total protein concentration when measured at 550 
nm and the assay is linear up to 130 g/1.
The assigned value for the standard was 60.3 g/1 (54.9 - 65.7 g/1 range). The mean intra-assay 
coefficient of variation on a value of 59.2 g/1 was 0.50 % (n = 10) and inter-assay coefficient of 
variation on a value of 60.9 was 6.14 % (n = 12).
2.2.7 Analysis of total apoHpoprotein B (apo
The working reagent (Apolipoprotein B - immunoturbidimetric immunoassay), calibrator 
(provided in kit) and QC (Lipid Control level 1) were supplied in kit form from Randox 
Laboratories Ltd., (Crumlin, Co. Antrim).
Principle
The method is based on the reaction of a sample containing human apo B and a specific 
antiserum to form particles which are measured by immunoturbidimetry. The antigen-antibody 
complex causes a decrease in transmitted light that is dependent on the concentration of the 
particles in suspension. Serial dilutions of the calibrator were performed automatically on the 
COBAS Mira Plus and a standard curve produced. The samples and QCs were automatically 
diluted by the autoanalyser and the apo B values determined from the standard curve.
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The intensity of colour is dependent on the apo B concentration when measured at 340 nm which 
can be measured effectively up to a concentration of 2 g/1.
The assigned value for the QC was 0.981 g/1 (0.785 - 1.77 g/1 range). Due to expense, only an 
inter-assay coefficient of variation was determined which was 1.11 % on a mean value of 1.03 g/1 
(n = 3).
2.3 Analysis of in su l m
2.3.1 Principie
Insulin was measured by a radio-immunoassay (RIA) originally described by Albano et a l 
(1972) and adapted by Hampton et a l (1988). The method is a double antibody RIA technique 
involving the incubation of plasma samples with antisera to insulin and a fixed amount of 
radiolabelled insulin. Competition between the radiolabelled and unlabelled insulin causes 
variations in the level of antibody-radiolabelled antigen which are proportional to the level of 
insulin in the plasma. The unbound radiolabelled insulin is removed after adding an antiserum to 
guinea pig IgG which binds to the primary antibody and causes the precipitation of the antibody- 
antigen complexes in the presence of polyethylene glycol (PEG).
2.3.2 Materials
■ Normal guinea pig serum (NGPS), donkey anti-guinea pig antiserum (DAGP) were provided 
by Guildhay Antisera Ltd., (Guildford, Surrey).
■ Albumin, Bovine serum (BSA) and polyethlyene glycol 6000 (PEG) were supplied by Sigma, 
(Poole, Dorset).
a ^^^I-insulin, charcoal stripped serum (CSS), low medium and high QC and insulin standard 
were a gift from Dr Shelagh Hampton, University of Surrey, (Guildford, Surrey)
■ NazHPO  ^anhydrous salt, NaH2P0^.2H20 and charcoal activated (Norit A) were supplied by 
BDH Chemicals Ltd., (Poole, Dorset).
2.3.2.1 Stock and working solutions
Reverse osmosis (RO) water was used for preparing all buffers unless otherwise stated.
Stock solution
0.04 MPhosphate buffer (pH 7.4) - stock buffer
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Five litres of stock buffer were prepared from 23 g ofNa^HPO^ and 5.97 g of NaH2P0^.2H20 
which once prepared were stored at 4®C.
0.04 Phosphate buffered saline (pH 7.4) PBS - assay buffer
0.04M phosphate buffer containing 0.5 % (w/v) BSA was prepared by adding 50 mg of BSA per 
100 ml of 0.04M phosphate buffer, then stored at 4‘’C.
Working solutions
Insulin antiserum
The antiserum was raised in a guinea pig injected with porcine insulin conjugated to ovalbumin, 
the conjugate was prepared using a glutaraldehyde reaction. The antiserum used in the assay was 
MF/GP/6 VIIA. Aliquots of antiserum were stored at -20°C, and diluted 1:5,000 with assay 
buffer for use.
Insulin standard
The insulin standard was diluted in assay buffer and 100 pi aliquots of 15,000 pmol/L 
concentration were stored at -20°C. The insulin standard was reconstituted to 1 ml with assay 
buffer to give a top standard of 1500 pmol/1 (200 mU/1), which was then double diluted in assay 
buffer to give standards with concentrations of 750, 375, 188, 94, 47 and 23 pmol/1.
Charcoal stripped serum (CSS)
A serum pool was collected from fasted volunteers. Twenty grams of Norit A charcoal was 
added per 100 ml of serum and roller-mixed overnight at 4°C. The charcoal is allowed to settle 
and the aspirated supernatant centrifuged at 3000 rpm for 30 min (2.47 x lO'^  g.min). The 
supernatant was then filtered through a Seitz filter until all charcoal was removed. Aliquots of 
10 ml were stored at -20°C and defrosted when required.
Insulin
Each ^^ I^nsulin ampoule was stored at -20°C and contained approximately 65.11 KBq of 
radioactivity. This was diluted 1 in 60 with assay buffer.
Normal guinea pig serum (NGPS)
NGPS was stored at 4°C then diluted 1:200 with assay buffer for use.
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Donkey anti-guinea pig serum (DAGPS)
DAGPS was stored at 4°C then diluted 1:16 with assay buffer.
Polyethylene Glycol (PEG)
PEG 4 % (w/v) was made up with stock buffer and stored at 4°C,
Quality controls (QC)
Venous blood was taken from volunteers who were fasted and then at 30 and 60 min after 
consuming a carbohydrate-rich snack. The blood was centrifuged at 3000 rpm for 10 min (8.56 
X 10^  g.min) and plasma collected. This plasma was used to produce low, medium and high level 
quality controls respectively. Aliquots of 2 ml were stored at -20‘"C and defrosted when required.
2.3.2.2 Method
Each subjects samples were assayed for non-specific binding (NSB), with one NSB sample in 
duplicate for each subject.
On day one, PBS, standards and insulin antiserum were prepared. Assay buffer, insulin standard, 
CSS, QC plasmas (low medium and high QC) sample and antiserum were added sequentially to 
all tubes except the total counts in the order shown in Table 1. All tubes were then vortexed and 
incubated for 24 h at 4‘"C.
On the second day the insulin label was added to all tubes, which were then vortexed and 
incubated for 24 h at 4°C.
On the third day, the NGPS, DAGPS and 4 % (w/v) PEG was added to all tubes except the totals, 
which were then vortexed and incubated for 2 hr at 4°C. All tubes were then centrifuged in a 
Beckman J-6B at 2500 rpm for 30 min at 4 °C. The resulting supernatant was aspirated off and 
the pellet counted on a gamma counter. Multigamma 1260, program I-10 manufactured by 
Wallac (Cambridge, Cambridgeshire) within one week of experimentation. The assay was 
sensitive down to 19 pmol/1.
The inter assay coefficient of for high QC (445.7 pmol/L) was 6.07 % (n-3), medium (311 
pmol/L) was 6.73 % (n=3) and low (75 pmol/L) was 22.70 % (n=3).
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Table 1: Insulin assay procedure
Day 1 Total NSB STD OSTD STD NSB QC QC NSB Unknown
Assay
buffer 350 pi 250 pi 200 pi 350 pi 250 pi 350 pi 250 pi
Insulin
STD 50 pi
CSS 50 pi 50 pi 50 pi
QC
plasma 50 pi 50 pi
Sample 50 pi 50 pi
Anti­
serum 100 pi 100 pi 100 pi 100 pi
Vortex mix ^ bat4"C #
Day 2
Label 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi
Voitex mk all tubes and fn^ hat4*C
Day 3
NGPS 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi
DAGP 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi
4 % PEG 700 pi 700 pi 700 pi 700 pi 700 pi 700 pi 700 pi
Vortex mix all tubes and incubate for 2 h at 4"( 
a^irate and count the pellet
2. Centrifuge at 2500 i^m (or 30 min,^
NSB: non-specific binding 
NGPS: normal guinea pig serum
CSS: charcoal stripped serum 
DAGPS: donkey anti-guinea pig serum
PEG: polyethylene glycol
2.4 STATISTICAL ANALYSIS
Statistically significant differences between samples before and after the four dietary treatments; 
ethanol, carbohydrate, MUFA and n-3 PUFA were assessed using STATISTIC A (version 5, 
1997), taking the level of significance as /?<0.05. Prior to running any statistical tests, all data 
was tested for normality using the Komologorov-Smimov test, if the data was normally 
distributed parametric tests were employed. If the data was not normally distributed it was 
transformed by being logged as suggested by Bland (1996). When postprandial study days were 
undertaken, as in the ethanol and MUFA studies, changes in concentrations with time were 
assessed by repeated measures analysis of variance (ANOVA), using treatment and time as the
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repeated measures (within subjects) factors. Where ANOVA showed significant differences, the 
Duncan’s multiple range post hoc test was used to identify where the differences lay. 
Postprandial data was also analysed as areas under the curve (AUC), calculated using the 
trapezoidal rule in an excel spreadsheet. These were calculated from the basal period (mean of 
-10 and 0 min values) to 480 min later. Incremental area under the curve (IAUC) was calculated 
by subtracting the mean baseline value from the postprandial area, extrapolated over 480 min, 
thus reflecting changes occurring after the meal. Differences in AUC and lAUC were analysed 
by paired Student’s t-test. Differences in fasting samples before and after the dietary treatment in 
the case of carbohydrate and n-3 PUFA diets were assessed using the Student’s t-test. Simple 
linear regression was used to assess univariate associations between variables, a value of /?<0,05 
was considered significant.
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CHAPTER 3:
TRIACYLGLYCEROL-RICH LIPOPROTEIN IODIXANOL SELF-FORMING 
GRADIENT METHOD DEVELOPMENT
Iodixanol is a non-ionic material capable of forming self-generating gradients for the rapid 
separation of plasma lipoproteins. Iodixanol gradients are more rapid and reproducible than 
traditional salt-gradients and thus offer considerable advantages in the analysis of lipoprotein 
heterogeneity. An iodixanol gradient was designed for the rapid separation of TGRL fractions.
Numerous methods have been used to isolate VLDL, with separations based largely on the 
principles of size, density, electrical charge, apolipoprotein content and chemical composition. 
Pioneering work on the isolation of VLDL was undertaken by Gofman et a l (1949) in Lindgren 
et a l (1971). However, VLDL isolation has been ‘confounded’ by the difficulty in separating 
exogenous CM from endogenous VLDL, (operationally defined as CM > 400 Sf and VLDL 20- 
400 Sf), as a result of an overlap in size and buoyancy between the two (Levy and Fredrickson, 
1966 in Lindgren et a l (1971). The isolation of VLDL has been significantly advanced by the 
development of centrifugation technology; ultracentrifugation enables faster centrifugation 
speeds with swing-out rotors giving high performance with long radial paths. Several methods to 
separate VLDL subclasses have been described in the literature. These include; zonal 
ultracentrifugation, cumulative flotation ultracentrifugation, density gradient ultracentrifugation, 
gel filtration chromatography, heparin-sepharose affinity chromatography, preparative agarose 
gel electrophoresis and the use of VLDL kinetics as illustrated in Table 2.
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3 .1  DISADVANTAGES OF CURRENT METHODS
The key problems with the currently available methods for isolation and identification of VLDL 
subclasses include; 1) the labour intensity of VLDL isolation which requires long 
ultracentrifugation runs, for example cumulative flotation takes up to two days to complete the 
isolation of VLDL. Such long runs have been suggested to lead to microbial lipoprotein 
degradation, lipid peroxidation (Leonhardt et al, 1994) and structural instability during 
prolonged and repeated centrifugation (Lindgren et al, 1971); 2) the expense of the procedure, 
for example, VLDL kinetics by radiolabelling; 3) problems with low resolution, for example, gel 
filtration chromatography and preparative agarose gel electrophoresis have been shown to 
produce a poorer quality isolation compared to ultracentrifugation. These all make the above 
methods unsuitable for the isolation of VLDL from large numbers of subjects, i.e. a postprandial 
study or for the analysis of TGRL sub-components during the conduct of clinical studies 
(Lindgren ef a/., 1971).
Due to the greater specificity and reliability of ultracentrifugation most studies have used 
cumulative flotation as the method of choice for the separation of TGRL and isolation of VLDL 
subclasses. Historically, there appear to have been three major contributors to the development 
of cumulative flotation methodology, (Table 3). To summarise, Havel (1955) used only two salt 
gradient densities to isolate VLDL, a method more likely to produce a poor separation of large 
VLDL (Sf20-400) and CM (Sf> 400) since there is no preliminary run to remove CM (Sf> 400). 
Lindgren e ta l  1971) whilst allowing a separate spin to separate large VLDL (Sf20-400) and CM 
(Sf > 400), stated that it is likely that large VLDL (Sf20-400) is distorted since VLDL carry-over 
into the CM fraction (Sf > 400). Whilst Redgrave and Carlson (1979), employed an additional 
preliminary spin to the procedure of Lindgren et a l (1971) which only introduced further 
problems of instability.
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Table 3: Comparison of the three major methods of cumulative flotation
Reference Sample preparation Rotor Run conditions
(Havel, Sequentially isolated from plasma SW-40 105,000 g for 20-22 hr
1955) adjusted to 1.019 then 1.063 g/ml at 12-15°C
(Lindgren et Plasma adjusted to 1.065 overlayered Sf> 400 SW 25.3 Sf > 400 centrifuged
al, 1971) with 1.046 (4.5), 1.033 (4.4), 1.027 (3.4), 
10.19 (2.3), 1.017 (1.2), 1.006 g/ml (0.1 
ml) isolating Sf>400 in a 2 ml fraction. 
Plasma is adjusted to 1.0065 g/ml, 
overlayered with the same gradients as 
above apart from the first 2 levels 1 ml 
and 2 ml for the other 4, isolating Sf 
<400 in 0.5 ml.
Sf<400SW41 for 61 min at 20,000 
rpm at 23°C. Sf< 400 
sample mn for 144 
min at 35,000 rpm.
(Redgrave Plasma to 1.21 g/ml overlayered with 4 SW40T1 rotor 24 hr at 41,000 rpm at
and Carlson, ml of 1.10 g/ml, 3 ml of 1.065, 3 ml of 20 °C
1979) 1.020 and 3.4 ml of 1.006 g/ml
3 .2  lOPIXANOL
lodixanol is chemically known as 5,5’-([2-hydroxy-l,3-propanediyl)“bis(acetylimino)]bis -'[N,N’ 
-bis (2,3-dibydroxypropyl)-2,4,6-triiodo-l,3-benzenedicarboxamide], (Figure 12). The iodixanol 
structure is based on tri-iodobenzoic acid to which hydrophilic groups are attached thus 
increasing its solubility in water (Richwood, 1983). lodixanol is a non-ionic density gradient 
media that has a very low toxicity toward biological material (Ford et al, 1994), its properties 
are illustrated in Table 4, (Petta et al, 1998).
CH. OH1 ^
OH CHg NHGO 
OH
OK OK
GO OH
NGHg GHGH2 N
GONHGH2 GHGH2 OH
GH2 OH
GONHGH2 GH
OH
GONHGH2 GHGH2 OH
OH OH
Figure 12: Molecular structure of iodixanol (Ford et al, 1994)
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Table 4: Properties of iodixanol
lodixanol Properties Value
Absorption spectrum 245 nm
Molecular weight 1550 Da
Density 2.08 g/ml
Melting point 221-244 °C
10 % (nvV) iodixanol properties
concentration (M) 0.065
Refractive index 1.349
Density 1.052 g/ml
Osmolality 38 GSM
Iodixanol was initially developed by Nycomed Pharma AS, Oslo Norway, as a third generation 
X-ray contrast medium (Eivindvik and Sjogren, 1995). Formulated as a dimer from an existing 
X-ray contrast media, Nycodenz, (Ford et al, 1994). lodixanol with its heavy iodine atoms 
supplied X-ray absorbancy and together with its hydrophilic groups provided a desirable 
pharmacological profile with good water solubility (Priebe et al, 1999). It was recognised that 
these compounds were suitable for the formation of density gradients and offered new 
opportunities for improved separations of biological particles, in short periods of time. 
Nycodenz had already been used in ultracentrifugation gradients, and because iodixanol 
possesses twice the molecular mass of Nycodenz this meant that iodixanol could also readily 
form self-generating gradients. lodixanol covers a significantly greater density range than 
Nycodenz reaching 1.075-1.205 g/ml versus 1.105-1.178 g/ml respectively (Ford et al, 1994), 
Figure 13.
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Figure 13: A typical iodixanol TGRL profile
The use of iodixanol as a self-generating gradient to isolate VLDL was first outlined in 1997 in 
an abstract by Davies and Graham (1997) which briefly describes the formation of a preformed 
gradient consisting of a shallow 5 % (w/y) iodixanol gradient generated at 280,000 g for 16 hr in 
a SW 55Ti rotor. The advantages of a preformed gradient are that it minimises particle 
aggregation and means that the particles are free to float upwards to their isopycnic point (the 
point at which their buoyancy is equal to that of the media). The bottom 1 ml of the preformed 
gradient was replaced with 1 ml of a 15 % (w/v) iodixanol-plasma solution then recentrifuged at
280,000 g for 1-1.5 hr. This was reported to separate CM and VLDL and to subfractionate 
VLDL (Davies and Graham, 1997). The present method is based on an unpublished personal 
correspondence by Graham (unpublished); whereby a 6 % (w/v) iodixanol gradient was generated 
in a SW 55 Ti spun at 50,000 rpm for 20 min at 16°C (2.71 x lO^g.min), the bottom 1 ml was 
replaced with 1 ml of a 10 % (w/w) iodixanol-plasma solution then recentrifuged at 35,000 rpm 
for 1 hr 10 min at 16°C (1.04 x lO^g.min).
The advantages of iodixanol as a gradient media are firstly that it is quick, forming a self- 
generating gradient in a short period of time at a relatively low ‘g’-force. Nycodenz and 
metrizamide usually take at least 16 hr to form self-generated gradients (Ford et al, 1994). 
Secondly, iodixanol has no measurable cytotoxicity and has a low impact on most enzyme assays 
performed in its presence (Rickwood, 1983). lodixanol also has a low level of interference on 
enzyme activity when used to measure analytes after centrifugation (Rickwood, 1983), which has 
importance for the analysis of TAG and protein in the fractions of the iodixanol gradient. In
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addition to its non-ionic nature, electrophoretic analysis can be carried out on gradient fractions 
directly without removing the medium. Thirdly, iodixanol has the ability to form iso-osmotic 
solutions at densities up to 1.32 g/ml at high resolution and to as low as 1.1 g/ml (Graham et al,
1996). Finally, iodixanol gives a greater recovery and is more specific for the isolation of VLDL 
than other methods (Graham et a l, 1996). Graham et a l 1996) isolated VLDL, LDL and HDL 
by three separate methods using; iodixanol, a salt gradient and sequential ultracentrifugation. 
They measured the percentage recovery of cholesterol and TAG (taking into account the final 
dilution of the fraction), as shown in Figure 13. lodixanol gave the greatest percentage recovery 
of TAG at 98.01 % and cholesterol at 95.87 %, whilst the salt gradient gave a percentage 
recovery of 65.12 % and 62.18 % and sequential ultracentrifugation gave a percentage recovery 
of 36.72 % and 80.95 % respectively (Graham eta l, 1996).
Possible problems with the use of the iodixanol self-forming gradient in the isolation of VLDL 
include: Firstly, transfer of technology, the adaptation of the existing method described by 
Graham (unpublished). Secondly, one of the most direct methods of analysing a gradient, is 
through the application of the existing method for analysing gradients by continuous UV 
spectrophotometry (280 nm). lodixanol as it possesses a tri-iodinated benzene ring, gives a high 
absorption in the ultraviolet region of the spectrum, and hence it is impossible to carry out any 
spectrophotometric measurements below 400 nm (Rickwood, 1983). This excludes the usual 
method of measuring protein absorbance at 280 nm. Finally, iodixanol has been reported to 
interfere with protein assays based on the Folin phenol reagent i.e. the Lowry method (Lowry et 
al, 1951) as suggested by Ford e ta l  (1994).
3.3 A im s of study
The aim of this study was to develop a rapid, reproducible and inexpensive method to separate 
the principal constituents of TGRL (‘light TGRL’, ‘light’-VLDL and ‘dense’-VLDL) by 
modification of the unpublished method of Graham (unpublished).
55
3.4  M a t e r ia l s
CHEMICALS
• Bromophenol blue and barbitone were supplied by BDH laboratories supplies (Poole, Dorset).
• lodixanol [60 % (w/v)] ‘Optiprep’ was supplied by Lipotech Ltd (Liverpool, Merseyside).
• Perofluorodecalin (density 1.908 g/ml at 25”C) was supplied by Fluorochem Ltd (Old 
Glossop, Derbyshire).
• Phosphate buffered saline (PBS) pH 7.3 was supplied by Oxoid Ltd (Basingstoke, 
Hampshire).
• Glacial acetic acid (analytical grade), methanol (analytical grade), potassium bromide (KBr- 
analytical grade), sodium bromide (NaBr- analytical grade), sodium chloride (NaCl- analytical 
grade) and sucrose were supplied by Fisons Pharmaceuticals (Loughborough, Leicestershire).
• Agarose ni-A, Coomassie blue, di-sodium ethylenediamine-tetraectic acid (EDTA), N-[2- 
Hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid]) (Hepes) and electrophoresis gel loading 
solution were supplied by Sigma (Poole, Dorset).
DISPOSABLES
• 16 X 76 mm ultra-clear tubes of 13.5 ml capacity (70Ti rotor) and 14 x 95 mm ultra-clear 
ultracentrifuge tubes (40Ti rotor) were supplied by Beckman (High Wycombe, Bucks.).
ANALYTICAL EQUIPMENT
• Columns PDIO were supplied by Amersham Pharmacia Biotech (Little Chalfont, Bucks).
• Centricom 50 (50,000 MW cut off) concentrators were supplied by Amicon (Beverley, USA).
• Power pack was supplied by Bio-Rad (Hemel Hempstead, Hertfordshire).
• 150 mm wide horizontal electrophoresis tank was supplied by Flowgen (Lichfield, 
Staffordshire)
• Flat-bed electrophoresis tank was supplied by Medical and Biological Institute Ltd (Ashford, 
Kent)
■ Preformed Sebia hydragel lipo-Lp(a) agarose gels (pH 8.8) were supplied by Sebia (Issy-les- 
Moulineaux, France)
FOODS
• Fortisip nutrition drinks (6 g of protein, 5.8 g of fat of which 0.6 g were saturated fat, 4.7g of
• sugar per 100 ml, 6.3 kJ/ml) were supplied by Nutricia (Trowbridge, Wiltshire).
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3.5  M e t h o d  d e v e l o p m e n t
An unpublished procedure devised by Graham (unpublished) formed the basis for the 
development of the iodixanol gradient method. This method isolated VLDL between 1.015 - 
1.040 g/ml, i.e. higher than the expected hydrated density interval for VLDL of 0.95 - 1.06 g/ml, 
Graham (unpublished) used a Beckman SW 55Ti rotor holding only 5 ml total volume. This 
procedure had to be reproduced using the technology available at the University of Surrey, 
namely the SW 40Ti rotor, consisting of 13 ml of total volume. The method of Graham 
(unpublished) described two runs; a preparatory spin using 0.5 ml of saline overlaying 3 ml of 
plasma, centrifuged at 6.07 x lO^g.min for 20 min at 16°C, and a run of 16 h at 16°C to form the 
actual gradient, consisting of a 0-6 % (w/v) iodixanol 0.8 % (w/v) NaCl in 60 mM HBPES- 
buffered saline solution, pH 7.4, to which 1 ml of CM-free plasma, adjusted to a 10 % (w/v) 
iodixanol plasma solution, was added. The gradient was then centrifuged at 1.04 x lO^g.min for 
1 hr 10 min, at 16°C. In addition, the run time needed adjustment to ensure the accumulation of 
adequate ‘g’-force, and an increase in gradient volume to correspond with the greater tube 
volume in the SW40Ti tubes.
3.5.1 Conversion of existing methods run time and rotor specifications to a SW40Ti rotor
Firstly, this included the calculation of the relative centrifugal force and cumulative ‘g’-force of 
the two combined runs in the method used by Graham (unpublished) on the SW55Ti rotor. Then 
the run time for the SW40Ti was adjusted to obtain the equivalent g-force on the SW55 Ti rotor. 
This was achieved as follows: Graham (unpublished) used a pre-run at 50,000 rpm for 20 min 
and then a run of 55,000 rpm at 70 min in a SW55Ti rotor 108.5mm). This accumulated a 
cumulative g-force of 1.65 x 10^  g.min which corresponded on the SW 40Ti rotor (r^ g^  of 158.8 
mm) to 1 hr 16 min at 35,000 rpm (for calculations see Appendix 1). While Graham 
(unpublished) used a run of 16 h at 16°C to preform his gradient, in the present study a gradient 
pourer was employed in an attempt to exclude the need for this step and reduce 
ultracentrifugation run time. A preliminary test run was undertaken to see that the gradient 
pourer was functioning correctly. This ‘dummy-run’ involved adding 3-4 drops of bromophenol 
blue to a 6 % (w/V) sucrose - 0.8 % (w/v) NaCl in 60 mM HEPES solution, based on the principle 
that the darker the visible blue dye the greater the concentration of sucrose, providing a visual 
check on gradient formation. The gradient pourer functioned smoothly without disturbance to 
the gradient.
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3.5.2 Validation of fractionation method; downward versus upward-displacement
3.5.2.1 Methods
Two methods were evaluated for the fractionation of the gradient. Firstly, the gradient was 
upwardly displaced through the tube with a dense solution (method 1), and secondly by 
puncturing the base of the tube and dispensing the gradient fractions by gravity (method 2), as 
used by Graham (unpublished). For each method, two subjects (one with high and one with low 
fasting plasma TAG) were run six times, fractionated into 4 pools (for further pool details please 
refer to Section 3.7.2), and analysed for TAG using the Cobas Mira plus autoanalyser. 
Coefficients of variance (CV) and percentage recoveries were calculated for each method, and a 
two-way repeated measures ANOVA was used to see if pool-TAG values differed between the 
two methods for the two subjects.
3.5.2.2 Results
Table 5 illustrates the CV and percentage recoveries for each pool on each method. There was 
no significant difference between the two methods. Method 1 had a higher percentage recovery 
and lower CV than method 2, for both the low TAG subject 1 (fasting TAG <1.5 mmol/1) and 
the high TAG subject 2 (fasting TAG >1.5 mmol/1). This procedure differed from the method 
used by Graham (unpublished) who fractionated the gradient using method 2.
Table 5: Fractionation method CV and percentage recoveiy, results are expressed as mmol/1 of TAG corrected to 
plasma
Subject Subject 1 - TAG (1.1 mmol/1) Subject 2 -TAG (1.7 mmol/1)
Fractionation ‘Up’- ‘down’-displacement ‘Up’- ‘down’-displacement
method displacement Method 2 CV displacement Method 2 CV
Metliod 1 CV Method 1 CV
Pool 1 12.24 9.16 7.66 24.40
Pool 2 14.59 17.64 6.39 9.80
Pool 3 1.01 7.07 3.43 25.20
Pool 4 18.65 22.71 14.39 14.29
% Recovery 68 66 97 77
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3.5.3 Validation of fractionation number and volume
Validation of the fraction number and volume was undertaken to maximise resolution and 
minimise costs when fractionating by upward displacement, in the 12 ml gradient. The last 3 ml 
in the bottom of the tube were found to contain predominantly albumin and therefore were 
excluded. The upper 9 mis were fractionated into 90 x 100 pi fractions or 60 x 150 pi fractions. 
The latter was found to produce an adequate resolution of the lipoprotein profile and reduced the 
cost of kits for analysis of analytes.
3.5.4 Study to assess the effects of iodixanol on the measurement of TAG and protein
3.5.4.1 Methods
To validate the use of iodixanol as a substance for the isolation of TGRL it was essential to 
determine its chemical stability in assays for the measurement of TAG and total protein. Plasma 
from a single subject was diluted 1:1 with water, 0.8 % (w/v) NaCl in 60 mM HEPES and 10 % 
(w/p) iodixanol (the maximum concentration of iodixanol used within the gradient) to test 
whether iodixanol interfered with the TAG assay (see Section 2.2.1), n = 6. An identical 
procedure was carried out for the total protein assay, n = 6. Data was analysed using a non- 
parametric unpaired Mann Whitney test, taking (p<0.05) as the level of significance.
3.5.4.2 Results
At a concentration of 10 % iodixanol produced no significant effects on either the measurement 
of TAG or protein, (Table 6). This was in accord with the findings of Graham et a l 1996 and 
Rickwood (1983).
Table 6: Comparison of 1:1 plasma and H^ O with 1:1 plasma and HEPES or 10 % (w/v) iodixanol
Solution ( compared to 1:1 plasma + H^ O) TAG {p value) Total protein {p value)
1:1 plasma + Hepes 0.42 0.06
1:1 plasma + 10 % (w/v) iodixanol 0.99 0.05
3.5.5 Optimisation of gradient reagent volume
Graham (unpublished) employed a ratio of plasma to iodixanol of 1:3, in a total tube volume of 5 
ml (SW 55Ti). The present method used 13 ml (SW 40Ti) tubes, using the same 1:3 ratio 
applied 3 ml of 10 % (w/v) iodixanol plasma solution and 9 ml of 6 % (w/v) iodixanol and 0.8 %
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(w/v) NaCl in 60 mM HEPES solution which was found to provide the most satisfactory 
separation of components.
3.5.6 Validation of correct density of iodixanol - plasma solution - 10 % fw/vl vs. 15 % 
(yy/v)
3.5.6.1 Methods
Davies and Graham (1997) used a 15 % (w/v) iodixanol - plasma solution for the isolation of 
TGRL, in contrast to later work by Graham (unpublished) who used a 10 % (w/v) iodixanol - 
plasma solution. It was necessary to determine the optimum separation of TGRL in a 
preliminary run time of 1 hr. Densities of 10 % (w/v) and 15 % (w/v) iodixanol-plasma were run 
in parallel, fractionated into 60 x 150 pi fractions and analysed for TAG. To determine the 
density range for both the 10 % (w/v) and 15 % (w/v) iodixanol - plasma solutions and a blank 
gradient was run (1.006 g/ml KBr solution substituted for plasma) for each. These were 
fractionated into 1 ml fractions and the density was measured (g/ml) using a digital density meter 
- DMA 35 (PAAR Scientific Ltd, (Raynes Park, London). The proportion of plasma TAG 
recovered in the gradient was analysed by calculating the AUC under each profile.
3.5.6.2 Results
The 10 % (w/v) iodixanol - plasma solution recovered relatively more TGRL-TAG, AUC 51.56 
110 pi fraction.mmol.r^ compared to 44.70 110 pl.mmol.U, on the 15 % gradient (Figure 14). 
In addition the 10 % (w/v) iodixanol - plasma solution (1.07 g/ml vs. 1.09 g/ml) recovered 
fractions of a lower density than the 15 % (w/v) iodixanol - plasma solution.
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Figure 14: The isolation of TGRL-TAG using 10 % (wA>) and 15 % (wA>) iodixanol-plasma solutions. Graph A 
shows TGRL-TAG profiles and graph B density profiles. 10 % (wA) iodixanol-plasma solution is represented by
O  and 15 % (wA) iodixanol-plasma solution by H ,  results are expressed as mmol/1 of TAG corrected to plasma.
3.5.7 * Optimisation’ of run time
3.5.7.1 Methods
Run times of 1 hr 16 min and 2 hr at 35,000 rpm were tested to establish which run time 
produced the best resolution of TGRL. The gradients were fractionated into 60 x 150 pi 
fractions and analysed for TAG as before. For each run time, a blank gradient was included
61
(1.006 g/ml KBr solution substituted for plasma) to determine the density range on 12 x 1 ml 
fractions. The AUC was measured for both run times.
3.S.7.2 Results
The 1 hr 16 min run provided a wider density range than the longer run time of 2 hr. The ranges 
were from 1.012 to 1.055 g/ml and from 1.016 to 1.045 g/ml for the 1 hr 16 min and 2 hr 
respectively. AUC values for TAG were 46.41 min.mmol.l'^ for 1 hr 16 min and 41.76 
min.mmol.l \  for 2 hr respectively, as shown in Figure 15.
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Figure 15: The isolation of TGRL-TAG at 35,000 ipm for 1 h 16 min and 2 h. Graph A shows VLDL-TAG 
profiles and graph B density profiles. 1 hr 16 min nm time is represented by CH and 2 hr run time is represented 
by H ,  results were expressed as mmol/1 of TAG corrected to plasma.
3.6 The iodixanol self-forming gradient
3.6.1 Method
Stock solutions
60 %  {w/v)  i o d i x a n o l
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0.8 % (w/v) NaCl in 60 mM HEPES-NaOH, pH 7.4 (buffered saline) solution 
Density solutions
• 6 % (v/v) lodixanol in 0.8% (w/v) NaCl, 60 mM HEPES-NaOH, pH 7.4 (buffered saline) 
gradient solution
• 10 % (v/v) lodixanol in plasma solution
Prior to underlaying the plasma on the iodixanol gradient, it was pre-centrifuged at 10,000 rpm 
for 30 min at 4°C (2.75 x 10^  g.min) to remove CM. The pre-centrifuged plasma (2.5 ml) density 
was then adjusted to 10 % (v/v) iodixanol solution by the addition of 60 % iodixanol (0.5 ml), 
mixed and placed at the base of Beckman 14 x 95 mm ultra-clear ultracentrifugation tubes (40Ti 
rotor). The HEPES-buffered saline (13.5 ml) was then placed in the left compartment of the 
gradient-forming column and the 6 % (v/v) iodixanol solution (13.5 ml) in the right side 
compartment of the gradient column to achieve an overlaying of the 10 % (w/v) plasma (Figure 
16).
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Gradient pourer
Figure 16; The iodixanol self-forming gradient. A = Separation tap; B = flea
Once the solutions were placed into the column a Pasteur pipette was used to remove any air 
bubbles blocking the flow of solution between the separate columns. The iodixanol stirrer (B) 
was switched on, the column tap (A) was opened, and the peristaltic pump (Walton & Marlow, 
Falmouth, Cornwall) transferred liquid at 9 rpm (0.5 ml per second) into three SW40ti rotor 
tubes for each run.
The gradient was then centrifuged in a Beckman SW40Ti rotor at 35,000 rpm, for 76 min at 16
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°C (1.65 X 10^g.min) in an Optima XL 100 centrifuge [acceleration program 7 (170 rpm in 4 min) 
and decelerated without a brake].
3.6.2 Gradient fractionation
Once ultracentrifugation was completed, each tube was placed in a Beckman fraction recovery 
system, (Figure 17). The tubes were pierced by a needle attached to an infusion pump and the 
gradient upwardly displaced by a dense hydrophobic fluid (peroflurodecalin density 1.908 g/L). 
The eluate was fractionated, and collected and analysed for TAG.
POOL 1-4
‘Ught’-VLDL (3 )
dense-VLDL ( 4 )
Fraction collector
Infusion pump
Fraction Recovery System
Figure 17: The Beckman fraction recovery system.
3.7 V a l id a t io n  o f  t g r l  io d ix a n o l  g r a d ie n t
3.7.1 Co-isolation of VLDL subclasses prepared bv cumulative flotation on the iodixanol 
gradient for validation of TGRL distribution
A discontinuous density gradient was prepared by the sequential layering of solutions of 
successively lower densities, thus allowing lipoprotein fractions of differing hydrated densities to 
be isolated by sequential flotation (Lindgren et ai, 1971).
TGRL from both fasting (n = 10) and postprandial samples (n = 3) were used for this validation 
procedure. For the postprandial samples, subjects fasted overnight, then from 9.00 am consumed 
a Fortisip drink (1 ml/kg body weight) every hour, for 4 hr. Blood samples (10 ml) were taken at
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time 0 (30 min prior to their first drink) and postprandially at time 4 hr (30 min after their fourth 
and final drink). TGRL lipoproteins were fractionated at each time-point and analysed for TAG.
3.7.1.1 Discontinuous density gradient (Mackness and Durrington. 19921
For each subject, (tubes x 6), 2 ml of fresh plasma was adjusted to a density of 1.118 g/L by 
adding 0.341 g of NaCl solution (for calculation see Appendix II), mixed for 30 min, and placed 
in the following gradient, (Figure 18).
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Figure 18: Discontinuoiis density gradient (Mackness and Durrington, 1992)
The gradient was centrifuged at 39,000 rpm for 1 hr 26 min [2.32 x 10^  g.min (run time 
modified from original method, due to differences in rotor and run-down time of each 
ultracentrifuge, see Appendix III for calculations)] at 23°C. An aliquot (1 ml), containing ‘light’- 
VLDL (Sf > 60) was aspirated from the top of the tube isolated by cumulative flotation. The 
gradient was then over-layered with 1 ml of density {d) Na Br salt solution d  = 1.058 g/ml. The 
rotor buckets were then recentrifuged at 18,500 rpm for a further 15 hr 32 min (5.62 x 10^  g.min) 
at 23°C. After this period, a 0.5 ml aliquot containing ‘heavy’-VLDL (Sf 20-60) was aspirated 
from the top of the tube.
These fractions (VLDL, and VLDL^ ) together with unmodified plasma (2.5 ml of each) were 
then applied to separate iodixanol gradients. On completion, each gradient was fractionated and 
analysed for TAG using the COBAS Mira Plus. The resulting profiles were compared, by 
overlaying the profiles to determine the range of 4 pools, (Figure 21). Fractions were collected 
along the gradient (1 ml), and superimposed on the total TAG-profiles.
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3 .7 .1 .2  R esu lts
Examples of TGRL profiles including ‘light’-VLDL and ‘dense’-VLDL from a male with raised
fasting serum TAG (1.65 mmol/1) - (subject A) and a female with relatively low serum fasting 
TAG (1.10 mmol/1) - (subject B) are shown in Figures 19 and 20.
67
(Subject A - high TAG )
0.35 -,
0.3 -
0.25 -
0.2
0.05 -
CMO o CO 00 s s o§o
Density (g/ml)
(Subject B - low TAG)
0.3 ^
0.25 -
g
0.05 -
CM CD CO COO O)CO inoCM
Density (g/mi)
Figure 19: Pre-prandial TAG profiles of ‘dense’-VLDLj and Tight’-VLDL, (prepared by cumulative flotation) co­
isolated with TGRL from plasma TAG on the TGRL iodixanol gradient. Subject ( A ) - high TAG and subject ( B 
) - low TAG. The TGRL from plasma is represented by H , the ‘light’-VLDLby I  and the ‘dense’-VLDL by H .
The postprandial ‘dense’-VLDL and ‘light’-VLDL isolations (Figure 20), show greater variation 
in VLDL postprandially between low and high TAG subjects compared to fasting values. 
Subject A (high fasting TAG), compared to Subject B (low fasting TAG), had a distinct increase 
in ‘light’-VLDL whereas subject B had a distinct increase in ‘dense’-VLDL.
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Figure 20: Postprandial TAG profiles of ‘dense’-VLDLjand Tight’-VLDLi (prepared by cumulative flotation) co­
isolated with plasma TAG on the TGRL iodixanol gradient. Subjects (A ) - high TAG and subject ( B ) - low 
TAG. The plasma profile is showi by H, the ‘light’-VLDLby I and the ‘dense’-VLDL by B.
3.7.2 Inter- and intra-assav coefficients of variation (CV)
3.7.2.1 Methods
A greater separation of ‘dense’-VLDL and ‘light’-VLDL was obtained in pre-prandial samples 
(fasting), which was used to subdivide the total TGRL profile into 4 pools (based on the isolation
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of ‘light’-TGRL, CM and CM-R, light'-VLDL and ‘dense’-VLDL). Once the pool ranges were 
delineated, method reproducibility was determined by calculating the inter and intra-assay CVs 
on three different subjects (each subject x 6 gradients, on two rotors on separate days), as shown 
in tables 9 and 10. Each gradient was fractionated into 60 x 150 pi fractions and assayed for 
TAG, as before.
3.7.2.2 Results
Figure 21 illustrates how the four pool ranges were delineated, by 4 division marked I - IV, in 
subject A.
( Subject A )
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Figure 21: Sub-division of plasma total TGRL profiles into pools based on the comparison of the pre-prandial 
pattern of VLDL, and VLDLj isolated by cumulative flotation and fasting plasma total TGRL-TAG profile on the 
TGRL iodixanol gradient. Plasma total TGRL-TAG profile is represented by I, the Tight’-VLDL by H and the 
‘dense’-VLDL by I.
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Delineation of TGRL pools
The exact positioning of each cut-off point (I-IV), as illustrated in Figure 21 was determined by
the following criteria:
1. The relative distribution of light and dense VLDL fractions, prepared by cumulative flotation 
with respect to plasma TGRL on the iodixanol gradient. The intersection of the TAG profiles 
for VLDLi and VLDL^ (Point HI) marks the division between pools 3 and 4.
2. To ensure adequate enrichment of each pool (measured through TAG or protein) whilst 
minimising carry over between pools, as illustrated in Table 7.
Table 7: Properties and delineation of the 4 pools, separation of Ti^it’ VLDL from ‘dense’ VLDL’
Pool Density Sf value Fraction No.
Pool 1: CM/CM-Ri 1.012-1.0135 >400 1-5
Pool 2: CM-R2 1.0135-1.017 <400 6-19
Pool 3: ‘light’ VLDL 1.017-1.025 20-400 20-35
Pool 4: ‘dense’ VLDL 1.025 - 1.035 0-20 36-55
Description of TGRL pools 1-4
Pool 1: A distinct peak in nearly all subjects which increased significantly in postprandial 
plasma. This finding, together with the ‘S/ and density values calculated from the cumulative 
and iodixanol gradients (Table 8), suggests that this pool consists mainly of lighter and larger 
TGRL particles of intestinal origin i.e. CM and CM-R.
Pool 2: This pool does not provide a distinct peak, but functions as an intermediate pool, which 
serves to separate pools 1 and 3, and in different individuals is therefore likely to contain TGRL 
from both of these pools, both Tight’-TGRL and Tight’-VLDL.
Pool 3; This pool corresponds in density to the larger, Tighter’-VLDL believed to contain 
VLDLi type particles isolated by cumulative flotation.
Pool 4: This pool corresponds in density to the smaller, ‘denser’-VLDL believed to contain 
VLDLg type particles isolated by cumulative flotation.
It is important to note that since CMRs express a wide range of particle sizes and densities, it is 
likely that small numbers of these particles extend into pools 3 and 4, in variable concentrations. 
Only further analysis in the form of gel electrophoresis would confirm that these pools did not 
contain LDL.
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Table 8 represents ten fasted subjects’ plasmas performance on the TGRL iodixanol gradient. 
The location of the four divisions I-IV was identified visually along each TGRL profile as shown 
in Figure 21.
Table 8: Fraction numbers indicating how TGRL pools were derived, n = 10 (SD = standard deviation, CV = 
coefficient of variation).
1 Subject C M - R i C M - R 2 Tight-VLDL ‘dense’-VLDL j
1 (I division) (n  division) (m  division) (TV division) I
1^ 8 21 38 55 1
1 B 6 18 35 55 I
1 ^ 3 13 39 52 1I d 2 15 38 55 1
1 E 4 22 32 56 1
1 F 6 21 35 60 1
r 6 17 35 50 11H 7 21 36 57 1l l 7 22 35 55
i 5 19 38 57 11 Average 5.40 18.90 36.40 55.20 11 SD 1.90 3.11 2.17 2.74 1
l e v 35.13 16.44 5.96 4.96 I
Subject inter-assay variation is displayed in Table 9 and intra-assay variation in Table 10 (for raw 
data see Appendix VI)
Subject 1 produced the lowest pool inter-assay CV range, from 13.51 % for pool 1 to 3.70 % for 
pool 3, whilst subject 3 produced the highest inter-assay CV range from 31.11 % for pool 1 and 
13.88 % for pool 4. For all three subjects pool 1 gave the greatest pool inter-assay CV and pools 
3 and 4 the lowest inter-assay CV. A similar pattern was evident for pool intra-assay CVs, with 
pool 1 showing the highest intra-assay CV of the three subjects and the lowest intra-assay CVs 
found in pools 3 and 4. When the subjects’ fasting plasma TAGs are considered, subject 1, the 
subject with the lowest pool CVs had the highest fasting plasma TAG of 2.36 mmol/1. Whilst 
subject 3 the subject with highest pool CV had the lowest fasting plasma TAG of 1.06 mmol/1. 
Subject 2 had CVs and a fasting TAG of 1.60 mmol/1, midway between the two other subjects.
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3.7.3 Validation of the TGRL fractions isolated bv the iodixanol self-forming gradient using 
agarose gel electrophoresis
Plasma lipoproteins show distinctly different electrophoretic mobilities on agarose gel and can 
therefore be separated and characterised on this basis. Agarose gel electrophoresis was 
undertaken to provide evidence to demonstrate the nature of the TGRL in each pool, specifically 
the homogeneity of pool 1, 3 and 4 with respect to CM/CM-R and VLDL respectively. Two 
approaches were undertaken, firstly using gel prepared in the lab based on the method of Sparks 
and Phillips (1992) but which used an increased agarose concentration of 1 % {w/v) to increase 
gel strength. The second method (2) used preformed agarose gels to validate the isolation of 
VLDL from LDL.
3.7.3.1.1 Method (11 
Pre-gel preparation:
Lipoproteins; VLDL, LDL, HDL and TGRL-pools to be applied to gels were isolated by 
preparative and iodixanol gradient ultracentrifugation respectively. VLDL^ and VLDL^ were 
isolated using the method described in Section 3.7.1. LDL was isolated after a further two spins, 
the first spin (39,000 rpm, 2 h 12 min, 23°C or 3.57 x 10^  g.min) isolating IDL followed by a 
(30,000 rpm, 2 hr 4 min, 23®C or 1.9 x 10^  g.min) to isolate the LDL. HDL was isolated using 
the method described by Chow-Wein (1996). These lipoprotein fractions required concentration 
before electrophoresis. This was achieved by ultrafiltration of the sample solutions through an 
anisotrophic membrane using centricom concentrators (Beverly, USA). Centrifugal force drives 
solvents and low molecular weight solutes through the membranes into the filtrate vial. Retained 
macrosolutes remain above the membrane inside the sample reservoir. The samples were 
recovered by inverting the concentrator then centrifuging briefly, minimising sample losses to the 
membrane and the reservoir.
Agarose preparation:
1 % {w/v) agarose gel in distilled water
Procedure:
1.5 g analytical grade agarose, 5 g sucrose, 0.035 ml di-sodium EDTA were added to 150 ml of 
distilled water, dissolved to a transparent solution by heating, on a medium setting in a 
microwave oven for approximately 2 min.
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Solutions for agarose gel:
Working solutions:
Reagents:
loading dye, buffer, stain and destain.
Barbitone buffer:
0.5 M barbitone solution containing 0.35 g/1 di-sodium EDTA at pH 8.6 .
Coomassie stain:
0.125 % (w/v) Coomassie blue R250, made up a 100 ml solution of methanol : distilled water : 
glacial acetic acid: 5:4:1 (v/v/v)
Destain:
methanol : acetic acid : water: 35:25:40 (v/v/v)
Procedure:
The 1 % (w/v) agarose gel was submerged in 0.5 M barbitone buffer. 10 pi of concentrated 
sample with 5 pi of loading dye was loaded into each gel well. A Bio-Rad power supply was 
used to apply a voltage of 100 volts across the gel for 2 hr with 0.5 M barbitone running buffer in 
a 150 mm wide horizontal electrophoresis tank. The gel was then stained for 30 min with 
Coomassie blue stain, followed by destaining for a maximum of 24 hr or until the lipoprotein 
bands were visible. Migration distances were calculated from a photograph using a Imagemaster 
YDS gel documentation system (Pharmacia Biotech, Little Chalfont, Bucks.). The measurement 
specifications used to capture the gel image are listed in Table 11. Once the gel image was 
converted to a ‘.tif file the image could be accessed by the ‘LIPCAP capture application’ 
(Pharmacia Biotech) which enabled manipulation of data to produce gel profiles.
Concentrated samples of VLDLj, YLDL^, LDL and HDLg, from frozen aliquots were run 
adjacent to fresh pools 3 and 4, (whilst pools 1 and 2 (CM-R) remained at the origin) from a high 
TAG subject (4.47 mmol/1) on the gel.
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Table 11: Standard setting for the Imagemaster visual documentation system
Settings Level
Focal length 12 (mm)
Aperture 4 (f.stops)
Focus 2 (m)
Time 1/1000 sec
Gain 2
Brightness level 5
r 0.45
3.7.3.12. Results
The gel separated LDL, VLDL^, VLDL^ and HDL^ according to the electrophoretic classification 
of; p, pre-p and a  electrophoretic positions respectively. VLDL^ migrated further than VLDL^ 
as also found by Sparks and Phillips (1992). However, the isolated native lipoproteins could 
only be qualitatively compared to VLDLj and VLDL^, in terms of their quality, because the 
native lipoproteins were isolated from a different subject to VLDLj and VLDL^. The native 
lipoproteins were from a frozen plasma pool of 3 subjects, whereas VLDL^ and VLDL^ were 
from a subject with a high TAG value of 4.47 mmol/1. In addition, it was evident from the gel 
scans that one subject had p-VLDL (Dallongeville et al, 1991). This consists of atherogenic 
cholesterol rich CM and VLDL-remnants that accumulate in the plasma of Type III 
hyperlipoproteinaemic subjects, as shown in Figuie 22 and 23.
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mm#
VI V2 LDL HDL2 P3 P4
Figure 22: Gel scan comparing VLDL, and VLDL; isolated by cumulative flotation conçared to pool 3 
and 4 isolated by the TGRL-iodixanol gradient. VI = VLDL, (lane 2), V2 = VLDL; (lane 3), P3 = 
Tight’-VLDL (lane 8 ), P4 = ‘dense’-VLDL (lane 9), LDL (lane 5), and HDL; (lane 10).
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Figure 23 : Lipoprotein profiles of scanned lanes. ( A ) Pool 3 (‘dense’-VLDL ) and 4 (‘light’-VLDL ) profiles ( B 
) VLDL„ VLDLj, LDL and HDLj profiles. VI = VLDL„ V2 = VLDL,
3.7.3.2.1 Method (2)
Method 2 involved the fractionation of an iodixanol gradient, (method described in Section 3 .6) 
into 0.5 ml X 21 fractions which were analysed for TAG, total cholesterol, total protein on an 0.8 
% (w/v) agarose gel, together with one sample of fresh plasma
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Agarose gel
0.8 g/dl agarose in alkaline buffer pH 8.8 + 0.1
Solutions:
Reagents: 
stain, destain.
Tris-harhital buffer:
75 ml distilled water containing 1.84 g/ml barbital, 7.2 g/ml Tris, Sodium barbital 10.3 g/ml and 
0.1 g/ml sodium azide pH 9.2 + 0.3.
Sudan black stain:
2 ml of Sudan black stock solution (6.6 g/dL in dimethylformamide) was added to 160 ml of pure 
ethanol and 140 ml of distilled water.
Destain:
Ethanol : water; 45:55 (v/v)
Procedure:
The 0.8 % (w/v) agarose gel was placed on top of blotting paper strips in a flat bed 
electrophoresis tank. The blotting paper acted as ‘wicks’ enabling the transfer of current across 
the gel from the two reservoirs of buffer at either end of the gel, on a flat bed electrophoresis 
tank. A sample template was aligned on top of the gel and 2 |.il of concentrated sample was 
added to each well, and allowed to diffuse for 5 minutes before reapplying another 2 |il of 
sample. A voltage of 50 volts was applied (27 mA per gel), for 75 min, the apparatus cooled by 
circulating cold water. The gels were dried in an oven at 80‘’C for 35 min, then stained for 15 
min with Sudan black, followed by destaining for 5 min. Migration distances were analysed by 
using the Imagemaster VDS gel documentation system (Pharmacia Biotech, Little Chalfont, 
Bucks.) as previously described in Section 3.7.3.1.1. Coefficients of variation for this technique 
were provided by Sebia. The inter-assay CV values for VLDL (n = 8) was 8-4 % over a range in 
plasma TAG values of 0.57 - 5.5 mmol/1, whilst the intra-assay CV values for plasma TAG 
values of 2.48 and 1.66 mmol/1 for VLDL of 4.16-1.73 %.
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3.7.3.2.2. Results
The concentration of plasma TAG, total cholesterol and protein in individual fractions (500 |al 
each) from the iodixanol gradient are illustrated in Figure 24. Whilst gel photographs and scans 
of the fractionated gradient are illustrated in Figures 25 and 26 respectively. Examination of the 
lipid and protein profiles of the fractionated iodixanol gradient (Figure 24), revealed that TAG 
levels decreased, whilst total cholesterol and protein levels increased from fraction 15, at 
approximately the division between VLDL/ LDL, such an increase in total cholesterol, protein 
and decrease in TAG being characteristic of LDL. Further photographic evidence (Figure 25) 
showed the separation of Tight’-TGRL CM-R found in pools 1 and 2, (fractions 1-5), Tight’- 
VLDL found in pool 3 (fractions 6-10) and ‘dense’-VLDL found in pool 4 (fractions 11-14), 
from LDL and HDL found in >pool 4, (fraction 15-19) and total plasma profile (fasting TAG 
1.70 mmol/1) (fraction 20), percentage total plasma TAG recovery was found to be 95 %. When 
the differential migration distance was measured for the above 4 pools, LDL & HDL fraction and 
total plasma sample (Figures 26 and 27), TGRL; ‘light’-TGRL, CM-R (pools 1 and 2) had a 
migration distance from the origin of 215 mm, whilst ‘light’-VLDL (pool 3) and ‘dense’-VLDL 
(pool 4) had respective migration distances of 230 and 240 mm, (poorer separation in pool 3 due 
to a problem with this specific gel run). The example of a LDL & HDL fraction, fraction 17, not 
only demonstrated that the iodixanol gradient was accurately capturing all TGRL, since this 
fraction was void of any TGRL, and that pools 1-4 were free of smaller contaminating 
lipoproteins such as LDL and HDL are correctly being excluded from pools 1-4. Whilst Figure 
27 demonstrates the relative migration distances of VLDL, LDL and HDL relative to albumin.
79
( A )
0.16 X
0.14--
0.1 ■■
0.08 ■ -E
0.06 --
g ■ ■ ‘Ught’-TGRL 
0.02 • ■ CM-R CM-R ‘light’-VLDL ‘dense’- VLDL   ►
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
F r a c t i o n  (0 .5  m i)
(B )
1 -r
0.9 
0.8 - -  
0.7 -- 
0.6 - -  
0.5 
0.4 - 
0.3 - 
0.2 - -  
0.1 
0
U ^ t’ TGRL
CM-R CM-R '< X ----- ‘light’-VLDL ‘dense’- VLDL ---
rfr. t t r r f  1 T p
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
F r a c t i o n  (0 .5  m l)
( C )
18 y  
16 -- 
14 -- 
12  -  
10 
8 
6 
4 
2 
0
light’ TGRL
T CM-R CM-R 
<  ^ ‘light’-VLDL ‘dense’- VLDL   ►
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
F r a c t i o n  (0 .5  m l)
Figure 24: ( A ) Iodixanol TGRL profiles for TAG, ( B ) total cholesterol, and ( C ) total protein isolated into 21 
fractions, values are expressed as mmol/1 of TAG, corrected to plasma.
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Figure 26: Electrophoresis profiles of iodixanol gradient pools; Pool 1& 2 (‘very light-TGRL 
CM-R) ( A ), ( B ), Pool 3 (‘light’-VLDL) ( C ), Pool 4 (‘dense’-VLDL) and fraction 17 (LDL 
&HDL)
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Figure 27: Gel electrophoretic profile, fraction 20 total plasma
3.8 A d d it io n a l  m e t h o d  d e v e l o p m e n t
3.8.1 Percentage recovery of total plasma on the iodixanol gradient
3.8.1.1 Methods
Percentage recoveries of TGRL from total plasma TAG using the iodixanol gradient were 
calculated on both fasted and postprandial plasma samples by correcting each TAG fraction back 
to plasma (results are expressed as mmol/1 of TAG corrected to plasma), n = 14, (n = 6 NTG, n = 
8 HTG subjects), for further details see Appendix V.
3.8.1.2 Results
Percentage recoveries are illustrated in Figure 28, and show that a higher percentage recovery is 
found in fasting compared to postprandial samples at 360 min. It is likely that the percentage 
recovery was greater than 100 % due to the unequal distribution of TAG throughout the gradient, 
TAG favouring recovery in the larger lighter lipoprotein particles, at the top of the gradient.
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Figure 28: Percentage recoveries, results are expressed as mean + SD at 0 and 360 min after a fat-containing meal
3.8.2 Investigation into the requirement of an additional preparatory spin to remove the 
CM~rich fraction for the fractionation of postprandial samples
The technique of upward displacement was adversely affected by the adherence of lipid to 
surfaces and the inevitable carry-over of TAG to the lower fractions. Hence, to analyse 
postprandial samples it became necessary to carry out a preliminary CM spin to remove large 
CM. The preparatory CM spin involved overlaying 3 ml of plasma with 1 ml of saline, then 
centrifuging at 10,000 rpm, for 30 min at 4°C (2.75 x 10^  g.min). An example of the TAG 
profile on the iodixanol gradient, before and after a CM preparatory spin is shown below in 
Figure 29. No correction factor was implemented for this preparatory spin as the additional ‘g’- 
force was considered to be negligible relative to that incurred during the deceleration period. 
The AUC was calculated for both profiles and found to be 31.97 vs. 31.38 min.mmol.l'^ for 
plasma with and without the CM spin respectively.
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Figure 29: Effect of the preparatory CM spin on separation of TGRL from postprandial plasma. Plasma with a 
CM preliminary spin (10,000 rpm, 30 min 4 °C) is represented by, H  and plasma without a CM preliminary spin is 
represented by H , results are expressed as of mmol/1 of TAG corrected to plasma.
3.8.3 Effect of plasma storage (freezing at -20°C) on the TGRL iodixanol gradient 
performance
Whilst the instability of the TGRL, especially VLDL, during isolation by ultracentrifugation has 
been well documented (Zhao et al, 1995), the convenience of freezing samples enables a greater 
number of matched samples to be processed. Hence an investigation was undertaken to evaluate 
the effects of freezing (storage at -20/80°C) on the separation and composition of TGRL.
3.8.3.1 Methods
Blood samples (20 ml) were taken at the Royal Surrey County Hospital from 6 diabetic subjects 
with raised serum TAG values. Plasma was then either placed on the iodixanol gradient, for 
immediate separation or stored at -20°C for 4 weeks before being subfractionated on the 
iodixanol gradient. All gradients were fractionated into 60 x 150 pi fractions which were 
analysed for TAG, and then combined to give 4 pools (1-4). The concentration of TAG in each 
fraction and AUCs for both fresh and frozen plasma were calculated and the difference between 
the two tested by performing a paired Student’s t-test.
3.8.3.1 Results
The separation of TGRL from fresh plasma provided greater resolution and recovery of TAG in 
TGRL when compared to stored plasma. AUC and TGRL profiles are shown in Table 12 and 
Figure 30.
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Table 12: TGRL-TAG profile, fresh vs. frozen (stored at -20°C AUC and Student’s t-test (p values). Results are 
expressed as min.mmol. 1* of TAG corrected to plasma
Fresh (AUC) Frozen (AUC t-test ( p  value)
Average 24.93 19.63 p< 0.05
SD 15.75 8.88
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Figure 30: The effect of storage on the separation of the TGRL profile. A sample of fresh plasma was placed on 
the iodixanol gradient and compared with a sample that had been frozen at -20°C for 4 weeks. The separation of 
TGRL on the VLDL iodixanol gradient was measured by TAG profiles in subject ( D ). Fresh plasma is 
represented by H  and frozen plasma by H.
3.8.4 Effect of salt on the separation of TGRL from plasma on the TGRL iodixanol 
gradient
This experiment was undertaken to evaluate the effect of salt on the TGRL iodixanol gradient. 
Prior to placing the plasma into the iodixanol gradient, it was desalted using a Biotech Column 
PD-10 (containing Sephadex G-25).
3.8.4.1 Method
The first step was to equilibrate the column with buffer by passing through approximately 25 ml 
of HEPES buffer. Once the equilibration buffer had run through the column, 2.5 ml of sample 
plasma was applied. Once the plasma sample had run into the column, the column was then
8 6
flushed with 3 .5 ml of HEPES buffer, the eluate was then collected. The AUC was measured for 
both run times.
3.8.4.1 Results
AUC values for TAG were 33.47 and 34.08 min.mmol.1-1 for spins performed with and without 
removing salt respectively, as shown in Figure 31. This meant that the TORE iodixanol spin 
could be performed without removing salt.
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Figure 31: The isolation of plasma on the TGRL-iodixanol gradient of subject 1. Desalted plasma performance 
with salt is shown by H and without salt removal by I, results are expressed as of mmol/1 of TAG corrected to 
plasma.
3.9 Discussion
The main aim of this work was to set up a novel method for the isolation of TGRL, especially 
subclasses of VLDL, and validate its sensitivity and reproducibility. The investigation proved 
the iodixanol self-forming gradient to be a reproducible method which enabled the relatively easy 
and fast isolation of VLDL. Iodixanol was first used in gradient ultracentrifugation by Ford et 
al (1994), but it was not until three years later that the same authors used the iodixanol self- 
forming gradient in the isolation of VLDL (Davies and Graham, 1997) with a 15 % {w/v) 
iodixanol gradient. The present method was taken from a personal communication by Graham 
(unpublished) using a 10 % (w/v) self-forming iodixanol gradient.
Adaptation of iodixanol method
The initial 10 % (w/v) self-forming iodixanol gradient method of Graham (unpublished) was
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based on the use of a SW 55Ti rotor (4 ml gradient). The adaptation of this method to a SW40 
Ti rotor (12 ml gradient) involved validation of the following steps; the fractionation method 
itself, the volume and number of fractions, the volume of plasma and gradient, the percentage of 
iodixanol and spin time, and the potentially adverse effects of storage at -20 °C and salt and 
iodixanol on TAG and protein assays. An effective separation of TGRL was found using a 10 % 
(w/v) iodixanol gradient composed of 3 ml of 10 % (w/v) iodixanol-plasma (fresh<7 days) placed 
beneath a 9 ml graded 6-0 % (w/v) 0.8 % (w/v) NaCl in 60 mM HEPES solution.
Validation of method
Validation of this novel method for the separation of TGRL involved two methods; 
discontinuous density gradient ultracentrifugation and agarose gel electrophoresis. 
Discontinuous density gradient ultracentrifugation used the cumulative flotation of large, light 
VLDLi and smaller, denser VLDLg developed by Mackness and Durrington (1992). This was a 
new method used to characterise the TGRL separated on the iodixanol gradient. VLDL^ and 
VLDLg were isolated and then placed on the iodixanol gradient, ‘dense'-VLDL, ‘light’-VLDL’ 
and plasma fractions were analysed for TAG, the plots superimposed to compare relative cut-off 
points so that discrete pools could be collected along the gradient. This enabled the isolation of 
CM-Ri (pool 1), CM-Rg (pool 2), ‘light’-VLDL (pool 3) and ‘dense’-VLDL (pool 4). In the 10 
subjects analysed, pre-prandial separations were very good, giving distinct isolation into ‘dense’- 
VLDL and ‘light’-VLDL However, the TAG profile of postprandial samples were affected by a 
‘CM-smearing effect’ of TGRL, with CM-TAG samples being carried over into VLDL pools. 
This was largely removed when a preparatory CM spin was added removing large CM which 
would have otherwise been carried into the VLDL pools. In addition, further correspondence 
with John Graham revealed that a TLA 100.4 rotor (r^^ 48,5) had been used in the initial spin, 
Graham (unpublished). This indicated that the relative centrifugal force (RCF) was less than the 
cumulative g-force estimated in the present method, and that the present method had over­
estimated the spin time by 16 min. What this implies is that the present method isolated more 
VLDL (and possibly more LDL) than the Graham (unpublished) method, and that the VLDL had 
migrated further in the gradient. However evidence from agarose gel electrophoresis provided 
no support for this possibility.
The reproducibility of the iodixanol method was determined by calculating inter-assay and intra­
assay coefficients of variation (CV), achieved by the repeated isolation of TGRL-pools from 3
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subjects on two rotors ( n = 6 for each rotor). It was found that the highest reproducibility was 
found in subjects with a fasting plasma TAG level of >1.50 mmol/1 and the lowest 
reproducibility was found in the subjects with a fasting TAG of <1.50 mmol/1. The lowest 
reproducibility was found in pool 1, which was probably due to carry-over of CM, remaining 
from the preparatory CM spin. This was also a limitation of fractionating the gradient by upward 
displacement, losing pool 1-TAG as the lipid adheres to internal surfaces of the apparatus, 
leading to an underestimation of TAG in early fractions. Two of the three subjects (fasting 
plasma TAG of >1.50 mmol/1) produced the predictable differences between pools and a non­
significant difference between rotors.
The second method of validation, as used by Graham (unpublished), used agarose gel 
electrophoresis. Firstly, a 1 % (w/v) agarose gel was used to isolate native plasma lipoproteins 
LDL, ‘light’-VLDL ‘dense’-VLDL and HDLg were electrophoresed alongside TGRL pools 3 
and 4. Native VLDLi and pool 3 (‘light’-VLDL) had greater electrophoretic charges and thus 
migrated further than VLDLgand pool 4 (‘dense’-VLDL) these samples did not show differences 
in migration distance. This might be explained in part by native VLDLj and VLDL^ being 
isolated from the stored plasma of 3 individuals, whereas ‘dense’-VLDL and ‘light’-VLDL were 
taken from fresh plasma. In addition, a preformed 0.8 % (w/v) agarose gel was used to confirm 
that VLDL was being separated adequately from LDL as shown by Graham (unpublished).
Further method development
A significant drawback of the present method was the measurement of TAG as the means of 
generating a TGRL-profile, followed by the collection of TGRL pools 1-4. An alternative 
approach would be to pre-stain plasma with a protein dye, which could then be digitally 
photographed and analysed by means of purpose-built software. Other possible improvements to 
the existing method to increase reproducibility, include the use of a smaller centrifugation tube, 
thereby reducing the sedimentation path length of the gradient, and the incorporation of a 
commercially available gradient former. The measurement of apo B-48 in the TGRL pools 
would further differentiate lipoproteins of intestinal and hepatic origin respectively.
Conclusion
In conclusion, a reproducible method for the isolation of TGRL, and specifically VLDL, from 
fresh plasma has been developed. The iodixanol gradient has been shown to be specific for the
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isolation of VLDL both on fasting and postprandial plasma samples. The application of this 
gradient for the isolation of pools of CM and VLDL will provide important information on the 
effects of various dietary interventions on hepatic and intestinally derived lipoproteins. More 
specifically the provision of information on the TGRL is of relevance to the study of lipid 
disorders, and to the further characterisation of the ALP (Austin et al, 1990).
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CHAPTER 4:
THE ACUTE EFFECTS OF ETHANOL ON POSTPRANDIAL LIPAEMIA
4.1 I n t r o d u c t io n
The role of ethanol with respect to the health of the general public is paradoxical. A moderate 
consumption of ethanol is considered beneficial (Rimm et a l, 1996) to reduce the risk of 
coronary heart disease; by reducing plasma lipids (Porkka and Ehnholm, 1996), blood 
coagulation (Zakhari and Gordis, 1999), helping to avoid obesity (Poikolainen, 1995) and stress 
(Brick and Pohorecky, 1982). However, a high level of ethanol consumption is considered 
detrimental to health by increasing mortality through liver disease and cirrhosis (Vazquez-Del 
Mercado et a l, 1999), certain cancers of the oesophagus and the liver (lARC, 2000), and 
increased blood pressure (Stott et a l, 1987).
Relationship betfveen alcohol consumption and CHD mortality
A moderate consumption of ethanol is believed to be a protective factor in CHD whilst excess 
consumption is predictive of CHD. The literature presents conflicting ideas as to the relationship 
between ethanol consumption, total mortality and CHD mortality. Recent papers suggest that the 
relationship between ethanol consumption and total mortality is a J-shaped curve (Farchi et a l, 
1992; Cullen, 1993; Gronbaek et a l, 1994; Shaper and Wannamethee, 1998), whilst a U-shaped 
curve describes the relationship between ethanol consumption and CHD mortality (Boffetta and 
Garfinkel, 1990; Marmot and Brunner, 1991; Goldberg et a l, 1995; Constant, 1997; Manttari et 
a l, 1997; Kauhanen e/ûr/., 1999).
There is debate as to whether there is a ‘U- or ‘J-shaped’ relationship between ethanol 
consumption and CHD mortality. Both curves indicate that a moderate level of ethanol 
consumption reduces CHD risk. Whilst the former suggests that abstainers and high ethanol 
consumers have a greater risk of mortality, the latter suggests that those who consume a high 
level of ethanol have the greater risk of mortality over those who abstain. It has been proposed 
that studies which have produced a ‘U-shaped’ curve have incorrectly selected ex-drinkers or 
‘sick-quitters’ i.e. subjects with a past illness that has lead to abstinence from ethanol (Shaper et 
a l, 1988). Therefore as a group of ‘non-drinkers’ the relative risk will be artificially increased as 
found in the Kaiser-Permanente study (Klatsky et a l, 1989). There are also problems with the 
heaviest drinkers due to their inability to accurately record their ethanol intake or reluctance to
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take part in studies. Therefore in this group of ‘heavy drinkers’ relative risk will be artificially 
decreased (Boffetta and Garfinkel, 1990; Farchi e ta l, 1992; Shaper and Wannamethee, 1998).
Government guidelines
With regard to an acceptable moderate intake of ethanol consumption U.K. government 
guidelines as of December 1995, recommended a maximum consumption of 2 - 3 units of ethanol 
a day for women and a maximum of 3 - 4 units of ethanol a day for men, which over a week, 
avoiding binge drinking, adds up to no more than 14 - 21 units for women and 2 1 -2 8  units for 
men. With some 38 % of men and 21 % of women consuming more than the recommended daily 
benchmarks, that is more than 4 units on the heaviest drinking day of the week for men and more 
than 3 for women (Petersen et al, 2000). There is a great deal of variation in the meaning of a 
‘moderate’ ethanol consumption recommended in the literature with values from 1 to 6 g/d 
(Gronbæk et a l 1994); 11 to 29 ml/d (Ishimitsu et a l 1997); 10 to 20 g/d (Boffetta and Garfinkel 
1990; Rimm e ta l,  1999); 25 g/d (Kawashi et a l 1990); 30 g/d (Magaya et al 1999) to 50 g/d ( 
Dyer et a l, 1977; Miller et a l, 1990).
Binge versus weekday moderate drinkers
Apart from consuming a moderate dose of ethanol the duration of dose is also important. Most 
epidemiological studies have divided ethanol drinkers into regular weekday moderate drinkers 
and acute weekend binge drinkers. The evidence suggests a more favourable outcome in terms of 
reduced TAG, cholesterol, blood pressure (Puddey et al, 1999) and fewer artery occlusions 
(Gruchow et a l, 1982) for those drinkers who consumed a moderate level of ethanol 
consumption during the week as opposed to acute binge weekend drinkers (Mckee and Britton, 
1998; Rakic e ta l, 1998; Kauhanen e ta l, 1999).
Ethanol and atherosclerosis
One of the first reports of an effect of ethanol on the incidence of atherosclerosis, which showed 
fewer atherosclerotic lesions in autopsies of chronic alcoholic individuals was by Cabot (1904). 
Whilst an early study by Wilens (1947), into the effect of ethanol on atherosclerosis suggested 
that those with a chronically high consumption and a low incidence of atherosclerosis actually 
died at a young age, and as such, had a low frequency of diseases which predisposes to CHD such 
as diabetes. However, those that studied acute ethanol consumption noted a reduction in total 
cholesterol in the plasma (Epstein and Greenspan, 1996). Lieber et a l (1962) found a reduced 
level of free fatty acids after acute ethanol administration, in their study of peripheral free fatty 
acids venous-arterial difference across the forearm and leg after acute ethanol administration.
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This led to the idea that ethanol either reduced the release or increased the uptake of free fatty 
acids in peripheral tissues.
Criqui et a l (1987); Langer et a l (1992) suggested that up to 50 % of the impact of ethanol on 
health was due to the involvement of lipoproteins, however, exactly how ethanol confers this 
protection was not entirely clear. Ethanol is known to enhance postprandial lipaemia, a 
phenomenon that is a well known CHD risk factor (Zilversmit, 1979), with postprandial TAG 
being more indicative of CHD than fasting TAG (Patsch et a l, 1992).
Postprandial lipaemia and ethanol
Various investigations have examined the effects of altering meal frequency on lipid and 
carbohydrate metabolism in the fasting and postprandial state, some of which have included 
research into the acute and chronic effects of ethanol. Epidemiological data has generally shown 
that ethanol has additional effects to normal dietary metabolism in the moderate consumer 
(Camargo et a l, 1987), and when ethanol is consumed before, or with a meal, blood plasma 
becomes more lipaemic than with the ingestion of food alone. This therefore presents a paradox, 
since increased postprandial lipaemia is associated with an increased risk of CHD, yet there is a 
reduced risk of CHD associated with a moderate intake of ethanol. One of the first groups to 
record enhanced postprandial lipaemia after the acute administration of ethanol was Albrink and 
Klatskin (1957). Further studies, (Talbott and Keating, 1962; Nestel and Hirsch, 1965; Shapiro et 
al, 1965; Duthie, 1993; Hoffman and Gareval, 1995; Jialal and Dervaraj, 1996), have found 
similar findings of increased plasma TAG after ingestion of ethanol. Brewster et a l (1966) and 
later Barboriak and Meade (1968) investigated the effect of ethanol on serum TAG levels under 
more physiological conditions after the ingestion of a high-fat meal. They found the greatest 
increase in postprandial plasma TAG at 6 hours after consumption of the meal. Using a meal 
containing radiolabelled triolein-l-^'^C Barboriak and Meade (1968) postulated that the increase 
in postprandial TAG could be due to the faster absorption of dietary fat, delayed removal of 
absorbed dietary fat from the circulation, or to an increased production of endogenous TAG. 
Further support for the latter was provided by Bird et al (1997). Fewer studies have looked at 
the impact of ethanol on lipid metabolism in relation to the TGRL. Nestel and Hirsch (1965) 
showed that ethanol increases the synthesis of endogenous TAG (VLDL-TAG), a finding 
supported by others (Fredrickson et al, 1967;. Barona et al, 1973; Baraona and Lieber, 1979; 
Siler e ta l, 1998). Taskinen e ta l  (1985) found an increased hepatic production of VLDL-TAG 
in response to ethanol which was supported by other studies (Reboucas and Isselbacher, 1961;
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Goldberg et al, 1984; Fielding et al, 2000). The explanation for this was that ethanol increased 
estérification of accumulated fatty acids to TAG which exit the liver in VLDL particles (Fielding 
et a l, 2000). The increased synthesis of VLDL-TAG has been shown to be accompanied by a 
decreased oxidation of fatty acids in ethanol fed rat livers (Reboucas and Isselbacher, 1961) 
which may be an additional mechanism channelling fatty acids into this synthetic pathway. Not 
all studies have reported an increase in VLDL (Goldberg et a l, 1984) and other possible 
mechanisms include increased exogenous production (Mistiles and Ockner, 1972) and subnormal 
postheparin lipolytic activity (Losowsky et a l, 1963).
An increase in postprandial TAG subsequently leads to an increase in HDL, principally HDL-C 
through reverse cholesterol transport (Fraser et a l, 1983; Burr et a l, 1986; Andrade et al, 1990; 
Savolainen and Kesaniemi, 1995; Rimm et a l, 1996; Criqui and Golamb, 1998; Hendriks et al, 
1998; Van Toi et a l, 1998) which is beneficial to CHD risk (see Section 1.3.1.4). Raised HDL 
levels have been suggested to account for 50 % of the protective effect of ethanol by Van Toi et 
al (1998) and Taskinen e ta l  (1987). Some studies have isolated HDL subclasses and found that 
principally HDLz is increased after ethanol consumption (Zentella de pina et a l, 1991) or even 
that both HDLg and HDL3 increase postprandially after ethanol consumption (Hartung et a l, 
1983) or that the determination of the HDL subclass that is increased by ethanol is gender 
dependent (Valimaki et a l, 1993). A suggested explanation for this increase in HDL is due to a 
reduction in the transfer of TAG from the TGRL to HDL and LDL (Nishiwaki et a l, 1994). This 
view was further supported by research showing reduced CETP activity in response to ethanol 
ingestion which slowed down the transfer of TAG from the TGRL to the TAG-poor lipoproteins 
(TGPL) (Hannuksela et a l, 1992; Hannuksela et a l, 1992; Fumeron et a l, 1995; Hann et a l, 
1996; Liinamaa et a l, 1998), and increase in lecithin;cholesterol acyltransferase (LCAT) 
(Hendriks et a l, 1998). The impact of ethanol consumption after a fat-containing meal on the 
metabolism of non-esterified fatty acids (NEFA) is important with respect to the involvement of 
the latter in CHD risk (Frayn et a l, 1995). Ethanol has also been shown to reduce postprandial 
NEFA levels (Pownall, 1994). Changes in both NEFA and LPL activity together give an 
indication of the impact of ethanol on adipose tissue metabolism. Controversy exists on the 
effect of ethanol on LPL activity, some evidence suggests a reduction in LPL activity in adipose 
tissue (Pownall, 1994) and others an increase in LPL activity (Frohlich, 1996; Schneider et a l, 
1996). Ethanol has a more negative impact on insulin and glucose metabolism (McMonagle and 
Felig, 1975; Iturriaga e/ a/., 1986; Avogaro et a l, 1996; Christiansen et a l, 1996), and its effects
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on insulin resistance have been well documented (Shelmet e ta l, 1988; Liu et a l, 1998; Xu et a l, 
1998).
Ethanol has been shown to decrease LDL-C in the postprandial state (Hirano et a l, 1992; 
Nishiwaki et a l, 1994; Hein et al, 1996; Williams and Krauss, 1997; Van Toi et a l, 1998). The 
mechanism by which this occurs may involve the reduced conversion from VLDL to LDL 
resulting in accelerated catabolism LDL (Krauss, 1994). Ethanol favours the production of 
VLDL2 which produces large LDL whilst an increase in VLDLi produces the more atherogenic 
small dense LDL. Ethanol-induced changes in the concentration of microsomal transfer protein 
(MTP) have been implicated (Lin et a l, 1997). MTP is a major determinant of the assembly and 
secretion of apo B and has been shown to decrease in response to ethanol consumption.
Numerous studies have attempted to establish the protective effect of ethanol on CHD (Gey, 
1990). Other potentially protective effects of ethanol include actions on; haemostatic factors 
(Krobot e ta l, 1992; McConnell e ta l,  1997) such as reduced platelet aggregation (Renaud e ta l,  
1992), decreased fibrinogen levels and enhanced fibrinolytic activity (Pikaar e ta l, 1987) through 
the effects of reduced levels of PAI-1 (Meade et a l, 1979; Booyse et a l, 1999) and increased 
antioxidant status, otherwise known as the French paradox.
The French paradox
Many studies have investigated the French paradox, namely that the French, despite consuming a 
highrfat diet, smoking more cigarettes and exercising less than most Europeans or Americans, 
drink larger quantities of red wine and suffer 50 % fewer heart attacks than other European 
countries. One possible explanation for this difference lies in dietary antioxidants found in high 
concentrations in red wine. This is commonly known as the antioxidant hypothesis (Duthie, 
1993; Hoffman and Gareval, 1995; Jialal I and Dervaraj S, 1996). Wine and beer contain large 
amounts of polyphenolic compounds (Gorinstein et a l, 1998) especially flavonoids (Constant, 
1997; Nigdikar et al, 1998; Puddey et a l, 1999). Such antioxidants quench the action of free 
radicals, thereby reducing the oxidative damage to LDL (Rakic et a l, 1998). Flavonoids have 
also been shown to inhibit platelet aggregation (Van deWeil, 1998).
Despite the importance of TGRL levels in relation to CHD incidence, the effect of ethanol on the 
TGRL has received little attention. Few studies have been able to account for the relative 
importance of both intestinally derived apo B-48 and hepatically derived apo B-lOO lipoproteins.
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Problems in previous studies
Comparisons of studies on the effect of ethanol are confounded by considerable variation in study 
design. Variable factors include for example; acute or chronic ethanol administration, variation 
in units in which the ethanol was measured, the form in which the ethanol was administered, 
obtaining reliable ethanol consumption data (Marmot and Brunner, 1991), if food was given and 
the fat content of the food given, and the methods used to assess ethanol consumption, which all 
makes comparison between studies difficult.
4.2 A im s  o f  st u d y
Ethanol induces an increase in postprandial lipaemia. It is not clear as to whether this is due to an 
increase in the production of CM, or VLDL, or an effect on the clearance of both these particles. 
The aim of this study was to determine the origin of increased postprandial lipaemia after acute 
ethanol administration, and to provide information on the possible mechanisms involved in the 
postprandial lipaemic response to a meal by characterising TGRL. TGRL were separated by a 
self-forming gradient, CM levels were determined by measuring retinyl palmitate (RP) as a 
marker of CM, and apo B-48 levels in the TRL.
4.3 M a t e r ia l s
• The total lipase and hepatic lipase kits were supplied by Technoclone (Sevenoaks, Kent) a 
subsidiary of Progen (Heidelberg, Germany).
• UV-permeable acrylic cuvettes (2 ml) were supplied by Fisher (Loughborough, 
Leicestershire).
• Paracetomol (Panadol - 500 mg) was supplied by Smithkline Beecham (Brentford, 
Twickenham)
• Retinyl Palmitate (RP) was supplied by Roche products Ltd, (Welwyn Garden City, 
Hertfordshire).
EQUIPMENT
• Fluorometer:3000 fluorescence spectrometer was supplied by Perkin Elmer, Beaconsfield, 
Hemel Hempstead.
4.4 St u d y  P r o t o c o l
4.4.1 Subject recruitment
Eight healthy, male, non obese subjects were recruited from the University population, after
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receiving local research ethic committee approval. Subjects were rejected on the grounds of 
consuming more than 30 units of ethanol a week, cigarette smoking, having a BMI >30 kg/m^ 
and any condition known to affect glucose or lipid metabolism. The baseline of the 
characteristics of the subjects are shown in Table 13.
Table 13: Subject baseline characteristics
Subject (n = 8) Age (yr) BMI (kg W )
Mean + SD 32.8 + 12.8 22.3+2.8
Abbreviations: BMI: body mass index, SD: standard deviation
4.4.2 Study dav protocol
The investigation protocol was a single-blind, randomised cross-over design study. The subjects 
were asked to attend the University’s Clinical Investigation Unit (CIU), on two separate 
occasions, at 8 am after a 12 hour overnight fast. Subjects were asked to refrain from taking any 
aerobic exercise or drinking any ethanol the day before the study. On arrival at the unit, an 
indwelling cannulae was inserted into the forearm using lignocaine as a local anaesthetic and 0.9 
% (wty) NaCl saline solution was used to maintain the patency in the cannulae between blood 
collections. Two fasting blood samples (of 15 and 25 ml respectively) were taken at -10 and 0 
min.
4.4.3 Test meal
An oral fat tolerance test was undertaken by giving subjects a standard fat meal developed by the 
Nutrition Research Group at the University of Surrey which contained; 4382 kJ of energy: 51.1 g 
fat, 130.8 g CHO and 16.1 g protein. Just prior to consuming the test meal the subjects were 
given 3 x 0.5 mg of paracetamol. The test meal was freshly prepared and weighed out for each 
subject, and consisted of food items illustrated in Table 14. The subjects also received with the 
meal, either water (control) on one visit or ethanol (40 % w/v vodka) on the other visit. The 
ethanol was given on a body-weight basis (0.6 g/kg). Water-miscible RP was added to the orange 
juice (170,000 lU) as a marker of cholesteryl esters in chylomicrons. The subjects were allowed 
a 20 minute period to consume the meal, and were permitted decaffeinated drinks and water 
throughout the study.
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Table 14: Dietary composition of subject oral test meal
Food Quantity
orange juice 250 ml
full fat milk 120 g
double cream 75 g
strawberry jam 36 g
butter 10 g
white bread 135 g
Nesquick milkshake powder 15 g
4.4.4 Blood Sampling
In addition to the two fasting samples, 15 ml of blood was taken at 30, 60, 120, 180, 240, 300, 
420 and 480 min after the start of the meal, as illustrated in Figure 32. Larger blood samples (25 
ml) were taken at 0, 180, 360 and 480 min. After taking the 480 min sample each subject was 
given an injection of heparin (7500 units), through the indwelling cannulae to release LPL 
activity, and post-heparin blood samples of 5 ml were taken 5 and 15 minutes later.
Volume of blood (ml)
15 25 15 15 15 15 15 15 25 15 25 5 5t t t f t t t t t t t 11
-10 0 30 60 120 180 240 300 360 420 480+5+15
Î
Time (min) PH-LPL
Figure 32: Blood collection time line. PH-LPL = post-heparin lipoprotein lipase
4.4.5 Preparation of plasma samples
Blood samples were divided into two 10 ml EDTA tubes and kept on ice. The tubes were then 
immediately centrifuged at 3000 rpm, for 10 minutes (8.56 xlO^ g min), at room temperature. All 
plasma samples for analysis were stored at -80°C before analysis, except for TGRL analysis 
samples, which were analysed within 24 hours.
4.4.6 Separation of TJRL and TPL subfractions (0.360. 480 mini
TRL (flotation density d < 1.006 g/ml) and TPL (flotation density d > 1.006 g/ml) fractions were 
separated by a co-investigator, by the procedure of Isherwood (1996). Briefly, plasma (3.5 ml) 
was overlaid with 3.5 ml of saline {d ~ 1.006 g/ml) using a pipette. The samples were aliquoted 
into 38 ml polycarbonate tubes then centrifuged in a L6 Beckman ultracentrifuge 50Ti rotor at
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45,000 rpm for 30 min (1.33 x 10^  g.min) at 24 °C. The TRL supernatant was aspirated in a 
volume of 1.2 ml with a glass Pasteur pipette. For the analysis of apo B-48, a preservative 
cocktail was added at a volume of 5 % (v/V) of the total sample volume to protect from 
proteolytic cleavage (Edelstein and Scanu, 1986). All tubes were stored prior to analysis at - 
20‘’C.
4.5 Sam ple ANALYSIS
Measured analytes included; total plasma TAG, and total cholesterol, HDL-C, CETP and NEFA 
levels measured over the 480 min postprandial period. Carbohydrate metabolism was 
investigated by measuring plasma insulin and glucose levels over the 480 min postprandial 
period. LPL activity was also measured in the 5 and 15 min post-heparin samples plasma. 
Lastly, paracetomol (1500 mg) was measured as an indicator of gastric emptying, which together 
with breath ethanol concentration was used to monitor the rate of absorption.
4.5.1 Plasma TAG and total apo B
As described previously in Section 2 .2.
4.5.2 TRL-retinvl ester ŒE)
RE were measured as a marker of CM. This analysis was carried out by another investigator. RE 
in the TRL samples was measured using reverse-phase high performance liquid chromatography 
(HPLC) following chloroform extraction of the CM sample (Ruyter and De Leenheer, 1978) and 
expressed as p.g/ml of plasma.
4.5.3 TRL-apo B-48
Apo B-48 in the TRL fractions was measured by a co-investigator using an enzyme linked 
immunosorbent assay (ELISA) and a competitive assay developed by Lovegrove et a l (1996).
4.5.4 TGRL-TAG
The iodixanol self-forming gradient (Section 3.6), was used to separate the TGRL, into Tight’- 
TGRL, Tight’-VLDL and ‘dense’-VLDL, samples taken at 0, 360 and 480 min.
4.5.5 Lipoprotein lipase (LPLI and hepatic lipase (HLI activity measurement
The test principle is based on the hydrolysis of the lipid substrate 2-trinitrophenyl-amino- 
dodecanoyl-2-pyrendecanoyl-3-0-hexadecyl-sn-glycerol ( 12-TA-10-P-H6), a triglyceride in 
which the pyrene fluorescence is intramolecularly quenched by the trinitrophenyl group
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(Zandonella et a l, 1995; Duque et a l, 1996). In the presence of active lipase the quencher is 
hydrolysed and the pyrene fluorescence can then be detected. The lipase activity was 
proportional to the increase in fluorescence intensity at 37°C with time. The standard provided 
was the unquenched fluorescent derivative of the substrate exhibiting endpoint fluorescence.
4.5.5.1 Method
Tests for both hepatic and total lipase used the same method, which required 4 steps: step 1, 
setting up the standard curve (0.2 pmol/ml - 20 pmol/ml); step 2, quantification of the pyrenene 
fluorescence; step 3, the kinetic lipase assay; and step 4, calculation of the lipase activity.
Step 1: Standard curve
Buffer alone was used as a blank for fluorescence and this value was subtracted from all other 
standards to remove the background value. Fluorescence was measured at an excitation wave 
length of 342 nm and emission wavelength of 400 nm, with slit width set at 10. The scale of the 
fluorometer was adjusted so that the top standard was within a visible range and there was no 
signal overflow. A typical standard curves for total and HL measurements is shown in Figure 33, 
all samples were measured in a single batch, using only one standard curve to reduce inter-assay 
variation.
Step 2 : Pyrene fluorescence quantiflcation
A constant for the molar fluorescence of the pyrene group was first established in order to 
calculate the concentration of the unquenched pyrene group which accumulated over time in the 
lipase kinetic assay (step 3). The molar fluorescence of the unquenched pyrene group was the 
slope of the straight line obtained from a series of fluorescent standards. This was calculated 
using the ratio of the differences of the standard concentrations and their corresponding 
fluorescence values from the calibration straight line and expressed in relative fluorescence units 
(RFU).ml.pmol'^ i.e.
Yo - Yi = 58.6-1.5 = 1.7RFU.ml.pmof^
X2 -X 1 20-0.3
100
y = 2.8732X + 0.7432 
= 0.999350 -
U; 40 --
30 --
20 -
10 -
0 5 10 15 20
Concentration (pmol/ml)
Figure 33: Lipase activity standard curve. Y showing the slope of the straight line and the correlation between 
concentration and fluorescence.
Step 3: Kinetic lipase activity
Lipase activity corresponds to the appearance of pyrene fluorescence in the unquenched product 
over time. Reconstituted substrate (2 ml) was placed into a cuvette and warmed to 37°C in a 
water-bath. Plasma (10 pi) was added to 190 pi of buffer and mixed. From this, 20 pi of sample 
was taken, added to the substrate and immediately mixed by inversion. Fluorescence 
development was then followed for approximately 3 minutes or until the enzyme activity 
plateaued. A straight line was drawn through the values and the slope of this line was used to 
calculate the rate of increase in fluorescence with time as x RFU.min'V
Step 4
The molar fluorescence of the pyrene group calculated from the straight line of the standards in 
Step 2, was used to convert the activity value (step 3) to conventional units of pmol of substrate 
converted per ml per min.
X RFU.min'^— = x pmol.ml'\min'^
1.7 RFU.ml.pmof 1.7
Under conditions defined for measuring of total lipase and hepatic lipase activity, LPL was 
calculated, making the assumption that pancreatic lipase was making a minimal contribution to 
total lipase activity and therefore could be excluded from the equation. A further conversion 
from pmol.'\min'^ to pmol.l.hr'^ was made, as this is the standard format for expressing LPL 
activity based on a stable radioactive substrate emulsion with ^H-trioleolylglycerol (Nilsson-Ehle
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et al, 1977). The intra-assay CV for HL and total lipase was 6 % ( n = 6) and 18 % (n = 6) 
respectively.
4.5.6 Plasma cholesterol. HDLC. NEF A. glucose and insulin
As described previously in Chapter 2.
4.5.7 Plasma Low density lipoprotein (LPL-Cl
LDL-C was calculated using the formula derived by Friedewald et a l (1972) as described below:
LDL-cholesterol = total cholesterol - (HDL-cholesterol + total TAG!
2.2
The formula assumes that the level of total VLDL-C has a constant relationship with the level of 
TAG in the plasma and that total TAG is below 4.5 mmol/1. Since all postprandial TAG values 
were below 4.5 mmol/1 this equation was applied to all plasma samples.
4.5.8 Plasma cholestervl ester transfer protein (CETP)
CETP was analysed by competitive ELISA by another investigator, Dr Sharon Arrol, at the 
Institute of Diagnostic Research, Branford, Connecticut, USA.
4.5.9 Plasma ethanol
Breath ethanol levels were measured by a Lion A1 col meter™ 400 series supplied by Lion 
laboratories Ltd, (Barry, South Glamorgan). The breathalyser estimates the ethanol concentration 
in blood from the ethanol concentration of expired air. To convert to plasma ethanol levels, 
breath ethanol levels were multiplied by 2.3 to convert to mmol/1.
4.5.10 Plasma paracetomol
Postprandial plasma samples were measured using a kit supplied by Cambridge Life Sciences pic, 
(Cambridge, Cambridgeshire). The kit contained working reagent (acetaminophen assay kit), 
calibrator and QC (paracetomol standard).
Principle
The test employs an enzymatic colorimetric method based on the following reactions:
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Paracetomol aryl-acyl-amideaminohydrolase ^ p-aminophenol + acetate
p-aminophenol + o-cresol +__________ ^  Blue indophenol dye
ammoniacal copper solution
The intensity of the colour produced was proportional to the paracetomol concentration when 
measured at 615 nm and the assay was linear up to a concentration of 2 mmol/1.
The assigned value for the standard was 2 mmol/1 and plasma QC was 0.2 mmol/1. The mean 
intra-assay variation on a value of 0.19 mmol/1 was 1.99 % (n = 10) and inter-assay variation on a 
value of 0.20 mmol/1 was 1.74 % (n = 10).
4.6 Data  Analysis
As described previously in Section 2.4.
4.7 Results
4.7.1 Postprandial response - plasma TAG
The effect of ethanol on postprandial plasma TAG is shown in Figure 34. In both groups, plasma 
TAG showed a typical postprandial response to the fat-containing meal. In the ethanol group 
both the magnitude and duration of the postprandial lipaemia was increased after 240 min 
peaking in the late postprandial phase at 300 - 360 min, as compared to the control group which 
peaked earlier at 240 min. Although plasma TAG with ethanol declined at 480 min, unlike the 
control group, their values had not returned to fasting baseline levels by 480 min. At 360, 420 
and 480 min there were significant differences in TAG between the control and ethanol groups 
(p<0.05), (p<0.001) and (p<0.001) respectively. There was also a significant increase in the 
AUC ethanol versus control (1644.08 + 619.68 versus 909.10 + 307.90 min.mmol.r\ j?<0.05) 
and I AUC in the ethanol relative to control group (1050.08 + 351.31 versus 295.60 + 89.71 
min.mmol.r^,/?<0.001) over the 480 min study period.
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Figure 34: The effect of ethanol on plasma TAG over a 480 min postprandial period. Plasma TAG concentrations 
with the ethanol group are represented by I and for the control group by H. Results are means + SD for n = 8. 
**(p<0.001) *(p<0.05), where p  values refer to the difference in postprandial TAG with and without ethanol, after a 
repeated measures ANOVA.
4.7.2 Postprandial Response - TRL-RE
Postprandial TRL-RE levels, (Figure 35) demonstrated peaks between 120-180 min and 360-480 
min in both groups, with biphasic peaks in control and ethanol groups in 6 out of 8 subjects. In 
the ethanol group, the magnitude and duration of the postprandial TRL-RE response increased 
from a slightly earlier time point at 180 min, compared to 300 min in the control. There was a 
significant difference between the ethanol and control groups at 420 and 480 min, (p<0.05). 
There was also a significant difference in the AUC between groups at 360-480 min AUC ethanol 
versus control (117.32 ± 43.92 versus 37.70 + 25.13 min.mmol. l'\/?<0.05) and lAUC ethanol 
versus control (229.47 + 95.54 versus 139.78 ± 81.21 min.mmol.r\/?<0.05) over the 480 min 
study period.
4.7.3 Postprandial Response - total aoo B and TRL-aoo B-48
Total plasma apo B values, in both groups, showed no change during the postprandial test period. 
Control TRL apo B-48 (Figure 35) demonstrated response peaks at 180 min and 300-360 min 
falling to baseline levels at 480 min, with biphasic peaks in 6 out of 8 subjects. Postprandial 
TRL-apo B-48 levels in the ethanol group showed an enhanced and prolonged effect, compared 
to the control group. The first apo B-48 peak occurred at 180 min in both groups, whilst, in the 
ethanol group, the second peak occurred slightly later at 360 min compared to 300 min and was 
more pronounced. There was a significant difference (p<0.05), between the groups at the 420 
and 480 min time points and a significant increase in the AUC ethanol versus control (99.40 +
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23.62 versus 82.46 + 17.05 min mmol l ' \  /?<0.05) and lAUC ethanol versus control (65.63 + 
21.54 versus 43.35 + 11.95 min.mmol. l'\/?<0.05) over the 480 min study period.
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Figure 35; The effect of ethanol on ( A ) T(^L-RE and ( B ) TRL-apo B-48 levels over the 480 min postprandial 
period. TRL-RE, and TRL-apo B-48 concentrations with the ethanol group are represented by H  and for the control 
group by f l .  Results are means + SD for n = 8. **(p<0.05), *(/?<0.05) where p  values refer to differences in 
postprandial RE and apo B-48 with and without ethanol after a repeated measures ANOVA.
4.7.4 Postprandial Response - TGRL-TAG
When TGRL-TAG (Figure 36) were compared postprandially at 0, 360 and 480 min, the ethanol 
group showed increased levels compared to the control group, peaking at 360 min as found with 
total plasma TAG. Using repeated measures ANOVA there were no significant differences in the 
concentration of CM-TAG, CM-R-TAG and VLDL-TAG between the control and ethanol group 
at 360 min. However, when a comparison was made between the different VLDL subclasses.
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using a paired Student’s t-test, significant differences were found between ‘dense’-VLDL at 360 
min (49 %) and at 480 min using repeated measures ANOVA between ‘light’-TGRL CM, CM-R 
(p<0.001) and ‘light’-VLDL (p<0.05). Differences of border line significance were detected for 
‘light’-VLDL at 360 min and ‘dense’-VLDL at 480 min (p=0.08).
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Figure 36: The effect of ethanol on plasma TGRL-TAG over a 480 min postprandial period at ( A ) 0, ( B ) 360 and 
( C ) 480 iriin. The ethanol group are represented by H  and the control group by H . Results are means + SD for n = 
8. **(p<0.001) *(p<0.05) where p  values refer to the difference in TGRL-TAG values with and without ethanol by 
repeated measures ANOVA and a paired t-test.
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4.7.5 Post-heparin LPL and HL
In post-heparin plasma LPL activity decreased in 7 out of 8 subjects in response to ethanol 
relative to control (at 15 min). In contrast there was a significant decrease in HL activity after 
ethanol administration relative to control (-25 % ,/?<0.05), as shown in Figure 37. There was no 
difference in either LPL or HL in the 5 min sample.
(A )
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Figure 37: The effect of ethanol on ( A ) post-heparin lipoprotein lipase activity (PH-LPL) and ( B ) post-heparin 
hepatic lipase activity (PH-HL) at 15 min after a heparin injection (7500 U). The ethanol group are represented by 
H  and the control group by H . Results are means + SD for n = 8. *(p<0.05) where p  values refer to the difference in 
PH-HL values with and without ethanol, by a paired t-test.
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There was a significant inverse relationship between the increase in plasma TAG (control minus 
ethanol) with the decrease in LPL activity (control minus ethanol) at 5 min (r = 0.80, /?<0.005), 
Figure 38, at the peak of postprandial plasma TAG (360 min).
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Figure 38: Relationship between the change in TAG at 360 min and the change in LPL at 5 min (r = 0.80, /?<0.005)
4.7.6 Plasma total cholesterol and LDL-C
Plasma total cholesterol, showed no change during the postprandial test period and between the 
control and ethanol groups. Plasma LDL-C values, (Figure 39) also showed no change at 0, 360 
and 480 min time points in both groups, and no differences between the control and ethanol 
groups. However, the data did indicate a small decrease in LDL-C postprandially after ingestion 
of ethanol at time 360 and 480 min (11 %, 12 %), n = 8.
4.7.7 Plasma HDL-C
Plasma HDL-C, (Figure 39) showed no change at 0, 360 and 480 min time points, and no 
differences between the control and ethanol groups. However, the data did indicate a small 
decrease in HDL-C postprandially on ethanol at time 360 and 480 min (4 %, 2 % respectively), n 
=  8 .
4.7.8 Plasma CETP
Plasma CETP mass, (Figure 39) demonstrated no change at the 0, 360 and 480 min time points, 
and no differences between the control and ethanol groups. However, the data did show a small 
decrease in CETP mass postprandially after ethanol at time 360 and 480 min (15 %, 4 % 
respectively), n = 8. There was also a significant correlation between the change in CETP and 
HDL-C values at 360 min {r = 0.70, /?<0.05).
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Figure 39: The effect of ethanol on ( A ) plasma LDL-C, ( B ) HDL-C and ( C ) CETP mass over a 480 min 
postprandial period. Plasma LDL, HDL and CETP with ethanol are represented by I and for the control by H. 
Results are means + SD for n = 8.
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At the peak of postprandial TAG (360 min) there was an positive relationship between the 
increase in CETP mass (control minus ethanol) with the increase in HDL-C activity (control 
minus ethanol) at 360 min (r = 0.71,/?<0.05), Figure 40.
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Figure 40: Coirelation between the change in HDL-C and the change in CETP at 360 min (r = 0.71, p< 0.05) 
4.7.9 Plasma NEFA
Plasma NEFA levels in both the ethanol and control groups, demonstrated the classical ‘inverted 
bell-shape’ NEFA response, initially falling from 0 to 120 min then rising till the end of the study 
at 480 min, (Figure 41). There was little difference between plasma NEFA levels between the 
ethanol and control groups from 0 to 180 min. However from 180 min onwards the NEFA levels 
in the ethanol group fell below those of the control group. There was a significant difference in 
NEFA between groups at 240, 300, 360 and 420 min. There was also an increase in the AUC 
ethanol versus control (196.70 + 39.30 versus 135.8 + 30.3 min.mmol. l ’\ /KO.001) over the 480 
min study period. A correlation between the change in TAG and change in NEFA at 360 min 
was of borderline significance (r = 0.43,/?=0.07).
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Figure 41: The effect of ethanol on plasma NEFA levels over a 480 min postprandial period. Plasma NEFA 
concentrations with the ethanol group are represented by I and the control group by H. Results are means + SD for 
n = 8. ♦*(^0.001), *(p<0.05) where p  values refer to the difference between postprandial NEFA with and without 
ethanol, after a repeated measures ANOVA.
4.7.10 Plasma glucose
Plasma glucose peaked at 30-60 min and fell to fasting levels after 300 min in both control and 
ethanol groups, (Figure 42). However, plasma glucose in the ethanol group showed a 
pronounced peak at 30-60 min which remained above the control group until returning to baseline 
levels at a slightly later time of 300 min, compared to 240 min in the control group.
4.7.11 Plasma insulin
Plasma insulin showed a similar, but slightly delayed response compared to that of postprandial 
glucose levels (Figure 42). In the control, insulin and glucose peaked at 60 and 120 min 
respectively, with insulin taking slightly longer to fall back to baseline levels, 300 min for insulin 
and 240 min for glucose. When the insulin levels of the control and ethanol groups were 
compared the latter peaked earlier (60 versus 120 min) and took longer to return to its baseline 
values (300 versus 360 min). There was a significant difference in plasma insulin between 
groups at 240 and 300 min (^0 .0 0 1 ,/?<0.05), and a significant difference in the lAUC ethanol 
versus control (107655.23 + 17869.73 versus 89904.02 ± 1603.64 min.mmol. l'\p<0.05) over the 
480 min study period. A significant correlation was found between fasting plasma insulin levels 
(ethanol minus control group) and the change in ‘dense’-VLDL (ethanol minus control group), at 
360 min (r = 0.61,/><0.05).
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Figure 42: The effect of ethanol on ( A ) plasma glucose, ( B ) insulin levels over a 480 min postprandial period and 
( C ) the relationship between the change in ‘dense’-VLDL-TAG at 360 min and fasting insulin levels at time 0 min 
Plasma glucose and insulin concentrations with the ethanol group are represented by I and the control by H. 
Results are means + SD for n = 8. (r = 0.61, /?<0.05). **(p<0.001), *(/7<0.05) where p  values refer to the correlation 
between the change in ‘dense’-VLDL-TAG at 360 min and fasting insulin levels, after repeated measures ANOVA.
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4 .7 .12 P lasm a ethanol
Plasma ethanol peaked at 30 min and was undetectable by 300 min, Figure 43.
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Figure 43: Plasma ethanol levels over a 480 min postprandial period. Results are means + SD for n = 8.
4.7.13 Paracetomol
Plasma paracetomol, peaked at 120 min before falling towards baseline level at 480 min both in 
control and ethanol groups, (Figure 44). There was little difference in plasma paracetomol levels 
between the ethanol and control groups from 0 to 180 min, however from 180 min onwards the 
ethanol group tended to be elevated above the control level until the end of the study period.
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Figure 44: The effect of ethanol on plasma paracetomol levels over a 480 min postprandial period. Plasma 
paracetomol for the ethanol group are represented by H and the control group by I. Results are means + SD for n = 
8 .
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4 .8  D is c u s s io n
The main aim of the present study was to investigate the acute effect of ethanol in combination 
with a fat-containing test meal, on postprandial lipid metabolism. Various analytes were studied 
to elucidate the nature of possible mechanisms involved in ethanol-induced postprandial 
lipaemia.
Postprandial plasma JAG
Both the control and ethanol groups showed the typical postprandial TAG response to a fat 
containing test meal as shown previously by Pownall (1994) and van der Gaag et al (1999). In 
addition ethanol clearly enhanced the postprandial TAG response, as shown previously by others 
(Lieber etal, 1962; Verdy and Gallereau, 1967; Barboriak and Meade, 1968; Mishra e ta l, 1991; 
Hirsch et al, 1998; Fielding et al, 2000). The acute and chronic administration of ethanol have 
both been shown to enhance postprandial lipaemia, particularly in the late phase (Avogaro and 
Cazzolato, 1975; Contaldo et al^ 1989). The most dramatic differences between the groups in 
the present study were found from 360 to 480 min after starting the test meal, which is in 
accordance with the findings of Superko (1992) who found postprandial TAG to peak in the late 
postprandial phase from 420 to 540 min.
While subject age has been suggested to affect the postprandial response to ethanol (Hendriks et 
al, 1998), with older men showing an enhanced response after an acute moderate dose of ethanol 
(30 g) the present results however, do not support this finding. A single subject over 50 years of 
age produced a similar TAG response to the other 7 subjects who were all less than 35 years in 
age. A possible explanation for this discrepancy could be due to the moderate level of ethanol 
used. In the present study, a slightly higher level of ethanol, 45 + 5 g was given, sufficient to 
stimulate an enhanced postprandial level even in young men, or reduced catabolic capacity with 
age. Postulated mechanisms for an enhanced late postprandial response to ethanol include; a 
reduced clearance of TGRL due to reduced action of LPL (and HL), the rate limiting 
determinants of TAG hydrolysis (Taskinen et a l, 1987; Mishra et a l, 1991; Nishiwaki et a l, 
1994), which the present study would support. Alternatively, ethanol could promote an increase 
in TAG secretion through an increased production of TGRL, in the form of both VLDL and CM 
(Redgrave e ta l, 1975; Baraona and Lieber, 1979; Peel e ta l, 1993). In the latter case the present 
study would indicate increases in primarily VLDL at 360 min and both VLDL and CM (and their 
remnants) at 480 min.
115
Postprandial TRL-RE
Postprandial TRL-RE values were used as a marker of CM and CM-R and showed a similar 
postprandial response to plasma TAG, in that TRL-RE were enhanced in the ethanol group and 
significantly increased over the control group in the late postprandial phase at 420 to 480 min. 
Recent studies have shown similar effects to the postprandial RE response with ethanol; (Olefsky 
eta l, 1976; Kashyap e^a/., 1983; Berr andKem, 1984; Krasinski 1990; Mero a/., 2000. 
Visual comparison of TRL-RE values both with and without ethanol suggested a biphasic 
response, with mean RE levels, peaking at 180 and 360 min. A possible explanation for the 
biphasic nature of the CM response will be addressed later when discussing apo B-48 levels. 
Peel et a l (1993) also found a biphasic response, with RE values peaking at 180 and 360 min. 
Whilst some studies found a biphasic response after an earlier meal such as breakfast (Fielding 
and Fielding, 1996) or lunch (Peel et a l, 1993; Zampelas e ta l, 1994). Previous postprandial RE 
data with ethanol suggests that the enhanced TAG response is due to either a decreased clearance 
of the larger TGRL (Krasinski et a l, 1990; Pownall, 1994), or through an increased secretion of 
intestinal CM (Fielding et a l, 1996; Evans et a l, 1998). It is worth noting that RE data is 
generally considered unreliable in the later phases of postprandial lipaemia (Demacker et a l, 
1992; Karpe et al, 1997), with possible problems occurring in the transfer of CE to endogenous 
lipoproteins from 540-720 min after the fat-containing test meal (Berr and Kem, 1984; Krasinski 
et a l, 1990). Also the form in which the RP is administered has been questioned. In the present 
study, water-miscible RP was used which reduces the delayed CM effect found with oil-based RP 
compared to apo B-48.
Postprandial IRL-apoB-48 and plasma total apo B
A more accurate and reliable measurement of CM metabolism can be obtained through the direct 
measurement of apo B-48 using SDS-PAGE or ELISA. This provides a direct method for the 
quantification of CM specific for intestinal derived lipoproteins (Karpe and Hamsten, 1995), 
since each CM particle possesses only one apo B-48 molecule (Elovson e ta l,  1988).
Acute intakes of ethanol seem to have very little impact on total plasma apo B, however the 
response is very different compared to apo B-48. Postprandial TRL-apo B-48 showed an 
enhanced postprandial response with ethanol which was significantly higher compared to the 
control group at 420 and 480 min. What this suggests is that there was a difference in the rates of 
entry of CM or in the rates of clearance of CM and CM-R particles from circulation (Jackson et 
a l, 1999). The apo B-48 profile also suggested a biphasic response similar to that for RE, with
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the mean peak times for RE and apo B-48 being identical. This differs from the findings of 
others and would imply a delayed entry of RE relative to apo B-48 in the TRL. Olefsky et a l 
(1976) proposed that the first and later peak were of intestinal and hepatic origin respectively, as 
isolated by sequential ultracentrifugation. Cohn et a l (1989) explored this idea further by 
measuring both apo B-48 and apo B-lOO and suggested that CM contribute to the first peak and 
VLDL and CM to the second peak, and that release of apo B-48 containing lipoproteins is not 
constant. Taskinen, (1997) provided further support for this view by suggesting that after acute 
ethanol administration the greatest contributing factor to an increase in postprandial TAG due to 
ethanol was due to an increase in VLDL. Fielding et a l (1996) and Evans et a l (1998) suggested 
that the first peak may originate from the most recent meal and the second ‘shunting-out’ pre­
formed CM-TAG from the previous meal. Both the TRL-apo B-48 and RE data imply that 
ethanol, increases the residence time of CM either through a reduced clearance and/ or an 
increased secretion rate. One interpretation of the data is that from 360 - 480 min LPL is 
preferentially acting on larger TGRL at the expense of smaller TGRL (‘dense’-VLDL), and is 
therefore able to adequately remove CM but not VLDL. However, by 480 min, LPL had become 
saturated and thus was no longer capable of removing CM-R, hence the raised levels of CM-R in 
the ethanol compared to control group at 480 min.
TGRL-IAG
The postprandial TGRL-TAG response showed an increase with ethanol, which was greatest at 
360 min. This corresponded to the peak in plasma TAG which had not returned to a baseline 
level by 480 min. At 360 min, in a comparison between VLDL, there was a significant increase 
in ‘dense’-VLDL and a small increase in ‘light’-VLDL (/?=0.08). However, by 480 min the 
opposite was apparent, with significant increases in ‘light’-TGRL, CM-TAG, and CM-R This 
might again suggest that at 360 min LPL is acting on larger TGRL particles preferably clearing 
the larger over smaller TGRL, whereas by 480 min LPL is unable to adequately clear either the 
larger or smaller TGRL. The relative differences in TGRL between the ethanol and control 
groups would indicate that both small and larger TGRL contribute to the enhanced response at 
360 min and 480 min respectively (Cohn et al, 1989). An increase in postprandial VLDL with 
ethanol is well documented after both the acute and chronic intake of ethanol (Verdy and 
Gallereau, 1967; Baraona and Lieber, 1979; Crouse and Grundy, 1984; Contaldo et a l, 1989; 
Frohlich, 1996). A VLDL peak in the late phase of lipaemia following acute ethanol 
administration has also been demonstrated previously by Wilson et a l (1970). Schneider et a l 
(1985) reported VLDL to be the main lipoprotein affected by ethanol in long term chronic
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alcoholics. As with CM metabolism, there appears to be two possible mechanisms for the 
increase in VLDL after ethanol administration. Firstly, an increase in the secretion of VLDL 
particles into plasma (Goldberg et a l, 1984; Sane et a l, 1984; Taskinen et a l, 1985; Fielding et 
a l, 2000), as seen in chronic alcoholics (Brewster et a l, 1966; Gandhi and Raina, 1984). 
Secondly, a decrease in VLDL removal through either a reduction in post-heparin LPL activity 
(Schaefer et al, 1978) or by reduced clearance together with increased production (Lapolla et a l, 
1986). The actual mechanism cannot be accurately determined until VLDL turnover studies are 
performed using VLDL labelled with stable radio-isotope.
PH-LPL and HL activity
Before discussing the impact of ethanol on post-heparin LPL activity it is important to consider 
the accuracy of the method for indirectly measuring LPL activity by fluorometry. The method 
gave an intra-assay CV of 18 % (n = 6), an acceptable level for an enzyme assay which could be 
improved however, through the incorporation of an advanced fluorometer with digital display of 
the enzymatic rate. The present method gave values for control HL activity of 4.27 + 2 pmol/l/hr 
and LPL activity 7.1 + 4.9 pmol/Fhr which are similar to that previously reported for LPL of 9.3 
pmol/l/hr and HL of 6.6 pmol/l/hr (Connelly et a l, 1990).
Post-heparin LPL did not change significantly in the ethanol group compared to the controls, a 
finding which may have been due to the small number of subjects (n = 8). There is controversy 
in the literature as to the effect of ethanol on post-heparin LPL activity. In the present study the 
acute administration of ethanol indicated an apparent decrease in LPL activity. This was also 
reported by Wilson et a l (1970) and Nishiwaki et a l (1994) who examined the effects of a 
similar amount of ethanol (20-40 g/d in an individual with CETP deficiency). A reduced activity 
of LPL would be consistent with a reduction in TAG degradation as a possible mechanism to 
enhance postprandial lipaemia, as suggested by other groups (Hansson and Nilsson-Ehle, 1983; 
Schneider et al, 1985; Taskinen et al, 1987; Eckel, 1989; Pownall, 1994). A decrease in LPL 
activity has been reported with a slightly higher dose of ethanol (1 g/kg body weight) by Nilsson- 
Ehle et a l (1977). In the present study LPL activity was measured indirectly by quantifying total 
and HL activity. Verdy and Gallereau (1967) and Veenstra et a l (1990) measured LPL and 
found no change in LPL but a decrease in HL activity. Taskinen (1987) disagreed with Nilsson- 
Ehle et al (1977) by suggesting that the ethanol induced-inhibition of LPL is transient and 
returns to normal after 600 min, which provides a possible explanation for the large variation in 
findings between studies within the literature. While HL activity at 15 min showed a significant
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decrease after ethanol compared to the control group, this is consistent with the effects of both 
acute ethanol administration in humans (Taskinen et a t, 1985; Veenstra et a l, 1990), in healthy 
males (Goldberg et a l, 1984) and chronic ethanol administration, in rat studies (Goldberg e ta l,  
1989).
With regard to the potential mechanisms there are a limited number of possibilities. Nilsson-Ehle 
et a l 1977) postulated that LPL release from adipose tissue may be impaired after ethanol 
administration leading to a depression of LPL activity. Earher ideas suggested that ethanol 
increased concentrations of acetate, one of its principal metabolites. However, Nikkila et al
(1978) found that acetate did not affect LPL activity, and only accentuated postprandial lipaemia, 
at acetate concentrations above those seen after ethanol intake, implying that the effect is due to 
ethanol itself and not to its metabolites. Another possible mechanism was postulated by Bradford 
et a l (1999) who suggested that acute ethanol intake activates catalase-dependent ethanol 
catabolism in the liver, with Kupfer cells producing PGE2 mediators which leads to the inhibition 
of LPL and an increased supply of FA to the liver.
Postprandial total cholesterol
Plasma total cholesterol did not show any difference throughout the postprandial period in both 
control and ethanol groups. This is in accordance with the literature and suggests that an acute 
dose of ethanol with a fat-containing test meal has no effect on total cholesterol levels (Contaldo 
et a l, 1989; Ishmitsu e ta l, 1997). Barboriak and Hogan (1976) gave small amounts of alcoholic 
drinks to normal subjects before evening meals for 7 days and found that there was no significant 
difference in cholesterol levels. This finding is in contrast to the effects of the longer term 
administration of ethanol that has been shown to affect total cholesterol levels (Barboriak and 
Hogan, 1976; Crouse and Grundy, 1984). Nestel et al (1976) suggested that cholesterol turnover 
did not appear to change significantly, indicating that ethanol may divert cholesterol metabolism 
from direct excretion to conversion into bile acids. A possible explanation was provided by 
Barboriak and Hogan (1976) who proposed that plasma cholesterol levels in normolipaemic men 
are relatively resistant to the lipaemic effects of smaller amounts of ethanol. The present study 
suggests that the factors that regulate the synthesis and catabolism of plasma total cholesterol are 
unaffected by an acute dose of ethanol given with a 51 g fat containing test meal.
Postprandial LDL- C
Postprandial plasma LDL-C also showed no overall difference, but tended to be lower following
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ethanol compared to the control group. A similar decline in LCL-C levels with ethanol has been 
found in rats (Hojnacki et a t, 1988) and in humans (Baraona and Lieber, 1979; Taskinen et a l, 
1982; Sane et a l, 1984; Masarei et a l, 1986; Van Toi et a l, 1998). Some studies reported an 
increase in LDL-C only after a high level of ethanol consumption. Frohlich (1996) postulated a 
dosage effect of ethanol on LDL-C. They found that a reduction of LDL-C only occurred when 
ethanol exceeded 36 % of the dietary energy intake. In the present study ethanol only contributed 
28 % of the calories, which may explain why it did not produce a similar response. A possible 
mechanism for the suggested decline in LDL on ethanol has been put forward by Baraona and 
Lieber (1979) and Hirano et a l (1992) who proposed that the increase in TGRL, notably in 
VLDL, was preventing the exchange of cholesterol and TAG and transference of cholesterol from 
the larger TGRL to the smaller lipoproteins such as LDL. Baraona and Lieber (1979) inferred a 
reduction of plasma CETP activity and thus a reduction in neutral lipid exchange. It is possible 
that the decrease in LDL was associated with a decrease in HL Breckenridge et a l (1989) which 
would be consistent with the present study. It should be noted that the method used to measure 
LDL-C in the present study, was the indirect method based on the Friedwald formula which 
calculates LDL-C from HDL-C and plasma TAG values, and is only accurate at plasma TAG 
values <4.5 mmol/l. A more accurate method would involve the direct measurement of LDL-C 
using a colorimetric assay which will be discussed in Section 5.5.2.
Postprandial HDL-C
Postprandial plasma HDL-C levels did not show significant differences but tended to increase in 
the ethanol compared to the control group. The first evidence for an effect of ethanol on HDL-C 
was shown by Barr et at. (1951). The beneficial effect of ethanol on HDL levels has been well 
documented (Castelli et al, 1977; Garrison et al, 1978; Tateossian et al, 1985; Ishmitsu et al, 
1997). The first evidence that a long-term, high dose of ethanol decreased the rate of removal of 
HDL was provided by Hojnacki et a l (1992). Nilsson-Ehle et a l (1977) gave 75 g of ethanol 
daily to normal subjects and within 2 weeks TAG had already reached its maximum level and 
started to fall towards the baseline, while HDL increased steadily throughout the 5 week study 
period rising to 30 % above baseline. In this and other studies (Valimaki et al, 1988), the 
relationship between ethanol consumption and HDL-C levels were proposed to be both time 
(Hojnacki et a l, 1991), and dose dependent (Valimaki et a l, 1988) which may explain the non­
significant increase in HDL-C in the present study. The most popular explanation to link ethanol 
with increases in HDL is based on ethanol increasing the production of nascent HDL in the liver 
through an increase in the synthesis of lipid, lipoprotein or apo A-I and apo A-II (Cluette-Brown
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et a l, 1985; Tateossian e ta l, 1985; Moore and Pearson, 1986; Contaldo et a l, 1989; Nishiwaki 
e ta l,  1994; Savolainen and Kesaniemi, 1995; Gottrand et a l, 1997). Alternatively, ethanol may 
reduce HDL particle clearance, through increased levels of HL or decreased CETP activity 
(Savolainen et a l, 1990), which could retard the transfer of CE from HDL and therefore increase 
HDL-C. Both increased levels of HL and decreased CETP activity are known to alter the 
structure and or composition of the HDL particle (Sane et a l, 1984; Cluette-Brown et a l, 1985; 
Aral e ta l,  1994).
Postprandial CETP
In the present study, postprandial CETP levels showed no overall significant difference between 
the control and ethanol group, but there was a suggestion of decreased CETP activity in the 
presence of ethanol relative to the control group. The majority of the reports support a decrease in 
CETP activity (Savolainen e ta l,  1990; Hannuksela et a l, 1992; Hirano et a l, 1992 ; Liinamaa et 
a l, 1997; Liinamaa et al, 1998). Liinamaa et a l (1998) claimed that this effect on CETP is only 
transient, in that as soon as ethanol was withdrawn the particle distribution became more 
homogenous and the levels of CETP normalised. Hannuksela et a l (1994) demonstrated that 
ethanol drinkers had 30 % lower CETP activity and 48 % higher HDL-C than controls. Changes 
in CETP may be mediated through changes in the concentration of substrates in neutral lipid 
exchange reactions i.e. VLDL and HDL rather than a direct effect on the protein itself (Liinamaa 
et a l, 1997). This idea would be supported by evidence of a significant inverse correlation 
between the change in CETP levels against the change in HDL-C levels at 360 min at the height 
of postprandial lipaemia (Patsch et a l, 1992). Hannuksela et a l (1996) and Pownall et a l 
(1999), showed plasma NEFA to be an important determinant of the CETP-mediated 
redistribution of CE. Increased NEFA concentrations enhance the exchange of plasma VLDL- 
TAG for HDL-C. Thus a decrease in plasma NEFA might be associated with increased HDL-C 
and since nearly all cholesterol in HDL is in the esterified form there is an obligatory increase in 
plasma HDL-C.
Postprandial l^EEA
In the present study postprandial plasma NEFA levels showed a significant decrease, which was 
apparent from 240 to 480 min in the ethanol compared to control group, and corresponded with 
the increase in plasma TAG in the late postprandial phase, and is in keeping with reports of an 
ethanol-induced reduction in plasma NEFA (Leiber et al, 1962; Schneider et a l, 1996; West et 
a l, 1996; Trojan e ta l,  1999). The present study also revealed an inverse correlation at 360 min
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between the change in NEFA and the change in TAG {r = 0.443, p=0.07), suggesting that the 
lower the level of NEFA the higher the level of postprandial TAG. This observation may be 
explained by a reduction in NEFA which may perturb the activities of several processes involved 
in normal lipoprotein metabolism, among them, the inhibition of lipolysis, minor increases in 
insulin concentrations and an increase in the concentration of plasma acetate (Nishiwaki et al,
1994), The latter may exert a direct antilipolytic effect on adipocytes, which would suppress 
lipolysis directly (Crouse and Grundy, 1984; Avogaro et a/. 1993). Lieber et al (1962) suggested 
that the decrease in NEFA arises as a result of the enhanced extraction of NEFA by the liver. 
Alternatively, Pownall et a l (1999) proposed that NEFA production in peripheral tissues could 
be decreased by impairment of LPL or HL activity, a theory supported by West et a l (1996) and 
by the present study in that the reduction in NEFA could be due to a decreased activity of HL 
directly and LPL indirectly.
Postprandial glucose and insulin
Since the subjects in our study were given a mixed meal containing 130 g of carbohydrate it was 
important to consider the effect of ethanol on carbohydrate metabolism. Shishehbor et a l (1998) 
found that the consumption of over 75 g of CHO was associated with an increase in TAG (for 
further details see Chapter 5). Postprandial plasma glucose peaked at 60 min then returned to 
baseline levels by 300 min in the controls. Although, postprandial plasma glucose showed no 
significant difference in the ethanol group, as found previously by Ginsberg et a l (1974), in 
theory plasma glucose could be increased by ethanol, with the oxidation of ethanol causing a 
reduction of NAD resulting in decreased glycolysis. Ethanol has been shown to promote 
glycogenolysis (Mezey, 1985) and thus increases glucose production. Iturriaga et a l (1986) 
demonstrated that ethanol caused an increase in glucose, a decrease in glucose tolerance and an 
increase in insulin release 120 min after a glucose load. In conclusion, the literature indicated 
that a large intake of ethanol seen in chronic alcoholics (Bunout et a l, 1989) leads to glucose 
intolerance, whilst acute intakes of smaller amounts, as in the present study, leads to slightly 
raised glucose levels and a corresponding increase in plasma insulin as a physiological response 
to clear the subsequent rise in glucose.
Postprandial plasma insulin was intimately associated with lipids and lipoproteins. The 
concentration of insulin was positively related to Tight’-VLDL and CM-R and negatively related 
to HDL. Boquist et a l (2000) suggested that fasting plasma insulin was associated with the TAG 
response to a test-meal independently of BMI or blood glucose and proposed insulin sensitivity to
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be a major determinant of postprandial lipaemia. In the present study there was a positive 
association between fasting insulin and the change in ‘dense’-VLDL.
Postprandial paracetomol - a measure c f  gastric emptying
Plasma ethanol and paracetomol were measured as markers of the rate of ethanol absorption and 
gastric emptying respectively. These parameters have been used previously by Heading et al 
(1973) and Clement (1978). Paracetomol has been used as an indirect method of measuring 
gastric emptying since it is mainly absorbed by the duodenum, whilst ethanol is absorbed in the 
stomach (Maddem et a l, 1985). However more recent research has questioned the validity of 
using paracetomol, implying that it cannot accurately be used with non-liquid meals (Petring and 
Flachs, 1990; Van Wyk et a l, 1993), meal calorie intakes of greater than 300 kcal (Velchik et a l, 
1989), or foods high in fat (Menguly, 1959) in Petring and Flachs (1990) with the gold standard 
now regarded as scintigraphy (Stotzer et a l, 1999). Postprandial plasma paracetomol did not 
increase on the ethanol relative to the control group, implying no change in the rate of gastric 
emptying with ethanol. A non significant difference in gastric emptying was also observed by 
Brewster et al, (1966), in the administration of 6 oz of 86 % whiskey to rats, in hospitalised 
patients by Verdy and Gallereau (1967) and in healthy volunteers administered ethanol by a 
nasogastric tube (Moore et a l, 1981), However, Harichaux et a l (1971) in Baraona & Lieber
(1979) found that higher concentrations of ethanol inhibited or delayed gastric emptying. In 
general the literature on this subject is inconsistent. Contradictory findings, reflect variations in 
experimental protocols, ethanol content, composition of beverage, solid or liquid meal and the 
method of measuring gastric emptying (Mushambi et a l, 1993). Andersson (1967) suggested 
that ethanol enhanced the production of gastric juices, possibly by promoting the release of 
gastrin which accelerated the rate of gastric emptying. Alternative explanations include a direct 
effect of ethanol on the gastric muscle (Harichaux et al, 1971) or effects on the central control 
mechanisms or local neural irritation (Cooke, 1970). Additional evidence was found by 
Macgregor et al (1978) who postulated that ethanol, when taken with a homogenised meal, did 
not change the overall postprandial output of pancreatic enzyme but modified the kinetics of 
lipase secretion.
Thus it appears unlikely that differences in postprandial responses could be explained by effects 
of ethanol on gastric emptying.
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Problems with previous study
The study of the relationship between ethanol and CHD mortality has met with many problems, 
with differences in methodology and a distinct lack of uniformity in study design and criteria for 
subject selection. Firstly, there are different forms of expressing the ethanol dose i.e. g/day, 
(Marmot et a l, 1981; Lecomte et a l, 1996; Puddey and Croft, 1999), drinks per day (Schneider 
et a l, 1996), quintiles of ethanol intake (Farchi et a l, 1992) and ml per day (Ishmitsu et a l, 
1997). In addition, there is disagreement as to whether acute ethanol studies can replicate chronic 
ethanol consumption as in a real life situation. Various attempts have been made to correct for 
confounding variables such as cigarette smoking, weight, genetic polymorphisms and the subjects 
previous history of ethanol consumption or health problems.
Interpretation c f present study results
Interpretation of the results of the present study must consider the practical limitations of the 
methodology and study design. Firstly, with the direct methods for the specific measurement of 
apo B-48 and B-lOO, it would have been possible to measure the relative contributions of 
intestinal and hepatic lipoproteins to postprandial lipaemia. At the time of this study there was no 
method available for the measurement of apo B-100 in our laboratory and therefore the effect of 
ethanol on VLDL can only be speculative. It is also very likely that in addition to the fat 
consumed, the 130 g of CHO contained in the mixed meal also contributed to the enhanced 
postprandial lipaemia. Shishehbor et a l (1999) suggest that any meal containing greater than 70 
g of CHO will induce postprandial lipaemia, which makes it difficult to differentiate between the 
effects of CHO and fat on the postprandial response. Also, the test meal was designed to be a 
palatable, yet satiating, fat tolerance test and was not ideal for the analysis of the plasma glucose 
response to ethanol or the rate of gastric emptying.
Additional measurements
Additional measurements for future study could include; the analysis of LDL subclass profiles to 
examine the relationships between the VLDL and LDL size and density. Krauss (1994) 
suggested that the ethanol-induced increase in ‘dense’-VLDL leads to the production of large 
LDL and ‘light’-VLDL to small dense LDL. Moreover, ethanol consumers have been suggested 
to have unfavourable LDL profiles containing small dense LDL that are susceptible to oxidation, 
therefore the oxidisability of LDL would be an important measure to observe (Ayaori et a l, 
1997). Apo A-I should be measured since it has been found to be predictive of CHD (Ishikawa et 
al, 1978), is a direct measurement of HDL and an ethanol-induced increase in apo A-II may
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underlie the rise in HDL-C. The literature on HDL2/HDL3 is confused as to whether ethanol 
increases HDL2 or HDL3 or both (Valimaki et a l, 1993). Burr et a l (1986) suggest that it is 
mainly HDL2 over HDL3 whilst (Haskell et al, 1984) suggested that it is mainly HDL3 over 
HDL2 that is stimulated by ethanol. The examination of HDL subclasses may have provided 
clues as to the extent of the involvement of CETP in the effect of ethanol on HDL-C.
Conclusion
Overall, the anti-atherogenic effect of a moderate ethanol consumption most closely linked to the 
increase in TGRL is the impact on reverse cholesterol transport, and the inhibitory action of 
ethanol to CETP, though there is still debate as to the pro- versus anti-atherogenic effects of 
CETP (Fumeron et a l, 1995; Hann et a l, 1996; Hannuksela et a l, 1992). As already mentioned 
in the introduction, CETP is responsible for the transport of TAG from the TGRL in exchange for 
CE from HDL. A reduction in CETP action would lead to a lower level of CE transfer from HDL 
to LDL and TAG from LDL to HDL (Savolainen et al, 1990; Hannuksela et a l, 1992; 
Hannuksela et a l, 1996). This would result in an increase in HDL (Masarei et a l, 1986; 
Okamoto et a l, 1988; Rimm et a l, 1991), and a reduction in LDL-C (Hojnacki et a l, 1991; 
Hirano et a l, 1992), which are all anti-atherogenic (Yaari et a l, 1981). However the 
mechanisms by which ethanol influences CETP activity are not clear (Savolainen and Kesaniemi,
1995).
To conclude, the results of the study suggest that an acute administration of ethanol may be 
detrimental to CHD risk; by inducing enhanced levels of postprandial TAG either through 
increased secretion and possibly a reduced clearance of TGRL, with elevated CM levels at 180 
min and both CM and ‘dense’-VLDL at 360 min. Conversely anti-atherogenic mechanisms may 
involve an increase in HDL-C and a reduction in LDL-C and CETP activity. The present study 
replicates the real life situation of binge drinking, by administering a dose higher than the current 
public health recommendation of a moderate level of intake of 30 g/d which is believed to be 
protective to CHD (Rimm et al, 1999). Such binge drinking impairs the ability to clear 
postprandial fat, which may lead to a progressive increase in CHD risk especially to those 
members of the general population with compromised lipid clearance capabilities or an 
underlying defect in TAG metabolism, such as pre-diabetics, diabetics and those who possess the 
atherogenic lipoprotein phenotype (Austin e/a/., 1990).
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CHAPTER 5:
THE EFFECT OF ACUTE CARBOHYDRATE SUPPLEMENTATION ON TGRL
METABOLISM
5.1 I n t r o d u c t io n
Current trends in health promotion emphasise the importance of reducing dietary fat intake 
(COMA report, 1994) by advocating low-fat diets on the rationale that they will reduce weight, 
lower the risk of CHD and certain forms of cancer, and benefit diabetic patients (West and 
Kalbfleisch, 1971). U.K. government guidelines recommend a diet of 35 % fat and 50 % CHO, 
with a high percentage of the latter based on complex carbohydrates; fruit, vegetables, pulses and 
grains with only 10 % taken as simple CHO, since a high intake of simple CHO has been 
suggested to have a detrimental affect on TGRL metabolism.
Historical perspective
Higgins (1916) noted that fructose was more readily converted to fat than glucose. However, it 
was not until the 1950s that CHO induced HTG was observed in dietary manipulations aimed at 
reducing cholesterol (Watkin et a l, 1950; Portman et a l, 1956; Yudkin, 1957). Keys et al 
(1960) demonstrated that replacing CHO from fruits and vegetables with sucrose and lactose 
increased serum cholesterol in normal healthy men. Kuo and Bassett (1965) later reported that 
replacing starches with sucrose in hyperlipidaemic patients increased plasma TAG, cholesterol 
and PL. Ahrens et a l (1957) investigated the chemical composition of dietary fat and its effects 
on serum lipids. They studied a small number of subjects for 6 weeks, using liquid formula diets 
comprising casein, whey and CHO in the form of maltodextrin, to test the impact of dietary fat 
composition on cholesterol levels and found an increase in plasma TAG. In 1960 the classic 
study of Antonis and Bersohn, was undertaken on South African prisoners, and demonstrated a 
two-fold increase in plasma TAG, in response to a 70 % CHO diet after 3-5 weeks 
supplementation. This fell after 3-6 months and had returned to normal by 8 months. In the 
1960s epidemiological evidence emerged that subjects who subsisted on CHO as a major part of 
their diet had a reduced incidence of CHD e.g. rice consuming populations who consumed 85 % 
monosaccharides and polysaccharides did not have higher plasma TAGs. These findings 
highlighted the importance of genetic, hfestyle and environmental factors. A significant advance 
in our understanding occurred with the development of radiolabelled turnover technology by
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Farquhar et al. (1965) and Macdonald and Roberts (1965) who were among the first to apply 
mathematical modelling techniques to the investigation of lipoprotein kinetics.
Recent studies
There is no universal agreement about the effect of high-CHO/low-fat diets on CHD. The 
increased consumption of ‘fat-free or low-fat’ foods has meant an increase in the consumption of 
sugar which is not without problems (Connor and Connor, 1997). It is well documented that a 
high- CHO/low-fat diet is beneficial in that it decreases total cholesterol levels (Watkin et aL, 
1950; Dodson et al, 1981; Kasim-Karakas et a l, 2000), improves glycaemic control (Anderson 
et a l, 1989) and reduces plasma LDL-C (Kasim-Karakas et a l, 2000). These effects are 
associated with a decreased risk of CHD (Stamler et a l, 1986). However, low-fat diets have also 
been proven to be detrimental to CHD risk by resulting in an increase in plasma TAG (Antonis 
and Bersohn, 1960; Ahrens et a l, 1961; Reaven et a l, 1965; Olefsky et a l, 1974; Kasim-Karakas 
et a l, 2000). This arises from an increase VLDL-TAG (Nichols et a l, 1957; Nestel and Hirsch, 
1965; Hagenfeldt et al, 1974; Blades and Gorg, 1995; Hudgins et a l, 2000), either through an 
increase in the production of VLDL particles (Quarfordt et a l, 1970; Ruderman et a l, 1971), or 
an increase in the amount of TAG carried in each particle (Melish et a l, 1980) or a decrease in 
VLDL clearance (Grundy and Mok, 1976; Baum and Brown, 2000). Vessby and Carlson (1975) 
fed isocaloric (to a control low-CHO diet), fat-free diets with 92 % calories as CHO for 5 days to 
3 patients with HTG. They postulated that since the intestine could not produce CM on a fat- 
free-high-CHO diet there would be no cholesterol rich remnant particles from this source. 
Instead there was an increased inflow of hepatic VLDL particles into the plasma which were rich 
in TAG and relatively low in cholesterol and total apo B. In addition, high-CHO/low-fat diets 
tend to decrease HDL-C (Levy et a l, 1966; Turley et a l, 1998; Katan, 1999; Clifton and Noakes, 
2000; Kasim-Karakas et a l, 2000), an effect which is well accepted to be associated with an 
increased risk of CHD (Roche, 1999). Katan (1998) combined data from 27 trials and 
demonstrated that HDL-C fell by 0.012 mmol/1 for every 1 % of energy replaced by CHO.
Both the amount and type of CHO are factors known to increase HTG. It is generally considered 
that HTG effects can be attributed to the intake of simple CHO (Grant et a l, 1994), age, sex, 
obesity and genetic predisposition (Fredrickson et a l, 1967) and to the initial fasting TAG level 
(Hagenfeldt et a l, 1974). An increase in dietary CHO would be expected to.increase insulin 
concentrations in order to regulate plasma glucose levels (Reaven, 1997). However, several 
studies have provided evidence to the contrary, demonstrating that high-CHO diets have minimal
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effects on plasma insulin levels (Jeppesen et a l, 1995; Lombardo et a l, 1996; Daly et a l, 1998; 
Wolever, 2000), with evidence of insulin levels falling during consumption of high-SFA diets 
compared to the consumption of high- CHO/low-fat diets (Frost et a l, 1996; Marshall et a l, 
1997). Uric acid levels were also found to be reduced on high-CHO diets with potential 
beneficial effects for reducing the incidence of gout (Dessein et a l , 2000).
Factors affecting high-CHO diet induced HTG 
Quantity of dietary CHO
The amount of CHO taken in the diet seems to influence the extent of CHO-induced HTG; 
though there is no general consensus as to the lower limit needed to stimulate an HTG effect. For 
example, Weisweiler et a l (1986) replaced 10 % fat with CHO and found increases in plasma 
TAG and VLDL-TAG. Whereas (Ginsberg et a l, 1976) gave diets of 15:40:45 to 15:35:50 
(protein: fat: CHO) and only reported significant increases in plasma TAG if the food was in a 
liquid form. Lees and Fredrickson (1965) found a threshold of 7 g/kg/day of CHO being required 
to elevate plasma TAG above 2.27 mmol/1. In this case, the TAG levels actually decreased after 
7-14 days despite continuation of the diet. There is also an effect of the accompanying nutrients 
consumed with a high-CHO diet, as summarised in Table 15. Overall, the accumulation of 
evidence over the last 20-30 years has initiated a slow change in attitude towards the desirable 
amount of CHO in the diabetic diet. Back in 1979, the American Diabetic Association published 
its revised dietary recommendation for diabetic subjects moving away from a high-fat/high- 
protein diet to advising a diet consisting of 50 % CHO. Present dietary advice from the Diabetes 
and Nutrition Study Group (DNSG) 2000 still advocates a high percentage of energy intake in the 
form of CHO.
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Table 15: Studies on the effects of dietary CHO on plasma TAG
Findings Author
Positive effects of CHO
A relationship between plasma TAG, dietary CHO and (Lichtenstein and Schwab, 2000)
fat exists, and has been known for 60 years
50 g fat meal markedly reduced glucose and insulin (Wolever and Bolognesi, 1996)
response to a 130 g CHO load
Plasma TAG was lower as part of a mixed meal with (Reaven, 1979)
starch instead of dextrose / sucrose
Null effects of CHO
No dose-response in TAG in rats fed 20 and 40 % CHO (Tuovinen and Bender, 1975)
23 % sucrose diet produced the same effect when (Bantle 1986)
compared to isocaloric (55 % of energy intake as CHO)
starch diets in diabetics
No difference in plasma TAG in diabetics who (Pun eta/., 1988)
habitually consumed a high intake of CHO (55 % of
calories) compared to those who consumed a low intake
(28 % of calories)
Duration o f  dietary CHO
CHO-induced HTG can occur in subjects with TAG as low as 0.78 mmol/1 (Glueck et a l, 1969). 
The time taken for CHO-induced HTG to develop depends on several factors; namely the 
concentration of dietary CHO (as discussed previously), the form in which the CHO is 
administered, and the presence of dietary fibre. Antonis and Bersohn (1960) studied South 
African prisoners who were given a high-CHO diet for 30 weeks. Initially the plasma TAG level 
rose peaking at 5 weeks after the initial CHO supplementation, but in the long term fell to pre­
study levels. Glueck et a l (1969) found the peak in plasma TAG to be after 7 days, whereas Kuo 
and Bassett (1965) found that plasma TAG values had stabilised by 4-6 weeks whilst other 
subjects took 10-18 weeks to stabilise and return back to pre-CHO levels. Lichtenstein et al 
(1994) found the greatest increase in TAG after 1-5 weeks of CHO supplementation which then 
fell again from 6-10 weeks. Apart from studies on the amount of dietary CHO, the impact of 
short and long term CHO consumption has also been examined. Chronic CHO feeding-induced 
HTG was found to return to normal after 2 years (Huttunen et a l, 1975). Similarly, no increases 
in plasma TAG were seen in the Tarahumara Indians of Mexico who consume 75 % of their total
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energy intake from complex CHO as com and beans over many years (Cerqueria et a l, 1979). 
However, the number of other long term CHO-feeding studies in the literature is limited (Mayes, 
1993).
Quality of dietary CHO
High-CHO/low-fat diets are known to be beneficial in lowering total cholesterol and LDL-C but 
the suggestion has been made that the form in which the CHO is administered greatly affects this 
response, in that the beneficial effect is only found with complex CHO in combination with a 
high-fibre content (Srinivasan et a l, 1988; Luscombe et a l, 1999). In general, studies on the 
effects of complex versus simple CHO have produced conflicting results. Portman et a l (1956) 
first reported that sucrose substituted for starch in atherogenic diets of rats increased semm 
cholesterol levels. Cohen et a l (1961) compared the diet of Jews living in Yemen with the diet 
of Yemenite Jews living in Israel. The former group has a lower incidence of diabetes and 
ischaemic heart disease and lower serum cholesterol levels. The diets were fairly similar except 
that in Yemen no sugar was eaten whereas in Israel about 20 % of the CHO was sucrose. 
Macdonald and Brathwaite (1964) in Little et a l (1979) substituted 70 % of calories as sucrose 
for raw cornstarch in diets containing 12 % of calories as fat in normal men and the plasma TAG 
was found to be higher during the 25-day period on sucrose than on starch. More recent studies 
have also found sucrose induced HTG (Nestel et a l, 1970; Grande et a l, 1974 ; Reiser et a l, 
1979; Cara e ta l, 1992; Sandstrom e ta l, 1994; Chicco et a l, 1999). Kuo and Bassett (1965) fed 
atherosclerotic patients a diet consisting of 23:28:51 (protein: fat: CHO) and found that sugar and 
starch increased and decreased plasma TAG respectively. There is also evidence to suggest that 
the difference in the kind of ingested CHO can modulate the plasma glucose and insulin 
responses, thus raising the possibility of dietary manipulation. When Reaven (1979) studied the 
effect of CHO, as part of either a mixed meal or starch and glucose drink, on plasma glucose and 
insulin levels, he found differences and similarities between the activities of the different kinds of 
starch, potato being the most like dextrose and rice the least. In contrast, there have been many 
reports of there being no difference between the effects of simple and complex CHO 
supplementation on lipid metabolism (Dunnigan et al, 1970; Coulston et al, 1987; Bantle et al, 
1993). Roberts (1973) in Little et a l (1979) studied 18 young men at an Antarctic base, and 
compared diets of 10 to 0.5 % of calories from sucrose prepared by substituting glucose and 
dextrins for sucrose. The total diet contained about 45 % of calories as CHO and 38 % as fat. 
During the low-sucrose period of 4 weeks the mean serum TAG did not change significantly. On
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return to the diet with 10 % of calories as sucrose, serum TAG levels rose, gradually returning to 
baseline levels by 24 weeks.
Recent studies have focused on the comparison of the glycaemic index of different sources of 
CHO, which they believe may provide a more accurate measurement of CHO-induced HTG 
(Katan, 1999; Riccardi and Rivellese, 2000; Wolever, 2000). Glycaemic index is defined as the 
area of the blood-glucose curve produced by a certain food expressed as a percentage of the area 
produced by the same amount of CHO eaten as glucose or white bread, and was initially used to 
help diabetic patients to minimise their rise in blood glucose. Recent work by (Katan, 1999; 
Riccardi and Rivellese 2000; Wolever 2000) has postulated that carbohydrates with a high 
glycaemic index are less beneficial than low glycaemic index carbohydrates, with respect to 
lipoprotein metabolism, and specifically have adverse effects on HDL.
A high-CHO diet can also affect other physiological mechanisms, for example a diet high in 
CHO and fibre can slow gastric emptying. Dietary fibre can reduce and or delay lipid 
émulsification and lipolysis of dietary fat as well as slow the rate of intestinal absorption. Such 
high-CHO diets have also been associated with various problems. They can adversely affect the 
metabolism of calcium in several ways, leading to an increased risk of osteoporosis (Grundy and 
Denke, 1990). Bostom e ta l  (1999) have also suggested that high-CHO/low-fat diets lead to sub- 
optimal intakes of vitamin B-12, and reduced intakes of folate, vitamin C and homocysteine.
Problems with interpretation of some previous studies
Despite the importance of CHO to HTG in relation to CHD, few studies have been able to 
account for the relative importance of both intestinally derived (apo B-48) and hepatically 
derived apo B-lOO lipoproteins. Furthermore, interpretation of the literature is difficult because 
of variable study designs, the amount and type of CHO administered, the form in which the CHO 
source is given and more importantly whether a postprandial study was undertaken. Further 
experimentation is needed to verify earlier results and to investigate the mechanism by which 
they occur.
5.2 A im s  OF STUDY
The present study was designed to examine the effects of CHO-loading on the distribution of 
TGRL subclasses, testing the hypothesis that CHO-induced HTG arises from the production of 
smaller TGRL, in the size range of Targe’-VLDL rather than increasing the number or size of 
larger TGRL, i.e. CM and CM-R.
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5.3 Materials
DISPOSABLES
• 2ml Eppendorfs were supplied by BDH laboratory supplies (Poole, Dorset).
Analytical ktts
• Lipoprint HDL kit was supplied by Quantimetrix Corporation (California, USA).
FOODS
• ‘Liquorice allsorts’, ‘jelly babies’, and ‘soft mints’ were supplied by Bassetts as part of Trebor 
(Ireland). Whilst ‘jelly tots’, ‘fruit pastels’ and Nesquick milkshake powder were supplied by 
Nestle, (York, Yorkshire).
5.4 Study Protocol
5.4.1 Study design
During the study the subjects were asked to consume a low-fat/high-CHO diet, principally a 
high- sucrose diet (30 % of total energy) as illustrated in Figure 45.
Recruitment
&
screening
Baseline
period
Test
period
Assessment of 
habitual diet
CHO
supplementation 
n = 8
-14 -7
® (Days)
Screening 
blood sample 
25 ml
Blood sample 
25 ml
Blood sample 
25 ml
= 5-day food diary
Figure 45: Study design for low-fat/high-CHO study
132
5.4.2 Subject recruitment
Eight, healthy, non obese male subjects were recruited, after receiving local research ethic 
committee approval. Subjects were rejected on the grounds of consuming more than 30 units of 
alcohol a week, smoking, having a BMI of more than 30 kg/m^ and any illness known to affect 
glucose or lipid metabolism. The subjects characteristics are show in Table 16.
Table 16: Baseline characteristics of subjects on a low-fat/high-CHO study
Subject (n = 8) Age (yr) BMI (kg/m")
Mean + SD 31.8 + 5.8 23.3+3.8
5.4.3 Study protocol
The study protocol consisted of 4 days of carbohydrate supplementation. Prior to the start a 
screening blood sample was taken for the determination of total plasma TAG, cholesterol and 
glucose. The habitual dietary intake of each subject was assessed by recording a 5-day dietary 
intake and analysed using the ‘Diet-plan 5 programme’, Foresterfield (Horsham, West Sussex). 
Each subject had an individual supplementation programme calculated on the basis of their 
baseline sucrose intake, with the overall aim of consuming 30 % of total energy as sucrose. The 
subjects were then given their carbohydrate supplementation and dietary advice on how to reduce 
their intake of dietary saturated fat, after the 4 day period. On day 1 and day 5, (pre- and post­
carbohydrate supplementation), the subjects were asked to attend the clinical investigation unit, 
at the University of Surrey, at 9 am after a 12 hour overnight fast. Subjects were asked to refrain 
from taking any aerobic exercise or drinking any alcohol 24 hr before and during the study day. 
Subject weight and a blood sample were taken on each visit.
5.4.4 Carbohydrate supplementation
On each day of the supplementation period subjects were asked to consume a low-fat/high- 
carbohydrate diet with calculated carbohydrate supplementation in the form of 15 g of milkshake 
powder with 10 g of fructose, and a combination of Liquorice Allsorts, Jelly Babies, Jelly Tots, 
Fruit Pastels and Softmints to make a 30 % target sucrose intake, actual subject intakes ranged 
from 24.1 - 28.2 % of energy.
5.4.5 Blood Sampling
Venous blood samples (25 ml) were taken on the two occasions, pre- and post-carbohydrate
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supplementation.
5.4.6 Preparation of plasma samples
Blood samples were collected into appropriate containers (EDTA and lithium heparin tubes) and 
kept on ice. The tubes were then immediately centrifuged at 3000 rpm, for 10 minutes (8.56 x 
10^  g min), at room temperature. All plasma samples were stored at -SO^ 'C before analysis with 
the exception of plasma for the separation of TGRL subclasses which was undertaken 
immediately.
5.5 Sample analysis
Plasma TAG, TGRL-TAG, TGRL-protein, total apo B, total cholesterol, HDL-C, NEFA, glucose 
and insulin were analysed as previously described in Chapters 2 and 3.
5.5.1 TGRL-Apo B-48 analysis
Apo B-48 analysis was measured in the TGRL fractions by another investigator using separation 
on SDS-PAGE with Western blotting, which was visualised with a specific apo B-48 antiserum 
and quantified with a chemiluminescent label recorded on photographic film.
5.5.2 LDL-C analysis
The working reagent (Direct LDL-C), calibrator (Direct LDL/HDL-C calibrator) and QC (Lipid 
level 1 - LLl) were supplied in kit form from Randox Laboratories Ltd., (Crumlin, Co. Antrim). 
Principle
The method employed was an enzymatic colorimetric method based on two distinct steps:
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In the first reaction CM, VLDL-C and HDL-C are eliminated by cholesterol esterase, 
cholesterol oxidase and subsequently catalase.
Cholesterol ester + H 2O Qtolesterol esteras^ Cholesterol + Fatty acids
Cholesterol+ 0 2  Cholesteroloxidase^ Cholestenone+H2Q2
H2O2 _______________Catalyse_______^  H2O +O2
In the second reaction the specific measurement of LDL-C occurs after release of 
LDL-C by detergents in a second reagent (containing sodium azide which inhibits 
catalase activity).
Cholesterol esteraseCholesterol ester + H 2O — ..... ► Cholesterol + Fatty acids
CholesteroloxidaseCholesterol + 0 2---------------------------- ► Cholestenone +H2Q2
Peroxidase2H2O2 + 4-AA + HD AOS     ^  Quinone pigment + 4H 2O
4-AA = 4-Aminoantipyrine
HD AOS = N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyamllne
The intensity of the colour produced by quinoneimine dye was directly proportional to the LDL- 
C concentration when measured at 600 nm. The assay was linear up to a concentration of 25.8 
mmol/1. The assigned value for LLl was 2.37 mmol/1, (1.92 - 2.88 mmol/1 range). The mean 
intra-assay variation on a value of 2.41 was 0.64 % (n = 8) and inter-assay variation on a mean 
value of 2.45 was 4.91 % (n = 3).
5.5.3 HDL subclass analysis
5.5.3.1 HDL subclass method 
Materials
• Pre-cast high resolution tube polyacrylamide (8.5 % wAi) gels
• Loading gel solution (acrylamide 2.4 g/dL, N, N methylenebisacrylamide 0.2 g/dL, Sudan 
black B 6.0 mg/dL, Catalyst, Stabiliser, Buffer)
• Electrophoresis buffer [tris (hydroxymethyl) aminomethane (66.1 % w/w), boric acid (33.9 % 
wA), pH solution 8.2-8.6]
Analytical equipment
• Fluorescent preparation light
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• Electrophoresis tank
• Bio-rad power pack
W orking solution
Tris electrophoresis buffer (pH 8.2-8.6)
Buffer was prepared according to the instructions provided in the kit and was used up to a 
maximum of five times and stored at room temperature for up to a week.
Method
Plasma samples (25 |il) and loading gel (300 pi) were mixed prior to being loaded onto the 
polyacrylamide gel. Once loaded, the gels were positioned against the fluorescent preparation 
light and photopolymerised for 30 min. After polymerisation, the gels were inserted into the 
upper electrophoresis chamber and electrophoresed at 3 mA per tube, at 300 V, for 
approximately 80 min or until the albumin fraction was approximately 1 cm from the base of the 
tube. The migration distance was photographed using a Imagemaster VDS gel documentation 
system (Pharmacia Biotech, Little Chalfont, Bucks), using pre-set specifications to capture and 
analyse the gel image as listed in Section 3.7.3.1.1. The Rf value of the HDL subtraction peaks 
were calculated from input values for the VLDL and LDL band set at 0.00 (VLDL and LDL 
bands were not separated), with the albumin front at 1.00. The HDLj peak (n = 12) was 
identified by its Rf value of 0.15 + 0.02 and HDL3 (n = 12) was identified by a Rf value of 0.32 + 
0.01 (Figure 46). Background absorbance was subtracted from all gel readings. The area under 
the curve (AUC) of the HDL subfraction peaks was calculated automatically and expressed in 
optical density units. The percentage AUC was then used to proportionate HDL-C into HDL^-C 
and HDL3-C.
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VLDL/LDL 
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Figure 46: Rfvalues used to detect HDL subclass peak
Relative front (RJ = Distance of migration from origin 
Distance from origin to albumin
5.5.4 Uric acid analysis
The working reagent (uric acid liquid reagent, peroxidase without ascorbate), calibrator 
(calibrator level 1) and QC (Multi-serum normal level 1- MSNl) were supplied in kit fporm from 
Randox Laboratories Ltd., (Crumlin, Co. Antrim).
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
Uric acid + O2 + 2H2O Unease ^ Allantoin + CO2+ H2O2
ZH2O2 + 3,5-dichloro-2-hydroxybenzenesulfonic acid + 4-aminophenazone
Peroxidase ^
N-(4-antipyryl)-3-chloro-5-sulphonate-p-benzo-quinoneimine 
The intensity of the colour produced by the quinoneimine dye was directly proportional to the 
uric acid concentration when measured at 520 nm and the assay was linear up to a concentration 
of 1.189 mmol/1.
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The assigned value for MSNl was 0.368 mmol/1, (0.314 - 0.422 mmol/1 range). The mean intra­
assay variation on a value of 0.343 was 1.24 % (n = 12) and inter-assay variation on a value of
0.341 was 2.16 % (n = 5).
5.6 Data  Analysis
Statistically significant differences between plasma TAG, TGRL-TAG, TGRL-protein, TGRL- 
apo B-48, total apo B, total cholesterol, HDL-C, LDL-C, NEFA, glucose, insulin and uric acid 
pre- and post-CHO supplementation, were determined by using STATISTICA (version 5, 1997), 
taking the level of significance as (p<0.05). Changes in concentrations pre- and post-CHO levels 
were assessed using a paired Student’s t-test analysis. Whilst changes in TGRL-TAG, TGRL- 
protein, TGRL-apo B-48 were assessed by repeated measures analysis of variance (ANOVA) 
using treatment as the repeated measures (within subjects) factor. Prior to running any statistical 
tests all data was tested for normality, in addition simple linear regression was performed as 
previously described in Section 2.4.
5.7 Results
5.7.1 Dietary analysis
After CHO supplementation there was a significant decrease in percentage fat alcohol, and 
increase in percentage CHO and in sucrose, (Table 17). There was overall no significant change 
in energy intake and weight.
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Table 17: Pre- and post-CHO supplementation dietary intakes of macronutrients as a percentage of energy intake 
after a 4 day period n = 8. Values are presented as means + SD. **(p<0.001) where p  values refer to the 
difference between pre- and post-CHO energy and macronutrients
Dietary composition 
(% total energy) Pre-CHO Post-CHO
Energy (kJ) 13588 ±4627 12484 ±4961
Protein 15.49 ±4.21 15.65 ±2.27
Carbohydrate 43.94 ±3.52 65.32 ±8.22 **
Sucrose 2.91 ± 1.27 28.12 ± 0.02 **
Fat 35.20 ±3.39 19.05 ±8.41 **
NSP (g/d) 20.48 ± 10.67 12.08 ±8.56
Alcohol 5.09 ±2.98 0 **
Weight (kg) 76.44 ±14.03 76.01 ± 13.88
5.7.2 Plasma TAG
There was no significant difference in plasma TAG between screening and baseline samples, but 
a significant increase after CHO supplementation (36 %,/?<0.05) as shown in Figure 47.
9  1.6
P r e - C H O  P o s t - C H O
C H O  s u p p l e m e n t a t i o n
Figure 47: The effect of CHO siqiplementation on plasma TAG after a 4 day supplementation period. Plasma 
TAG concentrations pre-CHO supplementation are represented by I  and post-CHO by H. Results are means + 
SD for n = 8. *(p<0.05) where the p  value refers to the difference in plasma TAG pre- and post-CHO
supplementation, after a paired t-test.
5.7.3 TGRL-TAG
TGRL-TAG pre- and post-CHO supplementation are shown in Figure 48-A. After CHO
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supplementation there was an increase in TGRL-TAG. The greatest increase in TAG was seen in 
the larger Tight’-TGRL, CM-R^ (118 %) and CM-R2 (97 %), whilst CM-TAG (isolated using the 
method described in Section 3.6) decreased in 5 out of the 8 volunteers after CHO 
supplementation, producing an overall non-significant decrease in CM-TAG. There was a 
significant positive correlation between the change in plasma TAG and the change in ‘ dense’- 
VLDL-TAG (r = 0.82,/><0.05) as shown in Figure 48-C.
5,7,4 TGRL-protein
TGRL-protein pre- and post-CHO supplementation are shown in Figure 48-B. After CHO 
supplementation there was found to be a significant increase in the protein values of ‘ dense’- 
VLDL (224 %), Tight’-VLDL (98 %) and a very significant increase in CM-Rj-protein (135 %).
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Figure 48: The effect of CHO siçplementation on ( A ) TGRL-TAG ( B ) TGRL-protein and ( C ) correlation 
between the change in plasma TAG and change in ‘dense’-VLDL-TAG. (r = 0.82, p<0.05) after a 4 day 
si^jplementation period. TGRL-TAG and protein concentrations pre-CHO supplementation are represented by I 
and post-CHO by H. Results are means + SD for n = 8. **(p<0.0001), *(^0.05) where p  values refer to the 
difference in TGRL-TAG or TGRL-protein pre- and post-CHO supplementation, after repeated measures ANOVA.
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5.7.5 XGRL~ Apo B-48
TGRL-apo B-48 levels pre- and post-CHO supplementation, are shown in Figure 49. Post-CHO 
supplementation there was an increase in ‘light’-TGRL, CM-Rj, CM-R^, ‘light’-VLDL and a 
decrease in dense’-VLDL, but only the change in CM-R2 pre- and post-CHO supplementation 
was statistically significant (97 %,/?<0.05).
CM-R1 CM-R2 light’-VLDL
TGRL fractions
dense'-VLDL
Figure 49: The effect of CHO supplementation on TGRL-^o B-48 after a 4 day supplementation period TGRL- 
apo B-48 concentrations pre-CHO supplementation are represented by I and post-CHO siq)plementation by H. 
Results are means + SD for n = 8. *(p< 0.05) where p  values refers to the difference in TGRL-apo B-48 pre and 
post-CHO siq)plementation, after repeated measures ANOVA.
5.7.6 Plasma total apo B
Plasma total apo B levels pre- and post-CHO supplementation are shown in Figure 50. After 
CHO supplementation there was a slight but non-significant decrease in plasma total apo B 
values relative to pre-CHO levels. However, there was a significant correlation between the 
change in apo B and the change in ‘dense’-VLDL-TAG (r = 0.81,/7<0.05).
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Figure 50: ( A ) The effect of CHO supplementation on plasma total apo after a 4 day supplementation period and 
( B ) correlation between the change in ^ o  B and change in ‘dense’-VLDL-TAG (r = 0.81, /;<0.05). Plasma total
apo B concentrations pre-CHO supplementation are represented by I and post-CHO supplementation by H. 
Results are means + SD for n = 8.
5.7.7 Plasma total cholesterol and LDL-C
There was no significant difference in total cholesterol between screening and baseline samples. 
Plasma total cholesterol and LDL-C levels showed a slight but non-significant decrease after 
CHO supplementation, (Table 18).
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Table 18: Total plasma and LDL-cholesterol concentrations
CHO supplementation Pre-CHO Post-CHO
Total cholesterol (mmol/l) 5.02 ± 1.00 4.74 ± 0.99
LDL-C (mmol/l) 3.12 ±0.98 2.99 ±0.81
There was a significant positive correlation between the changes in total plasma cholesterol and 
change in LDL-C (r = 0.86, /?<0.05) (Figure 51), and a significant positive correlation between 
‘light’-VLDL-TAG and LDL-C (r = 0.74, /?<0.05). Examination of scatterplots for these 
relationships revealed evidence of two distinct subgroups common to both correlations. In Graph 
A (correlation between total and LDL-C), subgroup 1 had the largest increase in total and LDL-C 
whilst subgroup 2 showed the largest decrease. Similarly in Graph B, subgroup 1 had the largest 
increase in ‘light’-VLDL and in LDL-C, and subgroup 2 the smallest increase in LDL-C and a 
decrease in ‘light’-VLDL. Observing individual subjects it becomes apparent that there is a 
pattern, in that nearly all subjects with the greatest increase in ‘light’-VLDL also have the 
greatest increase in total and LDL-C
144
( A )
0.4  ^
0.2 -
•  •0 - Subgroup 1
g  - 0 . 2 -  
Vj  -0.4 --
_ i
- 0.6 - -
Subgroup 2
- 0.8 - -
-0.6 -0.4 -0.2 0 0.2 0.4-1.4 - 1.2 1 - 0.8
A in total cholesterol (mmol/l)
( B )
0.4 Subgroup 10.2 -
S  -0 .2  -
-I -0.4 -
- 0.6 -
Subgroup 2
- 0.8  -
-0.04 -0.02 0 0.02 0.04 0.06 0.08 0.12 0.140.1
A In 'Ilght'-VLDL TAG (mmol/l)
Figure 51: ( A ) Relationships between the change in total cholesterol and change in LDL-C (r = 0.86, p  < 0.05) 
and ( B ) change in ‘light’-VLDL-TAG and change in LDL-C (r = 0.74, p< 0.05).
5.7.8 Plasma HDL-C and subclasses
Plasma HDL-C levels pre- and post-CHO supplementation are shown, in Figure 52. After 
carbohydrate supplementation there was a significant (-12 %, p<0.05) decrease in plasma HDL- 
C concentrations.
Plasma HDLj and HDLg cholesterol levels extrapolated from HDL-C levels, HDL-C levels are 
shown in Figure 52, an example of a HDL2/3 profile, and a set of 8 polyacrylamide gels are 
shown in Figures 53. There was a decrease in both HDLj and HDL3 after carbohydrate 
supplementation but neither was significantly different in relation to baseline values. The
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decrease in HDLg was of baseline significance (p=0.08). As shown in Figure 54, 6 out of the 8 
subjects demonstrated a decline in HDL^-C post-CHO supplementation. There was also a 
significant negative correlation between the change in HDL^ and TAG on carbohydrate 
supplementation (r =0.77, /KG.05). Once again there was evidence of subgroups in terms of the 
HDL2 / TAG response, subgroup 1 had the highest increase in plasma TAG and decline in 
HDL2-C, whilst subgroup 2 had the smallest increase in plasma TAG and either a small decline 
or an increase in HDL2-C.
Pre-CHO Post-CHO
CHO supplementation
Figure 52; The effect of CHO supplementation on HDL-C levels after a 4 day CHO supplementation period 
Plasma HDL-C concentrations pre-CHO siqiplementation are represented by H  and post-CHO by H. Results are 
means + SD for n = 8. *(p<0.05) where p  values refer to the difference in HDL-C pre- and post-CHO
supplementation, after a paired t-test.
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Figure 53: ( A ) Example of HDL subclasses separated on polyacrylamide gels, and ( B ) Subject 8 pre- and post- 
CHO HDL subclass profile.
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Figure 54: ( A ) Relationship between the changes in plasma TAG and HDL^-C after a 4 day CHO 
supplementation period and ( B ) Correlation between the change in HDL  ^and change in TAG (r = 0.77, p  <0.05). 
Results are means + SD for n = 8.
5.7.9 Plasma NEFA. uric acid, glucose and insulin
There were no significant differences between pre- and post-CHO NEFA and uric acid levels. 
There was also no significant difference between screening and baseline plasma glucose levels. 
After CHO supplementation there was a significant decrease in plasma glucose, (Figure 55). 
Plasma insulin levels pre- and post-CHO supplementation did not show any significant changes.
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Figure 55: The effect of CHO supplementation on plasma glucose levels after a 4 day CHO supplementation 
period. Plasma glucose concentrations pre-CHO supplementation are represented by H  and post-CHO by H. 
Results are means + SD for n = 8. *(p<0.05) where p  values refer to the difference in glucose levels pre- and post- 
CHO supplementation, after a paired t-test.
5.8 DISCUSSION
The main aim of the present study was to test the hypothesis that a high-CHO/low-fat diet causes 
an increase in plasma TAG, VLDL-TAG and a decrease in HDL-C, and to characterise any 
differential effects on TGRL subclasses. With such effects being implicated in contributing to 
CHD risk within an ALP phenotype.
Dietary analysis
After CHO supplementation there was a decrease in energy intake (1 %), in fat intake (16 %) 
and a significant increase in percentage CHO (21 %) and sucrose (25 %) intake, without a 
significant change in subject weight. The minimal change in subject body weight is likely to be 
explained by the short duration of the intervention and minimal change in energy intake. (Krauss 
and Dreon, 1995) and (Katan, 1997) both stated that there is little evidence, so long as energy 
content is constant, that low-fat/high-CHO diets will lead to weight loss. Whilst others such as 
(Coppack et a l, 1990) have found significant reductions in subject weight after high-CHO diets.
Plasma TAG
Total plasma TAG levels was significantly increased after CHO supplementation. This finding 
was consistent with several other studies (Hagenfeldt et a l, 1974). A CHO-induced increase in 
serum TAG was also reported in diabetics (Chen et a l, 1995) and HTG subjects (Ruderman et
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a/., 1971). A possible explanation for the increase in plasma TAG in response to a high-CHO 
diet lies in the suppression of the oxidation of NEFA, leading to increased hepatic TAG synthesis 
(Mayes 1993). CHO-induced HTG has already been shown to be highly dependent on the 
duration of CHO feeding; plasma TAG returning to baseline levels after 7 days (Glueck et a l, 
1969), 5 weeks (Antonis and Bersohn, 1960), 6-10 weeks (Lichtenstein et a l, 1994), 4-18 weeks 
(Kuo and Bassett, 1965), or stabilising after 2 years (Retzlaff et a l, 1995). What this suggests is 
that the 4-day CHO administration in the present study is an acute exposure which is unlikely to 
allow sufficient time for plasma TAG levels to return to pre-CHO levels. Plasma TAG is also 
dependent on the form and amount in which the CHO is administered, solid CHO being less 
HTG than liquid CHO (Weisweiler et a l, 1986), and complex CHO being less HTG than simple 
CHO (Kuo and Bassett, 1965).
TGRL-TAG/Protdn
Examination of TGRL-TAG levels showed no significant change in CM-TAG after CHO 
supplementation, whilst the other larger ‘light’-TGRL fractions, CM-Ri and CM-R2 together with 
the smaller TGRL ‘light’-VLDL and ‘dense’-VLDL all showed a significant increase relative to 
pre-CHO values. The most prominent increase in VLDL was in the ‘dense’-VLDL compared to 
the ‘light’-VLDL, 58 % compared to a 26 % respectively. There was also a significant positive 
association between the change in plasma TAG on CHO and ‘dense’-VLDL which suggests that 
the increase in ‘light’-VLDL was more closely linked to the increase in plasma TAG than 
‘dense’-VLDL, and was more likely to be responsible for the elevated plasma TAG level. There 
was no change in CM-TAG (Guerci et a l, 2000), suggesting that endogenous lipoproteins 
predominantly account for the increase in plasma TAG. Support for a contributing role of the 
exogenous lipoproteins CM-R-TAG over CM-TAG to CHO-induced HTG was provided by 
(Abbasi et a l, 2000). Such an increase in CM-R is important, as (Karpe et a l, 1994) proposed, 
in that an individuals metabolic capacity for CM-R removal is related to the subsequent 
progression of atherosclerosis. Whilst an increase in VLDL-TAG after CHO-supplementation 
has been found by many workers (Nestel et a l, 1970), found a 3-fold increase in plasma TAG on 
a high-CHO diet, due to an increase in VLDL particles predominantly larger and lighter VLDL 
(Ruderman et a l, 1971), a finding corroborated by Shepherd (1987). Analysis of TGRL-protein 
after CHO supplementation revealed a significant increase in ‘light’-VLDL and ‘dense’-VLDL 
and a highly significant increase in CM-Rj. Mancini et a l (1973) took this increase in VLDL 
protein to be an indicator of an increase in the number of VLDL particles, which they
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substantiated with microscopic evidence. However, Schonfeld (1970) and Ruderman et al 
(1971) postulated that indicator of an increase in the number of VLDL particles, which they 
substantiated with microscopic evidence. However, Schonfeld (1970) and Ruderman et al 
(1971) postulated that the protein content of VLDL could increase, through changes in other 
apolipoproteins in the particle apart from apo B-100. Huff and Nestel (1982) observed that CHO 
feeding was associated with an increase in apo C-in in VLDL and a shift in apo E isoforms 
(Weisweiler et a l, 1986). What this implies is that an increase in protein does not necessarily 
mean an increase in VLDL particles. To confirm this, kinetic studies were undertaken by Nikki al 
and Kekki (1972) who followed the decay of stable isotopically-labelled sucrose and starch, and 
found that starch produced a lower level of VLDL secretion than sucrose, and thus concluded that 
sucrose increased VLDL secretion and not the removal of VLDL. Schonfeld (1970) found, after 
the consumption of an 80 % CHO diet for 14 days, that VLDL-TAG increased 1.5-fold (VLDLi x
1.6 and VLDL2 x 1.3, whilst the present study found a very similar increase in ‘ dense’-VLDL- 
protein x 1.9, versus ‘ light’-VLDL-protein x 1.7. Schonfeld (1971) and Ruderman et a l (1971) 
both found that CHO increases the ratio of TAG: protein which was corroborated in the present 
study.
There are three possible mechanisms by which CHO supplementation may increase VLDL; they 
include increased production, reduced clearance or increased de novo synthesis of VLDL.
1. Elevated production of VLDL
Hirano et a l (1988) proposed that the increased VLDL-TAG was due to an elevated production 
of VLDL. An increase in VLDL can either be through an increase in the number of VLDL 
particles or an increase in the amount of TAG carried by each VLDL particle (Ruderman et a l, 
1971) or both (Aarsland et a l, 1996). Kazumi et al (1991) fed Zucker rats 10 % (wV) CHO 
drinking solution for 14 days and found no significant difference in TAG levels but an increase in 
the size of VLDL-TAG. Mancini et a l (1973) also reported an increase in the ratio of VLDL- 
TAG to VLDL-protein (+ 230 %) in response to a 20:0:80 (protein: fat: CHO) diet. An increase 
in the VLDL-TAG to protein ratio was also found by Verschoor et al (1985). However, Olefsky 
et a l (1974) found HTG subjects demonstrated no increase in TAG and did not have higher rates 
of VLDL secretion when compared with subjects with normal fasting plasma TAG after a high- 
CHO diet.
2. Decreased clearance of VLDL
Reaven et a l (1965) and Yoshino et a l (1997) believe that CHO-induced HTG is primarily the
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result of a combination of overproduction and decreased efficiency of clearance of VLDL, 
suggesting saturation of LPL activity. There is much evidence to support a decreased efficiency 
of clearance (Quarfordt et a l, 1970; Verschoor et a l, 1985; Kazumi et ah, 1986; Hirano et a l, 
1988; Frayn and Kingman, 1995; Yoshino et a t, 1997; Baum and Brown, 2000). Further studies 
have found the half-life of VLDL-TAG to be longer in glucose as opposed to fructose fed 
subjects, who also had a lower E:C apolipoprotein ratio thereby contributing to the impairment of 
VLDL-TAG removal (Kazumi et ah, 1991). Kazumi et ah (1991) suggested that in order to 
avoid removal, the VLDL particles would have to be smaller after CHO supplementation, as in 
the present study. Hirano et ah (1989) measured LPL and HL activity after a high-CHO diet (10 
%) and found a significant decrease in HL after 14 days. Parks et ah (1999) gave a 44 % solid 
high-CHO high-frbre diet for 2 weeks and found that TAG increased by 60 %, due to a 37 % 
decrease in VLDL-TAG clearance and a 18 % decrease in oxidation. They proposed the 
mechanism responsible involved reduced clearance of VLDL but detected no evidence of an 
increase in de novo lipogenesis.
3. De novo lipogenesis
Increased conversion of CHO to fat in the liver through de novo lipogenesis results in increased 
production of VLDL-TAG as demonstrated by Schwarz et ah (1995) and Spolarics (1999). 
Schwarz et ah (1995) fed a high-CHO diet for 4 days and detected that the fractional hepatic de 
novo lipogenesis correlated closely with recent CHO energy intake. De novo lipogenesis has 
been shown to be affected by both the total CHO content and the type of CHO. Hudgins et ah 
(1996, 1998) state that an increase in hpogenesis is dependant on the type of CHO, as they 
reported a reduced fatty acid synthesis when 50 % of the CHO was complex compared to simple 
CHO. Hudgins et ah (1996) fed a liquid formula high-CHO diet for 4 weeks and discovered de 
novo lipogenesis contributed up to 30-40 % of the increase in VLDL palmitate. Increases in de 
novo synthesis after CHO supplementation were also found by Park et ah (1997) when 10 % 
liquid fructose was fed to rats. On the other hand, others have suggested that de novo lipogenesis 
has a limited contribution to CHO induced HTG, implying, de novo synthesis can only produce a 
small increase in VLDL (<0.5 % of VLDL-TAG), in normal healthy subjects, even when 
consuming high-fat diets (Hellerstein et ah, 1991).
Plasnia total apo B and TGRL-apo B-48
Total apo B levels showed no response to CHO supplementation, implying that there is no major 
increase or decrease in apo B containing lipoproteins after CHO supplementation. This is
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consistent with the findings of Melish et a l (1980) who gave a high 80 % CHO-low fat diet, in 4 
doses, over the period of a week (similar to the present study) and found a significant increase in 
VLDL but no change in apo B. No significant change in total apo B levels has also been reported 
in rat studies (Witztum and Schonfeld, 1978), and human studies (Ginsberg et a l, 1981; Abbott 
et a l, 1990; Parks et a l, 1999). Ginsberg et a l (1981) suggested that the apparently unchanged 
total apo B levels could provide a possible explanation for the decrease in LDL. Stabilisation in 
total apo B levels after CHO supplementation, through the precursor product relationship 
between VLDL and LDL, contributes to the proportion (16-42 %) of VLDL apo B that is 
converted to LDL in man (Ginsberg et a l, 1981). CHO supplementation possibly contributes to 
alterations in the routes of catabolism of apo B during CHO supplementation. In the present 
study there was a significant relationship between the change in total apo B and ‘dense’-VLDL- 
TAG, implying that the very slight increase in apo B was due mainly to an increase in ‘ dense’- 
VLDL-TAG and would subsequently led to an increase in LDL-C levels.
There were evidence of an increase in fasting apo B-48 after CHO supplementation, specifically 
in the larger ‘hght’-TGRL, principally CM-R2 with a tendency towards an increase in CM-Ri, 
‘light’- and ‘dense’-VLDL’ after CHO supplementation. The significant increase in CM-R (CM- 
Ri) of intestinal origin is consistent with the TGRL-protein values and the findings of Abbasi et 
al (2000) who showed that CM-R not CM made the greatest contribution of enhanced HTG. 
This would suggest that the iodixanol self-forming gradient was isolating apo B-48 containing 
particles not just in the ‘light’-TGRL fractions CM-Ri and CM-R2 but also co-isolating apo B-48 
particles with VLDL fractions of the same size, in TGRL fractions ‘light’- and ‘dense’-VLDL.
Few studies have measured apo B-48 after CHO supplementation but a similar finding has been 
reported by Parks et al (1999) who gave a 68 % CHO whole food-low fat diet to 6 
normolipidaemic and 5 HTG subjects and found significant increases in fasting apo B-48 as 
measured by SDS-PAGE, (a similar method to that used in the present study). The first 
surprising observation was that there was still CM present after a 10 hr fast and after a low-fat 
meal. What this implies is that the primary mechanism for CHO-induced HTG is reduced 
clearance of TGRL. Examination of RE, though not as reliable a marker of CM as apo B-48, was 
made by Blades and Gorg (1995). These workers showed an increase in RE in response to 50 g 
of fructose in a fat containing meal, a finding supported by Jeppesen et a l (1997).
Plasma total cholesterol
Total plasma cholesterol decreased after CHO supplementation in 5 out of 8 subjects providing a
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mean decrease of 10 %. This is in accordance with the literature (Nestel et a l, 1979; Kelly et a l , 
1980; Kasim-Karakas et a l, 2000). When rats were fed increasing amounts of CHO, in place of 
fat, the activity of hepatic HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis 
fell, and the rate of hepatic cholesterol synthesis was reduced (Kelly et a l, 1980). Simple sugars 
may also affect the conversion of cholesterol to bile acids (Kritchevsky et a l, 1974). During a 
high-CHO intake there is a greater proportion of bile acids to neutral sterols suggesting that bile 
acids are less efficiently reabsorbed during sucrose-rich, low-fat feeding. This results in an 
increased loss and production of bile acids and an equivalent decrease in the loss of neutral 
sterols.
Plasma LDL-C
The concentration of plasma LDL-C decreased slightly but not significantly, a finding that is also 
consistent with the literature (Ulhnann et a l, 1991; O’Brien et al, 1993; Lichtenstein et a l, 
1994; Clifton and Noakes, 2000; Kasim-Karakas et al, 2000. High- CHO diets (60 % CHO 
energy) decrease plasma cholesterol levels by apparently decreasing the conversion of VLDL to 
IDL and LDL (Abbott et a l, 1990). As expected, LDL-C was significantly associated with total 
cholesterol (Hanefeld et a l, 1970; Albrink and Ullrich, 1986. Previous studies (Shepherd et a l, 
1980; Stacpoole et al, 1991; Hara et a l, 1992), suggest the decrease in LDL was due to an 
increase in LDL clearance rate, as a result of increased binding affinity, intemahsation and 
degradation of LDL, through influences on LDL receptors (Tall, 1986). Although not analysed in 
the present study, a high-CHO diet has been shown to affect LDL subclasses. Individuals with 
the small dense LDL pattern ‘A’ have been postulated to benefit from consuming a high-CHO 
diet, because they changed their LDL type to small dense LDL, pattern ‘B’. Whereas individuals 
who exhibit pattern ‘B’ demonstrated no response to a high-CHO diet, despite their total LDL-C 
falling and their ratio of LDL to HDL rising (Dreon et a l, 1995; Krauss and Dreon, 1995; Dreon 
e ta l, 1999).
Plasma HDL-C
HDL-C showed a significant decrease after CHO supplementation, this is in agreement with the 
majority of studies (Levy a/., 1966; Liu a/., 1984; Ulhnann a/., 1991; Katan, 1999; Velez- 
Carrasco et a l, 1999; Clifton and Noakes, 2000; Kasim-Karakas et a l, 2000), especially in 
response to the ingestion of high glycaemic index foods Ford & Liu (2001). Lithell et a l (1982) 
found a decrease in HDL after 3 days of 70 % CHO supplementation as demonstrated in the 
present study after 4 days. A meta-analysis by Ernst et a l (1980) from the compiled data of 27
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trials and 682 subjects found a decrease in HDL-C of 0.012 nunol/1 for every 1 % energy from 
SFA that was replaced by CHO. The most pronounced effects on HDL were seen when CHO 
replaces saturated fats (Katan, 1998), but it is also seen when MUFA and PUFA replace CHO, 
this applies to both short and long term CHO supplementation. A possible solution is to replace 
some of the SFA with MUFA or PUFA as will be demonstrated in the following Chapter. Archer 
e ta l  (1998) suggested that replacement of SFA with CHO from grains, vegetables, legumes and 
fruit has only minimal effects on HDL-C and TAG. Eisenberg (1984) proposed that high-CHO 
diets decrease HDL-C through increased catabolism of HDL proteins. Further evidence for this 
idea comes from Kashyap et a l (1982) who demonstrated an increase in apo C-II over apo C-in 
which has repercussions for the metabolism of both VLDL and HDL. It is possible that an 
abnormal regulation of these apolipoproteins may be responsible for disordered lipid transport in 
man and may play a key role in the alteration of HDL subclasses. Hopkins and Barter (1986) 
postulated that the main mechanism for CHO-induced reduction in HDL was due to increases in 
VLDL-TAG and thus CETP activity (Rinninger and Pittman, 1988). The increased availability 
of VLDL-TAG would increase the rate at which the CETP exchanges CE and TAG from HDL 
for TAG from VLDL (Hopkins and Barter, 1986). The TAG acquired by HDL would be 
subsequently hydrolysed and removed from the circulation which would result in a decreased 
diameter of HDL particles, and subsequent alterations in HDL subclasses.
H D L  su bclasses
Both HDL2 and HDL3 were decreased after CHO supplementation, and changes in HDL2 were 
found to be significantly associated with changes in plasma TAG, suggesting that HDL2 had a 
stronger relationship with plasma TAG than HDL3 which agrees with Gonen et a l (1981) and 
Shepherd (1987), but not Zimmerman et a l (1986) who found significant decreases in HDL3 in 
normal and HTG subjects consuming a high-CHO diet. Kashyap et a l (1982) gave a high-CHO, 
high-frbre diet for 36 days and obtained changes in HDL3 values similar to the present study 
values, i.e. changes of: -0.11 + 0.16 mmol/1 compared to -0.09 ± 0.15 mmol/11 and for HDL2 of - 
0.08 + 0.17 mmol/1, compared to -0.08 + 0.16 mmol/1 for the present study compared to Kashyap 
et a l (1982) study respectively.
What is also interesting to note is that there appears to be a subgroup of subjects, with a greater 
susceptibility to the negative effects of CHO supplementation than others. This subgroup had the 
greatest inverse relationship between the change in HDL2-C and change in plasma TAG and
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greatest positive relationship between the change in LDL-C and change in Tight’-VLDL and total 
cholesterol respectively.
Plasma glucose and insulin
Plasma glucose and insulin levels showed a small decrease after CHO supplementation, in line 
with the findings of Himsworth (1935), who found improved glucose tolerance with 63-75 % of 
energy from CHO. A decrease in glucose also agrees with the literature (Crapo and Kolterman, 
1984; Fox et a l, 1985; Bantle et a l, 1992). Daly et a l (1997) found no increase in plasma 
glucose in subjects who were healthy and not overweight, which corresponds to the findings in 
the present study, in which all subjects were fit and healthy. Farquhar et a l (1966) proposed the 
mechanism of reduced plasma glucose levels after CHO supplementation to be mediated through 
an insulin stimulated glucose disposal, in that if CHO intake is increased an additional amount of 
insulin must be secreted in order to maintain glucose homeostasis. Another possible explanation 
for the fall in glucose could be due to an increase in fibre intake in the diet (Anderson et a l, 
1980; Frost et a l, 1999; Parks and Hellerstein, 2000), but this was not seen in the present study 
which found a non-significant decrease in fibre intake on CHO supplementation.
Problems were encountered with the measurement of insulin, in terms of sensitivity, in that the 
standard curve was too low for the subjects assayed. The present assay only went down to 19 
/?mol/l and 3 out of the 8 subjects had fasting insulin levels below the lowest standard (19 pmol/1) 
both before and after CHO supplementation. Therefore, the results were simply extrapolated 
from the lowest standard and given a value of 19 pmol/1. The present assay was developed and 
optimised for the analysis of postprandial samples and for older male subjects with higher insulin 
levels, not young healthy males as assayed in the present study.
Plasma uric acid
Fasting uric acid levels showed no significant difference after CHO supplementation, a finding 
also found by Curreri and Pruitt (1970) and Crapo and Kolterman (1984). Mayes (1993) reported 
that an acute load of fructose, unlike glucose and galactose, causes hyperuricaemia. Mayes 
(1993) further suggested that Ig/kg body weight of CHO induces hyperuricaemia in healthy 
subjects, which would have been approximately 76 kg using the average subjects weight in the 
present study. In fact, the levels given in the present study were well in excess of this amount at 
220 ± 58 g but still did not raise uric acid levels.
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Problems and limitations of CHO supplementation studies
Investigations into the relationship between CHO supplementation and HTG have met with many 
problems in study methodology and design. Some studies have used liquid formula feeds, whilst 
others used the foods habitually taken in the diet, making it difficult to extrapolate experimental 
findings to metabolic changes associated with more regular eating patterns. Such high sugar or 
liquid formula diets may be metabolised differently compared to whole food, high fibre-low fat 
diets consumed habitually (Parks e ta l,  1999). In addition, the duration of most studies has been 
too short to extrapolate to longer term consumption over a lifetime (Kuo and Bassett, 1965). 
Kinetic studies may provide useful information on TGRL metabolism, however they usually have 
to be undertaken with subjects consuming frequent but small amounts of energy throughout the 
day, which is both time consuming and unrepresentative of habitual behaviour.
Interpretation of the results from this investigation must consider the practical limitations of the 
study design. The small number of subjects (n = 8), limited the power of achieving statistically 
significant differences between biochemical analytes e.g. HDLg-C. The study also had no means 
of checking compliance or quality control. In studies of n-3 PUFA intervention subject 
compliance can be checked by measuring the incorporation of PUFA into the red blood cell 
membranes. This is not obviously available for the study of CHO, making it difficult to validate 
results relative to CHO consumption. Compliance to a low-fat diet have also been improved 
when subjects have been supplied with foods instead of them being provided with dietary advice 
and then relying on the subjects to accurately assess and purchase their own low-fat foods. In 
addition, there were problems with the palatability of the diet, 5 out of 8 subjects did not manage 
to achieve the target level of 30 % sucrose intake, the average intake being 28 %.
A d d itio n a l m easu rem en ts
Additional measurements for a future study could include the following; 1) VLDL-C, alterations 
of which may underlie changes in HDL-C, 2) LPL, since this enzyme activity is postulated to be 
reduced on a high-CHO diet (Basilico e ta l, 1983; Baum and Brown, 2000). 3) Apo’s A l, A ll to 
study the mechanisms responsible for the fall in HDL-C, i.e. increased secretion or decreased 
removal. Zimmerman et a l (1986) proposes that a decrease in HDL is due to a decrease in apo 
A-I synthesis. 4) LDL subclasses have been reported to shift from light to more dense LDL on a 
high-CHO intake (Dreon et a l, 1994). Preliminary work on the present study by another 
investigator found that out of the 5 subjects whose LDL subclasses were measured, 4 had a 
decrease in small dense LDL (LDL-III) and 3 out of 5 an increase in light LDL-II. 5) LDL
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oxidation should have been measured (Mayes, 1993), as this has been suggested to be increased 
after CHO supplementation. A more recent, investigation on the samples from the present study 
by another investigator, has shown that vitamin E levels were significantly reduced after CHO 
supplementation implying that the anti-oxidant capacity is reduced. 6) it would have been very 
useful to include a postprandial study day, to see if, in common with alcohol, CHO 
supplementation altered postprandial TGRL metabolism (Ginsberg et a l, 1976; Shishehbor et a l, 
1998; Zampelas e ta l,  1998).
Conclusion
To conclude, the results of the present study suggest that an acute 4-day supplementation with 
simple CHO is relevant to CHD, inducing an increase in plasma TAG through both CM-R and 
VLDL as evidenced by both the iodixanol gradient and apo B-48 data, whilst decreasing plasma 
HDL-C levels. High CHO-low fat diets accentuate the risk factors of those who are already at 
risk (Liu et a l, 1983). The present study indicates that such an acute CHO supplementation may 
impair the capacity to clear fat, which may lead to a progressive increase in CHD risk, especially 
in those members of the general population with a pre-existing defect in their capacity to remove 
TGRL, or CHO intolerance such as NEDDM individuals. The latter tend to be male (Beveridge et 
a l, 1964), white (Gerhard et a l, 1998), hyperinsulinaemic (Ford et a l, 1968) and glucose 
intolerant (Ahrens et a l, 1961). Sucrose in the diet is however important for palatability, and can 
lead to increased compliance with the objective of removing/replacing saturated fat and 
ultimately, may contribute to the overall normalisation of CHO and lipid metabolism. However, 
an acute intervention study of this kind provides no evidence of adaptability to a high CHO-low 
fat diet. A more appropriate alternative for NIDDM patients, may be through the consumption of 
a high complex CHO-low fat diet or an increased consumption of unsaturated fatty acids; n-3 
PUFA or MUFA (Katan et a l, 1997), which will be discussed in the following Chapter 6.
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CHAPTER 6:
EFFECTS OF TJNSATURATED FATTY ACIDS: N-3 PUFA AND N-9 MUFA ON 
TRIACYLGLYCEROL-mCH LIPOPROTEINS
6.1 Introduction
The COMA report in 1994 identified the National fat consumption to be a major non-genetic 
determinant of CHD (Keys, 1970). Of all dietary constituents, the strongest association lies 
between CHD mortality and SFA, which induces a hypercholesterolaemic effect (McNamara, 
1992). Government guidelines recommend that the general population needs to reduce their 
intake of SFA to 10 % of total energy intake and consume a high-CHO diet (50 % of total energy 
intake) (Graham et al. 1991; Coma Report 1994). As highlighted in the previous Chapter, this is 
not without problems. A high-CHO diet causes an increase in plasma TAG (Truswell 1994), an 
increase in VLDL-TAG (Harris et a l, 1984) and a decrease in HDL-C (Katan, 1998), all of 
which have been associated with the atherogenic lipoprotein phenotype (Austin et a l, 1990). 
Dietary unsaturated fatty acids (UFA) offer an additional option, as a substitute for SFA and thus 
reducing the risk of CHD. Hence, government recommendations are for a mixture of n-3 and n-6 
PUFA at 6 % (0.2 % as n-3 PUFA), and MUFA at 12 % of total energy intake (Department of 
Health report on health and social subjects, 1994).
6.1.1 MUFA
MUFA have always been regarded as a neutral fat, with respect to having minimal effects on 
lipoprotein metabolism (Ahrens et a l, 1957; Hegsted et a l, 1965; Keys et a l, 1965). 
Historically the Mediterranean population have been characterised by a low prevalence of CHD, 
despite the consumption of high-fat diets up to 30-45 % of total energy. It has been postulated 
that the apparent protection from CHD in these countries may be due to a high intake of dietary 
MUFA relative to SFA (Keys et a l, 1986), in addition to the consumption of a diet rich in fresh 
fruit and vegetables. This favourable relationship with CHD is largely attributed to the 
hypocholesterolaemic effect of MUFA when substituted for SFA, reducing total and LDL-C, 
whilst having a minimal effect on HDL-C (Mattson and Grundy, 1985; Mensink and Katan, 
1989; Abbey et a l, 1990; Berry et a l, 1991). Epidemiological studies have revealed that 
compared to other industrialised countries there is lower CHD mortality in the Mediterranean 
countries, where the diet is traditionally rich in olive oil, which is characterised by its high
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content of MUFA oleic acid C18;l n-9, (Keys et a l, 1986; Department of Health report on 
Health and Social Subjects, 1994). Olive oil is a rich but expensive source of MUFA, and its 
specific taste is not always considered suitable for traditional cooking in many countries. A more 
attractive alternative to olive oil is the widely available, rapeseed oil, which is less expensive, has 
a neutral taste, and is available as a pure oil, in liquid form and as a table margarine. It is also 
low in erucic acid, more resistant to oxidation than oils with high PUFA fatty acid content, and 
has been found to be suitable in most dishes as well as in baking (Nydahl et a l, 1994). In 
comparison to olive oil, rapeseed oil also provides the benefit of larger amounts of tocopherols 
and plant sterols (Nydahl e ta l,  1995), less saturates 5 % versus 10 %, and relatively high levels 
of linoleic (18:2) n-6, 10 % versus 13 %.
Before rapeseed oil had become generally available (--1970) the neutral effect of MUFA on 
dietary lipids was widely accepted. Then in 1985, Mattson and Grundy, showed that dietary 
MUFA produced the same LDL-lowering effect as dietary PUFA. Soon after, Grundy (1986) 
went on to demonstrate that dietary MUFA produced reductions in plasma LDL, total 
cholesterol, and elevations in HDL-C when compared to high-CHO/low-fat diets. Moreover, the 
role of MUFAs as a potentially favourable component of the diet was re-evaluated as evidence 
grew to suggest that PUFAs were more readily oxidised than MUFA (Reaven et a l, 1996). Garg 
(1998) also proposed that MUFA diets, through their minimal effect on glucose homeostasis, 
may be a preferred alternative to a high-CHO/low-fat diet in the management of diabetes. With 
recent recommendations from the Diabetes and Nutrition Study Group (DNSG) (2000) also 
suggesting a consumption of either 60-70 % of total energy as CHO or MUFA. Subsequent 
research has been inconsistent and either supports (Wardlaw et al, 1991) or disputes (Dreon et 
al, 1990) the earlier findings of Grundy.
Recent MUFA studies
In recent years, several studies have demonstrated that diets in which SFA were replaced by 
MUFA are effective in reducing serum lipid levels in both healthy and hyperlipidaemic subjects 
(Sirtori et al,. 1986; Garg et al,. 1988; Gustafsson et a., 1992; Valsta et al, 1992; Dreon et al,. 
1994; Gustafsson et al, 1994; Nydahl et al, 1994). The principle effect of MUFA on lipid 
metabolism is its effect on plasma cholesterol. Mensink and Katan (1987) confirmed the classic 
results of Keys’, when 20 % of total energy as CHO was replaced by olive oil, HDL-C was 
significantly raised and plasma TAG significantly reduced on olive oil compared to a high-
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CHO/low-fat diet. A summary of recent studies is given in Table 19. High MUFA diets appear 
to exert both hypo-triacylglycerolaemic and hypo-cholesterolaemic effect, lowering plasma 
TAG, total and LDL-C, however the effects on HDL-C remains inconsistent. Although the 
potential benefits of MUFA are accepted, the mechanism by which they exert their effects on 
plasma lipoproteins remains unclear, specifically the effect of MUFA on TGRL metabolism 
warrants further investigation.
Effects of MUFA from different dietary sources on lipid tnetaholism
MUFA from different dietary sources exerts differential effects on lipid metabolism and 
specifically on plasma cholesterol (Keys et a l, 1957; Truswell and Choudhury, 1998). 
Gustafsson et a l (1994) compared the effects of rapeseed oil with sunflower oil in HTG patients 
for 3 weeks. Both produced decreases in LDL, HDL and total cholesterol, whilst HDL-C 
decreased even on the rapeseed diet. An additional advantage of rapeseed oil is that it increases 
the n-3 PUFA ratio more than sunflower oil, but in the process (Turpeinen et a l, 1995) may 
increase oxidative stress due to the introduction of more carbon double bonds in the rapeseed oil 
diet versus the sunflower oil diet. However, there is evidence that MUFA-rich diets lower the 
oxidation of LDL (Frenkel et a l,  1994; Reaven et a l, 1996; Mata et a l, 1997). Truswell and 
Choudhury (1998) also compared olive oil with rapeseed oil and found that total and LDL-C 
were higher with olive oil relative to rapeseed oil. In addition to these effects on lipids, dietary 
MUFA are reported to reduce the concentration of clotting factors (Foley et a l, 1992; Roche et 
a l, 1998), particularly coagulation factor Vllg (Zampelas e ta l,  1998) and decrease plasminogen 
activator inhibitor -1 (PAI-1) (Lopez-Segura e ta l,  1996).
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Table 19: Effects of dietary n-9 MUFA on plasma lipids and lipoproteins
Analyte Diet Change Author
MUFA vs.
TAG -SFA decrease (Changea/., 1991)
- high-CHO decrease (Garg e/a/., 1988; Truswell, 1994)
Total MUFA vs. decrease (Mattson and Grundy, 1985; Sirtori et a l, 1986;
cholester SFA Mensink and Katan, 1987; Mensink et a l, 1989;
ol MUFA vs. Borryetal, 1991; Mata e/a/., 1992)
PUFA no effect (Gardner and Kraemer, 1995) meta-analysis of 15
& LDL-C dietary intervention trials
HDL-C MUFA vs. decrease less (Hollenbeck and Coulston, 1991; Thomsen et a l.
PUFA on MUFA 1999)
(Mattson and Grundy, 1985; Sirtori et a l, 1986;
HDL-C MUFA vs. 
PUFA
no effect Mensink and Katan, 1987; Mensink et a l, 1989; 
Berry et a l, 1991; Gustaffson et a l, 1992; 
Gardner and Kraemer, 1995)
high-MUFA decrease (Shah and Garg, 1996)
Glucose MUFA vs.
high-CHO decrease (Sanz-Paris e ta l, 1998) in NIDDM
6.1.2 Polyunsaturated fattv adds UPTJFA)
The small structural differences between n-3 and n-6 PUFA has major implications for the 
metabolic actions of these fatty acids. In comparison to the n-6 PUFA, n-3 PUFA are more 
readily used for energy, mobilised by lipolytic stimuli and preferentially incorporated into 
membrane structural lipids, where they appear to have beneficial effects in relation to insulin 
action (Storlien et a l, 1997). Harris et a l (1983) also noted that n-3 PUFA are considerably 
more hypotriacylglycerolaemic than n-6 PUFA, whilst Connor et a l (1998) claimed that n-6 has 
no hypotriacylglycerolaemic effect at all. Dietary n-3 PUFA may have a significant impact on 
the prevention and treatment of CHD (Burr et a l, 1989), as a result of their anti-thrombotic and 
anti-atherosclerotic effects on platelets and lipids respectively, anti-inflammatory effects on 
leukocytes (Schmidt et a l, 1989; Schmidt et a l, 1991), and through lowering blood pressure
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(Sanders and Hinds, 1992) and blood viscosity (Woodcock et a l, 1984; Leaf and Weber, 1988; 
Burre/«/., 1989; Schmidt e?a/., 1989; Kinsella e/a/., 1990; Simopoulos, 1991).
n-3 PUFA
Evidence for the beneficial effects of n-3 PUFA on CHD comes initially from research in 
Greenland Eskimos (Bang et a l, 1971; Dyerberg et a l, 1978), Tvho were estimated to consume 
13 g per 3000 calories, approximately 40-45 % of their calorie intake, from fat, with <10 g EPA 
showed lower LDL and VLDL levels than Eskimos now living in Denmark and consuming a 
Western style diet. Dyerberg et a l (1975) also found that coastland Japanese demonstrated a 
similar pattern and had a lower incidence of CHD than Japanese consuming a Westernised diet. 
Fish oil has been shown to have beneficial effects on blood lipids for CHD (Kromhout et a l, 
1985; Shekelle et a l, 1985; Dolecek and Grandits, 1991; Simopoulos, 1991; Saldeen et a l, 
1998), reversing the HTG effects of high-CHO diets (Harris et al. 1984) whilst at the same time 
increasing HDL-C (Harris 1989). However, many Western countries have a general resistance to 
the consumption of fish, resulting in a low average intake of 26 g per day in the U.K., of which 
25 % is oily fish, equivalent approximately to only 0.1 g of n-3 PUFA/d (Gregory et a l, 1990).
History of studies
Observations of Bertelsen (1940) in Harris (1989), recognised that the pattern of disease in the 
population of Greenland, consisting mainly of Eskimos, to be considerably different from that of 
the population of Denmark. However, in the 1950s the hypotriacylglycerolaemic effect of fish 
was not widely appreciated (Bronte-Stewart et a l, 1956; Keys et a l,  1957; Malmros and 
Wigland, 1957), and it was not until the early 1970s that epidemiological studies were conducted 
in Greenland Eskimos (Bang et al, 1971; Dyerberg al, 1975; Dyerberg et al, 1978). This led 
to the hypothesis that marine oils rich in n-3 fatty acid had anti-atherogenic properties, since 
CHD and diabetes mellitus were rare in this Eskimo population, despite their high intake of 
animal fats. In 1980 Kromann and Green, published the results of their comparative study of the 
incidence of chronic disease in Greenland and Denmark, which studied men aged 45-64 (Table 
20). Other classic studies of the time, the Zutphen Study (Kromhout et a l, 1985) and the 
Western Electric study (Shekelle et a l, 1985), also found fish consumption to be inversely 
related to mortality from CHD.
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Table 20: Dietary intakes, blood lipids and disease incidence in Greenland Eskimos and Danes (Kromaim and 
Green, 1980)
Comparison Greenland Eskimos Danes
% ischaemic heart disease 6.7% 32.8 %
Bleeding times higher lower
Plasma TAG, cholesterol 0.43, 5.58 mmol/1 * 0.98, 6.77 mmol/1 *
Primary food source marine origin (fish, seal - rich land-based origin (domestic
inEPA&DHA) animals -rich in SFA)
% intake from fat 39% 42%
% intake from SFA 9% 2 2 %
n-3 PUFA (g) 14 g 3 g
* figures based on the work of (Dyeiberg et a i, 1975)
Recent n-3 PUFA studies
Many studies have consistently found a lowering of plasma TAG after n-3 PUFA 
supplementation, but effects on cholesterol and other lipoprotein levels have varied (Harris, 
1989). A 21 country cross-cultural study (Dolecek and Grandits, 1991) found that the per capita 
fish consumption was related to National mortality rates. One of the largest prospective cohort 
studies of the early 1990s was the MRFIT study (Dolecek and Grandits, 1991) found significant 
reductions in plasma TAG levels. This was followed by the GISSI trial (GISSI-Prevenzione 
Investigators, 1999) which took place over a period of 2 years and supplemented 11,324 
myocardial infarction patients with 1 g/d of PUFA. The findings from this study are summarised 
in Table 21. Results with regard to the effects of n-3 PUFA on glucose homeostasis are 
inconsistent, with debate as to whether n-3 PUFA alters glucose or just insulin levels (Glauber et 
a l, 1988). It is well recognised that the oxidative modification of LDL plays a key role in the 
initiation and progression of atherosclerosis. Highly unsaturated FA, found in the PL monolayer 
of LDL, are more susceptible to peroxidation (Parthasarathy et a l, 1992) and act as triggers for 
propagating LDL oxidation.
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Table 21: Effects of dietary n-3 PUFA on blood lipids and glucose
Analyte Change Author
decrease in
fasting values (Harris and Muzio, 1993)
TAG decrease in
postprandial (Nordoy, 1985; Harris a/., 1988)
values
VLDL-TAG decrease (Nordoy e ta l,  1993; Pease andLeiper, 1996)
VLDL-C increase (Childs e ta l,  1990)
Total
cholesterol decrease (Harris and Muzio, 1993)
LDL-C decrease (Harris and Muzio, 1993)
HDL-C decrease (Harris and Muzio, 1993)
increase (Puhakainen et a l, 1991; Zambon et a l, 1992; Mackness et a l, 
1994; Morgan e ta l,  1995; Harris, 1996)
Glucose decrease (Zakefa/., 1989; VdxiWo et a l, 1992)
no change (Eritsland et a l,  1994; Puhakainen et a l, 1995; Chicco et a l, 
1996; QnmdXetal, 1995)
Effects of n-3 PUFA in HTG individuals
The greatest fish oil induced reductions in serum TAG have been found in HTG patients 
(Sanders et a l, 1981). Simons et a l (1985) gave 16 g/d and 6 g/d of fish oil and reported a 58 % 
and 33 % respective fall in plasma TAG, with the greatest fall being found in subjects with the 
highest baseline TAG (Singer et a l, 1986; Illingworth et a l, 1984). Harris (1997) who defined 
HTG subjects as those with a plasma TAG >2 mmol/1, reported a 34 % reduction in TAG, whilst 
LDL-C rose by 10.8 %, with no significant changes in HDL-C and total cholesterol. However, 
NTG subjects (<2 mmol/1) showed only a 25 % decrease in plasma TAG and increase in LDL-C 
of 4.5 %. The basis for this difference in response lies in the fact that subjects with HTG 
overproduce VLDL (Grundy and Mok, 1979) which has been found to be reduced after n-3 
PUFA supplementation (Harris et a l, 1990; Dallongeville et a l, 1991; Kasim-Karakas et a l, 
1995).
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Problems in the interpretation of studies
The results from various intervention studies have been inconsistent, especially with respect to 
the
concentration of plasma lipoprotein (Leaf and Weber, 1988). The probable explanation for this 
is the large number of factors which can modulate the actions of the n-3 PUFA. These include 
the nature of the population studied, the period of intervention, the source of n-3 PUFA, the 
background diet, and the diet during the intervention period.
Present study
Two studies were undertaken to examine the effects of MUFA-enriched (Study I) and n-3 PUFA 
enriched (Study II) diets as an alternative to a low-fat/high-CHO diet.
6.2 Aim s of stiidy I
The aim of the present study was to determine the effects of a MUFA-enriched diet on the 
distribution of TGRL subclasses, testing the hypothesis that MUFA may also act on the TGRL to 
reduce plasma TAG levels in HTG subjects. The study design was a 4 week dietary intervention, 
replacing approximately 18 % of energy from SFA with MUFA, the pre-intervention habitual 
diet of the subjects, acting as a control phase.
6.3 Study Protocol
6.3.1 Study I design
This single blind cross-over study was designed, organised and undertaken by another 
investigator as part of a 4 week dietary intervention trial, being run at the University of Surrey 
and the Royal Surrey County Hospital. The intervention diet consisted of a low fat (<10 % of 
total SFA energy intake) but a high MUFA diet (18 % of total energy intake) as illustrated in 
Figure 56.
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Figure 56: MUFA study design
6.3.2 Subject recruitment
Nine, non-obese, healthy male subjects were recruited from the Royal Surrey County Hospital 
diabetic type 2 clinic, after receiving local research ethic committee approval. Subjects were 
rejected on the grounds of consuming more than 30 units of alcohol a week and smoking. The 
characteristics and inclusion criteria for subject selection, which included an ALP, are show in 
Table 22.
Table 22: Subject characteristics and selection criteria
Subject (n = 9) mmol/1
TAG
Glucose
Total cholesterol 
HDL-C
BMI (kg/m"± SD) 
Age (yr ± SD)
>1.5 
< 7 
<6.5 
< 1
28.7 + 2.8 
47.2 + 4.8
Abbreviations; TAG: triacylglycerol, HDL-C: high density lipoprotein cholesterol
6.3.3 Dietary intervention protocol
A baseline 7 day food diary was completed by each subject prior to commencing the trial, to 
assess the habitual food intake, and analysed using ‘Diet-plan 5 (Foresterfield, Horsham, West
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Sussex). During the study, each subject was given individual dietary advice as to how best to 
follow a low-fat diet, reducing saturated fat intake to 10 % and replacing dietary saturated fat 
with MUFA (rapeseed oil), with the habitual diet acting as a baseline. The intervention involved 
MUFA supplementation using cooking oil and margarine, (rapeseed oil composition is described 
in Table 23), as well as manufactured foods enriched in MUFA - cakes, biscuits, breads and pasta 
sauces in exchange for snacks or as part of main meals. A unit system was established to assist 
volunteers in the consumption of individual items of food containing 2-3 units per day depending 
on the subjects weight, 1 unit equalled to 10 g of rapeseed oil, individual items of food contained 
either 10 g or 20 g of rapeseed oil. Subjects also attended the University for weekly meetings (in 
order to motivate and monitor progress) to discuss their diets in detail with the investigator.
Table 23: Rapeseed oil composition
Rapeseed oil composition Percentage
SFA 5.6
MUFA 68.1
PUFA 26.3
Linoleic acid 15.7
a-linoleic acid 10.6
6.3.4 Study dav protocol
All subjects were asked to attend the Clinical Investigation Unit, on two separate occasions, 
before and after the dietary intervention, at 8 am after a 12 hour overnight fast. On each visit, 
they performed an oral fat tolerance test, to study the effects of the dietary intervention on 
postprandial metabolism. Subjects were asked to refrain from taking any aerobic exercise or 
drink any alcohol 24 hours before the study day. On arrival at the unit, an indwelling cannulae 
was inserted into the forearm using lignocaine as a local anaesthetic, and 0.9 % (w/v) NaCl saline 
solution was used to prevent coagulation between blood collections. Two fasting blood samples 
were taken, one at -10 and another immediately before the meal at time 0.
6.3.5 Oral fat tolerance test
Subjects were given a standard fat meal developed by the Nutrition Research Group at the 
University of Surrey, which provided 4480 kJ: 82.7 g fat, 72.5 g CHO and 20.3 g protein. The 
test meal was freshly prepared and weighed-out for each subject and consisted of food items as
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shown in Table 24. The subjects were allowed a 20 minute period to consume the meal, and 
were permitted decaffeinated drinks and water throughout the study.
Table 24; Dietary composition of oral test meal
Food Quantity
orange juice 200 ml
white bread 70 g
margarine 10 g
Cheddar cheese 30 g
Nesquick milkshake powder 10 g
full fat milk 130 ml
double cream 120 g
6.3.6 Blood Sampling
In addition to the two fasting samples, (-10, 0 min) 25 ml of blood was taken at 30, 60, 90, 120, 
180, 240, 300, 420, 540 min and 35 ml at 0, 360 and 540 min after the start of the meal (Figure 
57). After the 540 min sample each subject was given an intravenous injection of heparin (7500 
units) through the cannulae and post-heparin blood samples of 5 ml were taken at 5 minutes.
Volume of blood (ml)
25 35 25 25 25 25 25 25 25 35 25 25 35 5t t t t t t t t t t t t f t
-10 0 30 60 90120 180 240 300 360 420 480 540 +5
t
Time (min) PH-LPL
F i^ re  57: Blood collection time line
6.3.7 Preparation of plasma samples
Blood samples were divided into duplicate 10 ml EDTA tubes and kept on ice. The tubes were 
then immediately centrifuged at 3000 rpm, for 10 minutes (8.56 xlO^ g min), at room 
temperature. All plasma samples were stored at -80°C before analysis, with the exception of 
plasma for the separation of TGRL subclasses which was undertaken immediately.
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6.3.8 Separation of TRL and TPL subfractions (0 and 360 min)
TRL (flotation density <^ < 1.006 g/ml) and TPL (flotation density d> 1.006 g/ml) fractions were 
separated by another investigator, following the procedure of Isherwood (1996). Plasma (3.5 ml) 
was overlayered with 3.5 ml of saline {d = 1,006 g/ml) using a pipette. The samples were stored 
in 30 ml polycarbonate tubes then centrifuged in a L6 Beckman ultracentrifuge 50Ti rotor at 
45,000 rpm for 30 min (1.33 x 10^  g.min) at 24 °C. The TRL supernatant (1.2 ml) was aspirated 
with a glass Pasteur pipette. For apo B-48 analysis a preservative cocktail was added to a final 
concentration of 5 % (v/v) to protect against proteolytic cleavage (Edelstein and Scanu, 1986). 
All tubes were stored prior to analysis at -20°C.
6.4 Sample ANALYSIS
The analysis of TGRL-TAG and protein analysis was only undertaken in 6 subjects, as described 
previously in Section 3.6. All dietary analysis, red blood cell membrane phospholipid fatty acid 
profile, TAG, TRL-apo B-48, LDL-C (calculated using the Friedewald formular), HDL-C, 
NEFA, glucose and insulin were undertaken by another investigator on all 9 subjects, using 
methodologies described in Chapter 2 . Red blood cell membrane phospholipid fatty acid profile 
was determined by gas chromatography according to the method of Folch et a l (1957), and apo 
B-48 by ELISA according to the method of Isherwood (1996).
6.4.1 Lipoprotein lipase activity measurement (LPL)
LPL activity in the post-heparin plasma samples was measured by another investigator using a 
radioactive substrate emulsion of ^H-trioleolylglycerol (Nilsson-Ehle et a l, 1977) which was 
added with heat-inactivated serum to each sample. The amount of radioactive oleate liberated 
was measured in the presence of two different sodium chloride concentrations 0.2 M and 4 M, 
the latter to inhibit LPL. Thus, the difference between these two measurements was taken as a 
measure of LPL activity.
6.5 Data  Analysis
As previously described in Section 2.4.
6.6 Results study 1
6.6.1 Dietary analysis
MUFA supplementation was accompanied by a significant percentage decrease in SFA intake
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and increase in CHO MUFA and total PUFA as shown in Table 25. 
Table 25: Dietaiy compositions at week 0 and week 4
Dietary 
composition 
(% total energy)
Habitual Diet Week 4
Energy (kJ) 11104.3 ±2017.1 13081.0 ±2649.6
CHO 39.6 + 4.3 43.8 ±5.7*
Protein 15.81 ±3.6 14.53 ± 1.3
Total fat 39.44 ±4.1 37.06 + 5.7
SFA 14.97 ±2.2 8.18 ± 2.0 **
MUFA 13.22 ±1.5 18.41 ±3.6*
PUFA 6.64 ±1.8 8.83 ±2.0 *
Body Weight (kg) 91.38 ±10.3 91.20 ±10.3
**(p< 0.001), * (p< 0.05) wherep  refers to the difference between macronutrients pre- and post-intervention.
6.6.2 Red blood cell fRBO phospholipid
RBC phospholipid data indicated a decrease in n-6, n-3, SFA and PUFA and an increase in 
MUFA in response to the MUFA-enriched diet, (Figure 58).
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Figure 58: The effect of MUFA diet on total n-6, n-3, SFA, MUFA and PUFA in RBC membrane phospholipids 
after a MUFA intervention period. Samples were taken at time 0 and 4 weeks after dietary intervention is 
represented by I and for the control by H. Results are means + SD for n = 12.
6.6.3 F a s t in g  b io c h e m ic a l  d a t a
The biochemical response to the MUFA-supplementation is presented below (Table 26).
Table 26:Fasting pre- and post-MUFA intervention analyte levels
Analyte Habitual diet MUFA diet
Triacylglycerol (mmol/1) 2.43 ±0.87 2.06 ±0.53 *
Cholesterol (mmol/1) 5.42 ± 1.27 4.81 ±0.97*
HDL-C (mmol/1) 0.76 ± 0.08 0.77 ±0.10
LDL-C (mmol/1) 3.55 ± 1.45 3.10± 1.04
NEFA (mmol/1) 0.28 ± 0.11 0.29 ±0.1
Glucose (mmol/1) 5.24 ±0.67 5.19 ±0.42
Insulin (pmol/1) 110.87 ±69.78 100.76 ±63.33
*(p< 0.05) where p  refers to the difference between analytes pre- and post-MUFA intervention, by a paired t-test.
Pre- and post-dietary comparison revealed a significant decrease in fasting plasma TAG (-16 % , 
p<0.05) and total cholesterol (-11 % ,/?<0.05). Reductions in plasma LDL-C and insulin by 13 
% and 9 % respectively were not significant.
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6.6.4 P o s t p r a n d ia l  b io c h e m ic a l  d a t a
6.6.4.1 TAG
Postprandial plasma TAG levels after the MUFA and control diets are shown in Figure 59. Both 
control and post-intervention plasma TAG values demonstrated a typical postprandial response to 
the fat-containing test meal. Pre- compared to post-MUFA TAG values were greater from 0 to 
540 min, especially after 240 min in the late phase of postprandial lipaemia. Interestingly, 3 out 
of 9 subjects demonstrated a bi-phasic postprandial response. Significant differences in plasma 
TAG between control and MUFA diets were found at all time points after 60 min. There was 
also a significant decrease in the AUC MUFA versus control diet (2088.55 + 565.91 versus 
1726.60 + 485.17 min.mmol.T% /KO.05) over the entire 540 min study period on the MUFA 
diet.
** ** ** **6.0 _
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Figure 59: The effect of a MUFA diet on plasma TAG over the 540 min posQirandial period. Plasma was taken 
after a 82.7 g fat-containing meal at -10 min, 0 min 30 min, 60 min then every 60 min for 540 min. Plasma TAG 
concentrations with the 4 week MUFA intervention group are represented by H  and the control groiq) by H . 
Results are means + SD for n = 9. **(p<0.001), *(p<0.05) where p  values refer to the difference in postprandial 
TAG pre- and post-MUFA dietary intervention after a repeated measures ANOVA.
6.6 4.2 TGRL-TAG
Postprandial TGRL-TAG after the control and MUFA diets are shown in Figure 60. TGRL- 
TAG increased after each test meal but decreased after the MUFA-diet relative to the control. 
The greatest change in fasting TGRL-TAG was seen in the CM-TAG (- 62 %, /KO.OOl) and in 
CM-R2-TAG which were significantly increased relative to the control (77 %, /?<0.05). At 360 
min TGRL-TAG was decreased in all fractions after the MUFA diet.
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Figure 60: The effect of a MUFA diet on plasma TGRL-TAG. TGRL-TAG was taken after a 82.7 g fat-containing 
meal ( A ) at 0 min and ( B ) at 360 min. TGRL-TAG concentrations after the 4 week MUFA intervention group 
are represented by I and the control group by H. Results are means + SD for n = 9. **(p<0.001), *0k0.05), 
where p  values refer to the difference in TGRL-TAG pre- and post-MUFA intervention after a repeated measures 
ANOVA.
6.6.4 3 TRL- apo B-48
Postprandial TRL-apo B-48 levels after the MUFA-diet are shown in Figure 61, having been 
previously separated from the TPL subfraction (Section 6.1.2.8). Both control and post­
intervention TRL-apo B-48 values showed a postprandial response to the fat-containing test 
meal. At baseline, TRL-apo B-48 values compared to post-MUFA intervention were 
significantly greater from 60 to 540 min, especially after 240 min in the late phase of
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postprandial lipaemia. Significant differences were found at all time points after 60 min and in 
the AUC MUFA diet versus control (197.63 + 66.30 versus 117.25 ± 34.82 min.mmol.l ’, 
/K0.005) over the 540 min study period.
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Figure 61: The effect of a MUFA diet on TRL- apo B-48 over the 540 min pos^randial period. Plasma was taken 
after a 82.7 g fat-containing meal at -10 min, 0 min, 30 min, 60 min then every 60 min for 540 min. TRL-total apo 
B-48 concentrations after the 4 week MUFA intervention groiq) are represented by H and the control groiq) by I. 
Results are means + SD for n = 9. **(p<0.001), *(p<0.05) where p  values refer to the difference in TRL-total apo 
B-48 pre- and post-MUFA dietary intervention after a repeated measures ANOVA.
6.6.4 4 Post-heparin LPL
Post-heparin LPL activity (Figure 62), demonstrated a significant increase after the MUFA-diet 
compared with the control, at 5 min (61%, /K0.05). A significant negative correlation was also 
observed between the change in LPL activity at 5 min and the change in fasting ‘light’-VLDL {r 
= - 0.86,/KO.05) and the change in CM-TAG at 360 min (r = - 0.96,/KO.005).
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Figure 62: ( A ) The effect of a MUFA diet on post-heparin lipoprotein lipase activity (PH-LPL) at 5 min post­
heparin injection. Plasma was taken at 540 min, + 5 min post-heparin (7500 U). Plasma LPL activity at 4 weeks 
post-MUFA diet are shown by H  and for the control group by I. Results are means ± SD for n = 9. * (p<0.05) 
where p  values refer to the difference in PH-LPL during the 4 week dietary intervention period after a paired t-test. 
( B ) Correlation of the change in ‘lig i^t’-VLDL-TAG at 0 min with LPL (5 min) at time 0, (r = - 0.86, p  < 0.05).
( C ) change in CM-TAG at 360 min with LPL (5 min), (r = - 0.96, p  <0.005) n = 6.
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6.6.4.S NEFA
Postprandial plasma NEFA responses after the control and MUFA-diets are shown in Figure 63. 
The profiles show the classical U-shaped NEFA response pre- and post-intervention, falling from 
0 to 120 min then rising until the end of the study at 540 min. A significant correlation was 
found between the change in TAG and change in NEFA at 360 min (r = 0.98, /?<0.001), n = 6, 
Figure 64.
E 0.5
90 120 180 240 300 360 420 480 540
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Figure 63; The effect of a MUFA diet on plasma NEFA levels over the 540 min postprandial period. Plasma was 
taken after a 82.7 g fat-containing meal at 0, 30 min, 60 min then every 60 min until 540 min. Plasma NEFA 
concentrations after the 4 week MUFA-diet are represented by I and for the control groiq) by I. Results are 
means + SD for n = 9.
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Figure 64: Correlation of the change in plasma NEFA and change in TAG at 360 min. (r = 0.98, /KO.OOl), n = 6 
6.6.4 6 Glucose and insulin
Postprandial plasma glucose, (Figure 65 A) peaked between 30-60 min then fell back to baseline 
levels by 90 min. Postprandial plasma glucose after the MUFA-diet showed no significant
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difference from pre-MUFA intervention levels. Postprandial plasma insulin, (Figure 65 B) 
showed a single peak after the MUFA-diet slightly earlier than the habitual diet, peaking after 30 
and 120 min respectively. There was also a significant relationship between the change in 
plasma glucose and changes in insulin at 0 min (r = 0.93, p<O.OS) and in change in insulin and 
change in plasma TAG at 360 min (r = 0.91,/?<0.05), (Figure 66).
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Figure 65; The effect of a MUFA diet on ( A ) plasma glucose, and ( B ) insulin levels over a 540 min 
postprandial period. Plasma sanqiles were taken after a 82.7 g fat-containing meal, at -10 min, 0 min, 30 min, 60 
min then every 60 min for 540 min. Plasma glucose and insulin concentrations after the 4 week MUFA 
intervention group are represented by H  and for the control group by I. Results are means + SD for n = 9. 
**(p<0.001), *(p<0.05) where p  values refer to the difference in plasma insulin pre- and post-MUFA dietary 
intervention after a repeated measures ANOVA.
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Figure 66: ( A) Relationship between the change in insulin and glucose at 0 min (r = 0.93, p  < 0.01) and ( B ) 
insulin and TAG at 360 min (r = 0.91, p  < 0.05) over a 12 week dietary intervention period. Results are means + 
SD for n = 6.
6.7 D is c u s sio n  st u d y  1
The main aim of the present study was to examine the effects of a MUFA-rich diet on plasma 
TAG and TGRL, with a view to MUFA lowering plasma TAG and modulating abnormalities 
associated with the ALP. After the MUFA diet there was no significant change in body weight 
and fatty acid composition of RBC PL, although an increase in MUFA levels was evident.
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Plasma TAG
In the present study, fasting plasma TAG decreased by 16 % relative to the control (habitual 
diet), which is approximately the same as in previous studies (Baggio et a l, 1980; Mensink and 
Katan, 1987; Garg et a l, 1988; Gustafsson et a l,  1994) with a 14 % decrease being found by 
Gustafsson et a l (1994). In a recent study by Zampelas et a l (1998) which examined 
differences in the lipaemic responses of Northern and Southern Europeans, a habitual diet high in 
MUFA resulted in a more rapid return to pre-prandial TAG levels, as demonstrated after only 4 
weeks of dietary intervention in the present study. In the latter, the decrease in TAG was not 
likely to be due to a lowering of body weight since there was no significant reduction in this 
parameter over the 4 week study period. Blades and Gorg (1995) proposed that the TAG- 
lowering produced by MUFA was due to a decreased production of VLDL-TAG in the liver, and 
not due to increased lipolysis in the circulation.
TGRL-TAG
In the present study, there was a significant decrease in the concentration of CM-TAG in 
response to the MUFA diet, in fasting plasma samples. Valsta et a l (1992) suggested that 
changes in CM/CM-R may make a more important contribution to the reduction in plasma TAG 
after MUFA intervention than VLDL. In contrast, Georgopoulos et a l (1998) proposed that a 
high-MUFA diet promotes an increase in CM-R through impaired fat clearance. Zampelas et a l
(1998) found that diets habitually high in MUFA also had a more rapid return to pre-prandial 
CM-TAG levels as in the present study. Reductions in VLDL-TAG in response to the MUFA 
diet were apparent in both fasted and postprandial states. A decline in VLDL-TAG after MUFA 
intervention has been a consistent finding (Garg et a l, 1988;Gustafsson et a l, 1994; Chang and 
Huang, 1998). Georgopoulos et a l (1998) reported a significant increase in 'dense'-VLDL in 
the fasting state, a finding similar to the present study. Valsta et a l (1992) proposed that the type 
of MUFA may be an important determinant of the effect on the TGRL, with rapeseed oil 
lowering VLDL-TAG to a lesser extent that sunflower oil, which is in accord with the present 
studies findings of a minimal effect of rapeseed oil on VLDL. From evidence to date, it is 
reasonable to speculate that the MUFA enriched diet was more beneficial postprandially, since all 
TGRL fractions were found to be reduced relative to fasting levels.
TRL-apo B-48
In addition to the effects on VLDL, the MUFA-enriched diet was also associated with a
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significant decrease in the TRL-apo B-48, which further supports the fall in Tight-TGRL’, (CM 
and CM-R-TAG). Zampelas et ah (1998) found that Southern Europeans habituated to a MUFA- 
rich diet had lower concentrations of apo B-48, as did Roche et a l (2000) when 40 g of olive oil 
was given per day over a 8 week MUFA intervention. However, the present study did not 
reproduce the previously found bi-phasic response to MUFA (Jackson et a l, 1999), which may 
be explained by the fact that only 18 % MUFA was supplemented in this case, a level below the 
threshold of 24 % MUFA, previously shown to give rise to a bi-phasic response by Jackson et a l
(1999).
PH-LPL
In line with the findings in the present study, a habitual diet enriched with MUFA has previously 
been associated with a higher LPL activity in post-heparin plasma and an inverse relationship 
between LPL activity and plasma TAG (Jackson et al, 2000). Although Williams et a l (1999) 
failed to show any significant difference in LPL, this study also failed to show any effect on 
plasma TAG after MUFA intervention. The present study revealed a relationship between the 
change in Tight’-VLDL at time 0 and LPL at 5 min and between the change in CM at 360 min 
and LPL at 5 min, which might imply that LPL activity was inversely related to the change in 
Tight’-TGRL after the MUFA dietary intervention.
Plasma total cholesterol  ^LDL-C, HDL-C
Total plasma cholesterol was significantly reduced after the MUFA-diet as found by other 
workers (Mattson and Grundy 1985; Sirtori et a l  1986; Mensink and Katan 1989; Berry et a l 
1991; Jansen et a l 2000). There was also a 13 % reduction in LDL-C, as found by Jansen et al
(2000). The mechanism by which MUFA reduces LDL-C is not fully understood but may be 
through stimulation of LDL receptor activity (Daumerie et a l, 1992). The impact of a MUFA 
intervention on HDL-C levels is also controversial. In the present study, the isocaloric 
replacement of SFA with MUFA had no effect on HDL-C, a finding supported by several other 
workers (Mattson and Grundy, 1985; Sirtori et a l, 1986; Grundy, 1989; Grundy and Denke, 
1990; Wardlaw e ta l,  1991; Berry e ta l,  1991; Mata e ta l,  1992).
Plasma NEFA
There was no significant difference between plasma NEFA levels before and after the MUFA 
intervention diet. This is contrary to the findings of Zampelas et a l (1998) who found that a
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high habitual intake of MUFA significantly reduced plasma NEFA However, despite the lack of 
response in NEFA, there was also a highly significant positive relationship between the change in 
NEFA and TAG at the peak of postprandial lipaemia at 360 min, suggesting that after the MUFA 
diet, (bar one subject) those subjects with the greatest decrease in NEFA had the greatest 
decrease in TAG.
Plastna glucose and insulin
There was no significant difference in plasma glucose between pre- and post-MUFA samples. 
This is in accord with the findings of others (Foley et a l, 1992; Roche et a l, 1998), and has also 
reported in hyperlipidaemic individuals (Nydahl e ta l,  1994).
The finding of a decrease in postprandial plasma insulin levels after a MUFA enriched diet is 
consistent with previous work (Lopez-Segura et a l, 1996; Roche et a l, 1998). Zampelas et a l 
(1998), also reported that plasma insulin levels showed higher peaks after a MUFA diet when 
compared with the control (habitual) diet, suggesting a more rapid response to dietary glucose, 
and, once stimulated, a more rapid return to baseline levels. There was also a significant 
relationship between the change in glucose and insulin at time 0 after the MUFA diet, indicating 
that those subjects with the greatest fall in glucose had the greatest fall in insulin post-MUFA. 
This might imply that high-MUFA diets improve insulin sensitivity, as postulated by Riccardi 
and Rivellese (2000). There was also a significant relationship between the change in plasma 
TAG and insulin at 360 min post-MUFA, once again suggesting that a MUFA-enriched diet may 
improve insulin responsiveness.
Additional measurements
Since MUFA tends to exert a greater effect than PUFA on cholesterol metabolism additional 
measurements could have included postprandial total cholesterol, HDL-C and LDL-C. In 
addition, since MUFA has been reported to increase the oxidative resistance of LDL, LDL 
oxidation should be measured (Mensink and Katan, 1992).
Conclusion
In the present study a MUFA-enriched diet was shown to produce a hypotriacylglycerolaemic 
effect, principally by ‘very-light’-TGRL in the form of CM and CM-R-TAG and TRL-apo B-48 
over VLDL. In addition, the MUFA diet lowered total and LDL-C, whilst preserving HDL-C 
levels, whilst having favourable effects on glucose and insulin levels. These changes in blood
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lipids in response to MUFA have positive implications for the use as MUFA as a substitute for 
high CHO diets in the replacement of dietary SFA.
6.8 A im s  o f  s t u d y  n
The aim of this study was to determine the effects of an n-3 PUFA-enriched diet on the 
distribution of TGRL subclasses, and to assess if this diet could influence the ALP through the 
redistribution of TGRL subclasses towards smaller and denser particles, principally VLDL. The 
present study design was a 12 week dietary intervention, replacing approximately 45 g of 
saturated fat per subject with either n-3 or n-6 PUFA.
6.9 MATERIALS 
FOODS
• Sunflower oil sachets were supplied by Savant Distribution Ltd (England) on behalf of Flora 
manufacturing and distribution (Canada)
• Rapeseed cooking oil was supplied by Sainsburys supermarket
• Monounsaturated fat margarine was supplied by St. Ivel (Swindon)
• Fish oil capsules ‘PikasoT (1 g capsules) were supplied by LUBE A/S (Denmark)
6.10 St u d y  Pr o t o c o l
6.10.1 Study design
This study was organised and undertaken by another investigator as part of a 12 week dietary 
intervention, at the University of Surrey in conjunction with the Royal Surrey County Hospital. 
The present study represents the data from the first two (A and B) of three cohorts.
Subjects were asked to follow one of two dietary interventions; n-6 PUFA-enriched or n-3 
PUFA-enriched diets run in parallel, (Figure 68), with the n-6 PUFA acting as the control diet.
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Figure 67: n-3 PUFA study design
6.10.2 Subject recruitment
Twelve, non obese, healthy male subjects were recruited from local GP surgeries, after receiving 
local research ethic committee approval. Subjects were rejected on the grounds of consuming 
more than 30 units of alcohol a week, smoking, having a BMI in excess of 30 kg/m^, or any 
illness known to affect glucose or lipid metabolism. The subjects entry criteria included the 
expression of an ALP characteristics are illustrated in Table 27, and subject characteristics are 
illustrated in Table 28.
Table 27: Subject selection criteria
Subject (n = 12) mmol/l
TAG
Total cholesterol 
HDL-C
1.5-4.5 
<(x5 
< 1
Abbreviations: TAG: triacyglycerol, HDL-C: high density lipoprotein cholesterol
Table 28: Subject characteristics
Subject Control (n-6 PUFA) group n-3 PUFA group
(n = 12) Age (yr) BMI (kg/m") Age (yr) BMI (kg/m")
Mean + SD 56 + 4.7 28.7 + 4.4 52 ±5.5 28.6 + 3.6
Abbreviations: BMI: body mass index, SD: standard deviation
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6.10.3 Dietary intervention protocol
A 7-day food diary was completed by each subject prior to commencing the trial to assess their 
habitual food intake, and was analysed using ‘Diet-plan 5 programme, (Foresterfield, Horsham, 
West Sussex). Subjects were then randomly allocated to one of two diets. During the study, 
each subject was given individual dietary advice as to how best to follow a low fat diet, whilst 
replacing approximately 45 g of dietary saturated fat with a fat of n-6 PUFA and n-3 PUFA, plus 
fish oil capsules. The intervention involved fat supplementation in three forms; cooking oil, oil 
sachets and margarine (Table 29). For further details on the composition of foods see Appendix
vn.
Table 29; Components of n-3 and n-6 PUFA dietary intervention
Diet code Intervention Cooking oil Oil sachets 
(15 g X 2/d)
Margarine Capsules 
(Ig X 6/d)
Y n-6 PUFA rapeseed oil sunflower oil MUFA —
Z n-3 PUFA rapeseed oil sunflower oil MUFA Fish oil
Abbreviations: d: day, g: gram
All subjects were instructed to use 2 oil sachets and in addition, if in the n-3 PUFA group, 6 fish 
oil capsules a day with meals providing a total of 3.02 g of EPA/DHA (1.68 g of EPA and 1.34 g 
of DBA). The subjects were also given dietary advice on how to incorporate the cooking oil and 
margarine into their diet.
6.10.3.1 Blood Sampling
Fasting blood samples (30 ml) were taken immediately prior to starting the intervention at week 
0 then weeks 6 and week 12 at the end of the study. On the day before sampling subjects were 
asked to fast overnight (14 hr) and refrain from any strenuous exercise or alcohol consumption 
for 24 hours prior.
6.10.3.2 Preparation of plasma samples
The blood samples were aliquoted into appropriate containers (EDTA and sodium citrate) and 
immediately centrifuged at 3000 rpm, for 10 minutes (8.56 x 10^  g min), at room temperature. 
All plasma samples were stored at -80°C before analysis with the exception of plasma for the 
separation of TGRL subclasses which was undertaken immediately.
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6.11 Sample analysis
The analyses of TGRL was undertaken as described in Section 3.6, (n = 12, n = 6 for each 
cohort). All other dietary analysis, red blood cell membrane phospholipid fatty acid composition 
(only available for cohort A, n = 6), total apo B (only available for cohort A, n = 6), plasma 
TAG, total cholesterol, LDL-C, HDL-C, glucose, (n = 12), were undertaken by another 
investigator using methodology described in Chapter 2 .
6.12 Data  Analysis
As described previously in Section 2.4
6.13 RESULTS
6.13.1 Dietary analysis
The n-3 and n-6 dietary interventions resulted in a significant increase in the intake of n-3 PUFA 
compared to the respective habitual diets (Table 30). However those on the n-6 PUFA 
intervention had a significant increase in body weight and an increase in the intake of total fat as 
a percentage of total energy intake. There was also a significant increase and decrease in the n- 
6:n-3 ratio after n-6 and n-3 PUFA dietary interventions respectively. Alcohol intake decreased 
after n-6 PUFA and increased after n-3 PUFA from 0 to 12 weeks.
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Table 30: Dietary composition analysed at time 0 and 12 weeks
Habitual Diet Week 12
Dietary Diet Y Dietz Diet Y Dietz
composition (n-6 PUFA) (n-3 PUFA) (n-6 PUFA) (n-3 PUFA)
(% total energy) n = 6 n = 6 n = 6 n = 6
Energy (kJ) 9978.8 + 1112.9 12133.6 ±1041.8 10104.3 ±1108.8 11288.4 ±1241.8
CHO 37.3 ±5.8 39.4 ±5.4 35.8 ±4.8 40.3 ± 5.9
Protein 14.2 ±2.5 16.0 ± 2 14.6 ±2.5 14.9 ±2.1
Alcohol 13.4 ±5 9.0 ±5.9 6.4 ±4.2* 11.5 ±1.5*
Fat 35.2±6.1 35.7 ±4.9 43.3 ± 6.8 * 39.7 ±5.7
SFA 13.9 + 5 14.2 ±3.1 12.4 ±2.7 10.5 ±1.8
MUFA 12.7 ±2.3 12.8 ±1.7 14.9 ±3.3 * 12.9 ±2.5
n-3 PUFA 0.1 ± 0.1 0.2 ± 0.2 0.3 ± 0.2 *Y 1.5 ±0.1 *
n-6 PUFA 1.5 ±0.5 1.2 ±0.5 7.7 ±0.3 * 7.0±0.1 *
n-6:n-3 PUFA ratio 9.7 ±2.0 8.0 ± 2.0 31.8 ±16.2 *YV 4.8 ± 0.28 *
Body Weight (kg) 84.7 ±12.4 92.2 ±12.6 86.1 ± 12.8 * 93.7 ±13.1
* (p< 0.05) wherep  refers to the macronutrient difference pre- and post-intervention.
V}/ {p< 0.05), vj/vj/ {p< 0.001), wherep  refers to the differences between n-3 and n- 6 PUFA diets.
6.13.2 Red blood cell membrane phospholipid fattv add profile
There was no effect in the red blood cell phospholipid composition in the n-6 PUFA group over 
the 12 week dietary intervention. However, the proportion of EPA was increased by 1 % on the 
n-6 PUFA diet, (Table 31). The levels of EPA (C20:5) were found to increase on the n-3 PUFA 
diet relative to the habitual diet at 6 weeks (p<0.05), and at 12 weeks (p<0.001). DHA (C22:6) 
levels were also found to be significantly greater from at 12 weeks on the n-3 PUFA diet relative 
to the habitual diet (p<0.05).
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Table 31: RBC phospholipid fatty acid composition
Time 0 week 6 week 12 week
RBC M FA 
(% area)
n-6 PUFA n-3 PUFA n-6 PUFA n-3 PUFA n-6 PUFA n-3 PUFA
EPA 2.7+1 4.2 + 1.9 2.6 + 1.6 9.3 + 3.3 * 3.3+ 2.1 9.4 + 3.2 ♦
(20:5 n-3)
DHA 3.2+ 0.3 3.7+ 0.7 3.2+ 0.5 3.9+ 0.8 3.1 + 0.5 4.3 + 0.6 *
(22:6 n-3)
**(p< 0.001), *(p< 0.05) where p  refer to the difference in post- from pre-intervention EPA and DHA levels, n = 
6 .
6.13.3 Plasma TAG
Fasting plasma TAG levels after dietary intervention are shown in Figure 68. On the n-3 PUFA 
enriched diet there was a significant decrease in plasma TAG relative to the habitual diet after 6 
weeks (-22 %,/?<0.01), and 12 weeks (-29 %,/?<0.001). There was also a significant decrease in 
fasting plasma TAG on the n-3 PUFA diet compared to the n-6 PUFA diet at 6 weeks (-26 %, 
/KO.005) and 12 weeks (-29 %,/KO.0001).
T im e  (w e e k )
Figure 68: The effect of a n-3 PUFA diet on fasting plasma TAG over the 12 week dietary intervention period 
Plasma was taken at time 0, 6 and 12 weeks after dietary intervention, the n-3 PUFA groiq) are represented by I. 
and the n-6 PUFA control group by H . Results are means + SD for n = 12. **(p<0.001), *(p<0.05) where p  
values refer to the difference in plasma TAG during the 12 week dietary intervention period, after a repeated 
measures ANOVA.
6.13.4 TGRL-TAG
The concentration of TGRL-TAG after dietary intervention are shown in Figure 69. Over time, a
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significant decrease on the n-6 PUFA diet was found in; the Tight’-TGRL (CM) fraction at 6 (- 
33 %) and 12 (-35 %) weeks compared to the habitual diet (p<0.05) and CM-R2 from 6 to 12 
weeks (-32 %,/?<0.05), The n-3 PUFA diet was accompanied by a decrease in all TGRL-TAG 
fractions relative to the habitual diet at 6 and 12 weeks. Significant decreases were found in the 
Tight’-TGRL CM (-50 %), CM-R^ (-36 %), CM-R^ (-42 %), Tight’-(-40 %) and ‘dense’-VLDL 
(-38 %) fractions at 12 weeks and from 6 to 12 weeks relative to the habitual diet (/?<0.001). 
Both ‘light’- (-25 %) and ‘dense’-VLDL (-18 %) were decreased on the n-3 PUFA diet relative 
to the n-6 diet (p<0.05) at 6 weeks. Highly significant correlations were evident between the 
change in plasma TAG and ‘dense’-VLDL on the n-3 PUFA diet at 6 (r = 0.76,p<0.005) and 12 
weeks (r = 0.66,p<0.05) respectively, (Figure 70),
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Figure 69: The effect of dietary intervention on TGRL-TAG fractions, measured at 0, 6 and 12 weeks for the ( A ) 
n-6 PUFA diet and, ( B ) n-3 PUFA diet. TGRL-TAG, for the n-3 PUFA group are represented by H  at week 0, HQ 
at week 6 and QH at week 12 and the n-6 PUFA group by H  at week 0, at week 6 IDII and O  at week 12. Results are 
means + SD for n = 12. **(p<0.001), *(p <0.05) where p  values refer to the difference in TGRL-TAG over time 
and <0.05) where p  values refer to the difference in TGRL-TAG, between diets, during the 12 week dietary 
intervention period after a repeated measures ANOVA.
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Figure 70: ( A ) Relationship between the changes in ‘dense’-VLDL and fasting plasma TAG at 6 weeks after the 
n-3 PUFA diet (r = 0.76, /7<0.005) and ( B ) 12 weeks (r = 0.66, p<  0.05). Results are means + SD for n = 12.
6.13.5 TGRL-protein
The concentration of TGRL-protein after the dietary interventions are shown, in Figure 71. The 
n-3 PUFA diet was associated with a small but non-significant decrease in TGRL-protein after 6 
and 12 weeks. There was a significant decrease in ‘dense’-VLDL, in n-3 relative to n-6 PUFA at 
6 weeks (-36 %,/KO.OOl).
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Figure 71: The effect of a dietary intervention on TGRL-protein fractions, measured at 0, 6 and 12 weeks, for the 
( A ) n-6 PUFA diet, ( B ) and n-3 PUFA diet. TGRL-protein, after dietary intervention, the n-3 PUFA group are 
represented by H  at week 0, DD] at week 6 and E3 at week 12 and the n-6 PUFA group by H  at week 0, QD at week 
6 and E] at week 12. Results are means + SD for n = 12. v|/(p <0.05) where p  values refer to the difference in 
TGRL-protein, between diets, during the 12 week dietary intervention period after a repeated measures ANOVA.
6.13.6 Plasma total apo B
Plasma total apo B levels after the dietary interventions are shown in Figure 72. There were no 
changes in plasma total apo B from time 0 to 6 and 12 weeks on both diets. On an individual 
subject basis, 3 out of 6 showed increases in apo B at 6 weeks after the n-6 PUFA diet whereas 5 
out of 6 had increases in apo B after 12 weeks.
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Figure 72: The effect of a n-3 PUFA diet on fasting plasma total apo B over the 12 week dietary intervention 
period, at times 0, 6 and 12 weeks. The n-3 PUFA groiq) are represented by H. and the n-6 PUFA control by H . 
Results are means + SD for n = 12.
6.13.7 Plasma total cholesterol. HDL-C. LDL-C
There were no significant differences with time or within and between n-3 and n-6 diets in 
plasma total cholesterol levels, HDL-C, LDL-C levels, (Table 32).
Table 32 : Pre- and post-diet total plasma cholesterol, LDL-C and HDL-C levels at 0, 6 and 12 weeks. Values are 
± SD, n = 12
Diet Total cholesterol (mmol/l) LDL-C (mmol/l) HDL-C (mmol/l)
Week 0 6 12 0 6 12 0 6 12
6.33 6.03 5.98 3.85 3.96 3.84 1.15 1.18 1.17
n-3 PUFA ± 1.48 ± 1.12 ± 1.31 ±0.79 ±0.67 ± 0.86 ±0.31 ±0.28 ±0.29
6.01 5.60 5.40 3.81 3.53 3.49 1.10 1.09 1.02
n-6 PUFA ± 1.02 ± 1.22 ±5.32 ±0.82 ±0.75 ±0.61 ± 0.21 ±0.26 ±0.19
6.13.8 Plasma glucose
Plasma glucose levels are shown, in Figure 73. There were no changes in fasting plasma glucose 
relative to the habitual diet at either 6 or 12 weeks after the n-3 and n-6 PUFA diets.
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Figure 73: The effect of a n-3 PUFA diet on plasma glucose over the 12 week dietary intervention period, at times 
0, 6 and 12 weeks. The n-3 PUFA groiq) are represented by H. and the n-6 PUFA control grotp by I. Results are 
means + SD for n = 12.
6.14 D is c u s sio n
The main aim of this study was to further characterise the hypotriacylglycerolaemic effects of 
dietary long chain n-3 PUFA in terms of changes in TGRL subclasses. This would provide 
information relating to the mechanisms by which these fatty acids modulate the lipoprotein 
abnormalities of an ALP.
Red blood cell phospholipid fatty acid membrane composition
EPA and DHA levels on the n-3 PUFA diet increased significantly relative to the habitual diet at 
6 and 12 weeks. Habitual EPA and DHA intakes have been shown to be very important in 
determining the extent to which n-3 PUFA are incorporated into membrane PL, in that if platelet 
PL EPA levels are high on the habitual diet, then the incremental gain will be low. An increase 
in PL EPA in response to n-3 PUFA is in accordance with the findings of Harris (1989). EPA 
and DHA have different catabolic rates, and are partitioned differently between tissues, with 
DHA achieving higher levels in adipose tissue than EPA after fish oil feeding (Gibney and Daly, 
1994). DHA is distributed largely in the inner layer of the membrane and EPA in the outer layer 
of the erythrocyte PL, DHA also has a longer half-life than EPA in erthyrocytes following the 
cessation of fish oil feeding. EPA, unlike DHA is therefore available for removal from 
erythrocytes through phospholipid exchange which persists for the 120 days of the erythrocytes 
life (Gibney and Daly, 1994). The reason being, as postulated by
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Sadou et a l (1995) and Davidson et a l (1997), is due to the preferential incorporation of DHA 
into the sn-2 position in fish oil TAG, which produces a 1.4-fold increase in 2-DHA- 
monoacylglycerol over 2-EPA-monoacylglycerol as a result of preferential attack of this position 
by lipase in accordance with studies in the rat (Yang et a l, 1989; Davidson et a l, 1997).
Body weight
After the n-6 PUFA enriched diet (control), there was a significant increase in body weight by 12 
weeks, which did not occur after the n-3 PUFA diej;. What this might indicate is a failure in the 
n-6 PUFA group to adjust their normal eating habits to compensate for the dietary supplements. 
It is also an undesirable side-effect in HTG subjects, but is the likely result of an insufficient 
reduction of SFA consumption during supplementation with n-6 PUFA. An increase in body 
weight in response to dietary fat supplementation has been found in a previous study (Lovegrove 
et a l, 1997), whilst others have recorded a constant weight throughout the dietary intervention 
period (Kestin e ta l, 1990; Chan e ta l, 1993; Mantzioris e ta l, 1995).
Plasma TAG
The n-3 PUFA intervention diet was associated with a significant decrease in fasting plasma 
TAG compared to n-6 PUFA diet with levels at 12 weeks falling by 29 %. The magnitude of the 
decrease on the n-3 PUFA diet was similar to that found by Harris (1989). The same author, 
later did a meta-analysis of 36 cross-over and 29 parallel studies, and found fasting plasma TAG 
was reduced by between 25-30 % on an n-3 PUFA diet (Harris, 1997). A reduction in plasma 
TAG is also consistent with the findings of other groups (Weintraub et a l, 1988; Blonk et a l, 
1990; Tidwell et a l, 1993; Harris, 1996; Roche and Gibney, 1996; Saldeen et a l, 1998; 
Delzenne et a l, 1998; Nestel, 2000). The same effect has been demonstrated in cell culture 
systems of both animals and humans (Nordoy, 1985). A possible explanation for the TAG- 
lowering action of n-3 PUFA is provided by studies in cultured hepatocytes, in which the 
synthesis and secretion of TAG is reduced on exposure to EPA and DHA, predominantly through 
a decrease in plasma VLDL-TAG (Rustan et a l, 1988). These fatty acids also exert an inhibitory 
effect on the estérification of other fatty acids, thereby promoting an overall diminution in the 
flux of FA directed into TAG synthesis (Clarke, 1990). In addition, reduced competition 
between VLDL and CM for LPL, or an increased level of LPL (Weintraub et a l, 1988; 
Zampelas et a l, 1994) could contribute to a reduced level of plasma TAG through increased 
catabolism.
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TGRL-TAG
The n-3 PUFA diet was accompanied by decreases in TGRL-TAG compared to n-6 PUFA at 6 
weeks, and at 12 weeks in ‘light’-TGRL, CM, CM-R^, CM-Rg and most notably in ‘dense’- 
VLDL, which was found to correlate with changes in plasma TAG, despite unchanged total apo 
B levels. A reduction in VLDL-TAG is in accordance with the literature (Nestel et a l, 1984; 
Sanders e ta l, 1985; Rustan e ta l, 1988; Blonk e ta l, 1990; Childs e ta l, 1990; Parks and Rudel, 
1990; Gibney and Daly, 1994; Mackness et a l, 1994; Connor et a l, 1998; Tinker et a l, 1999; 
Baker and Gibbons, 2000). Reductions in VLDL-TAG after n-3 PUFA supplementation have 
been found in both healthy (Gibney and Daly, 1994) and hypertriacylglycerolaemic subjects 
(Connor e ta l, 1998) as well as in animal (Sanders e ta l, 1985) and cultured cells (Rustan e ta l, 
1988; Parks and Rudel, 1990). Blonk et a l, (1990) postulated that only decreases in VLDL 
would lead to large decreases in the concentration of plasma TAG, which is the probable 
explanation for why HTG subjects show a marked response in VLDL-TAG to n-3 PUFA 
supplementation.
With regard to the impact of n-3 PUFA on VLDL heterogeneity, several kinetic studies (Nestel et 
a l, 1984; Sanders et a l, 1985), have shown that n-3 PUFA has a greater impact on the assembly 
of VLDL as compared to its effect on VLDL catabolism, principally by the production of smaller 
VLDL2 particles (Westphal et a l, 2000). This is supported by the present data, since after n-3 
PUFA supplementation ‘dense’-VLDL was significantly decreased from baseline (habitual 
intake) at 6 and 12 weeks, and also correlated with the change in plasma TAG at these time 
points. Packard et a l (1984) proposed that n-3 PUFA supplementation reduces the size of 
VLDL secreted by the liver, producing smaller VLDL, which are then more readily converted to 
LDL, and more easily removed in the peripheral tissues or by the liver as VLDL remnants 
(Phillipson et a l, 1985). The decreased formation of ‘dense’-VLDL after n-3 PUFA 
supplementation is supported by the suggested fall in VLDL-protein data from the habitual diet. 
Kinetic studies by Harris et a l (1990) in which the protein moiety of VLDL was radiolabelled, 
have confirmed a decrease in the hepatic production of VLDL on a n-3 PUFA diet, implying that 
there is a difference in both the amount and size of VLDL. There has been considerable 
speculation about possible mechanisms of action on n-3 PUFA on VLDL metabolism. Childs et 
a l (1990) postulated the decrease in VLDL-TAG was due to increased hepatic peroxisomal 
oxidation resulting in a decrease in VLDL-TAG production, an idea that is supported by the 
work of others (Harris et a l, 1984; Nestel et a l, 1984; Drevon et a l, 1995). Illingworth and
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Schmidt, (1993) suggested that n-3 PUFA could induce an increase in VLDL catabolism and 
reduction in particle size by influencing HL or LPL activity which was further supported by 
Weintraub et al. (1988) and Harris et al. (1990). Evidence from cultured rat and hepatocytes by 
Lang and Davis (1990) indicates that n-3 PUFA may impair the assembly and or secretion of 
VLDL. This theory is also supported by human data by Bordin et al. (1998) who found a 73 % 
decrease in the TAG pool and a 55 % decrease in the production rate of apo B-lOO containing 
lipoproteins. Kendrick et al. (1998) suggested that n-3 PUFAs inhibit the assembly of VLDL at 
an early stage and affect events in the RER lumen. Long chain n-3 PUFA have also been shown 
to inhibit two ‘rate limiting’ enzymes in TAG synthesis, phosphatidate phosphohydrolase (Marsh 
et a l, 1987) and acyl Co A: diacylglycerol acyl transferase, the last enzyme in the TAG synthetic 
pathway (Rustan et a l, 1988). Moreover, n-3 PUFA have been shown to divert fatty acid 
synthesis into phospholipid synthesis rather than the usual pathway of TAG synthesis (Benner et 
a l, 1990). Clarke (1990) studied rat liver and found that n-3 PUFA compared to n-6 PUFA 
reduces the activity of the enzymes involved in fat synthesis. This is due to decreases in the 
quantity of enzymes present, a decrease in m-RNA, and a decrease in transcription of the fatty 
acid synthase gene in the liver and adipose tissue (Murphy et a l, 1999).
The present study revealed a marked decrease in ‘light’-TGRL corresponding to CM-R^-TAG, 
CM-R2-TAG, from 6 weeks onwards after the n-3 PUFA diet. This finding is in accordance with 
that of several other groups (Conner and Connor, 1982; Chen et a l, 1987; Harris et a l, 1988; 
Weintraub et a l, 1988; Harris and Windsor, 1991; Demacker et a l, 1991; Tinker et a l, 1999). 
However, the majority of studies had given their subjects an oral fat tolerance test, whereas the 
present study focused attention the post-absorptive state, in which the production of CM is 
undetectable. Less data is available on CM-R, although a decrease after PUFA intervention has 
been reported (Dallongeville et a l, 1991; Pschierer et a l, 1995; Westphal et a l, 2000). CM-R 
may acquire an insufficient amount of apo E when CM levels remain high in the postprandial 
state. Only when CM levels decrease may sufficient apo E become available for CM-R, which in 
turn accelerates their removal. Harris et a l (1988) proposed that long chain n-3 PUFA inhibit or 
delay the synthesis and or secretion of CM from the gut. However, Harris and Windsor, (1991) 
concluded that this reduction in CM-R was not due to effects on CM production but through the 
acceleration of CM lipid clearance via LPL mediated lipolysis. The latter effect may arise as a 
result of either; chemical surface alteration by improving the action of LPL (Borensztajn and
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Kotlar, 1990), or reduced competition with VLDL since there are fewer VLDL particles (Eckel, 
1989; Karpe et a l, 1997), or through increased LPL activity (Harris et a l, 1997).
Plasma total cholesterol, LDL-C and HDL-C
There were no significant changes in total cholesterol, LDL-C and HDL-C. The lack of response 
in LDL-C is supported by meta-analysis conducted by Harris (1997). This included examination 
of 72 placebo-controlled human trials of at least 2 weeks in length and giving < 7 g of n-3 
PUP A/day, and found that in healthy subjects (TAG < 2 mmol/l) there was no net effect on total 
cholesterol levels. Similarly the lack of response in HDL-C is consistent with the findings of 
others (Childs et a l, 1990; Nenseter et a l, 1992; Tidwell et a l, 1993; Connor et a l, 1998). In 
addition, with HTG subjects, (TAG > 2 mmol/l) there were no significant changes in HDL-C 
(Harris, 1997). Although not measured in the present study, the n-3 PUFA effect on HDL is 
suggested to be due to a dose-dependent increase in HDL^-C and a decrease in HDL3-C 
(Schmidt, 1993). This provides a possible explanation for the lowering of TGRL, due to greater 
ability of HDLg-C to clear more TAG than HDL3-C (Schmidt, 1993). In this study, it would 
have been expected that since there was a significant decrease in the ‘dense’-VLDL that this 
would have also affected LDL-C, resulting in a reduction in LDL-C levels (Leaf et a l, 1994). 
Decreased VLDL levels, surprisingly, did not seem to have an effect on LDL-C, which implies 
that the unchanged LDL-C is mediated through mechanisms other than the accelerated 
conversion of VLDL to LDL (Kasim-Karakas, 1995).
Plasma glucose
Plasma glucose at both 6 and 12 weeks showed no significant change after supplementation, 
which is in accordance with the literature (Demacker et a l, 1991; Williams et a l, 1992; Connor 
et a l, 1993; Nydahl et a l, 1994; Grundt et a l, 1995; Puhakainen et a l, 1995). Saldeen et a l 
(1998) suggested that there is only an increase in glucose in response to n-3 PUFA if there are 
inadequate antioxidant levels within the fish oil. Due to the instability of fish oil, inadequate 
antioxidant levels can promote lipid peroxidation in the pancreatic beta cells resulting in 
decreased insulin secretion and thus increased plasma glucose levels.
Problems and linntations of n-3 PUFA dietary intervention studies
The results from intervention studies are generally difficult to compare (Leaf and Weber, 1988), 
due to a large numbers of factors which modulate the n-3 PUFA effect; including the population
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studied, differences in experimental design, dose and form in which the n-3 PUFA are 
administered, the period of intervention and the background diet. All of these variables could 
help to explain the heterogeneous responses (Childs e ta l, 1990). Most governments recommend 
the consumption of fish twice a week, of which at least one should be oily fish (Burr et a l, 1989) 
but this has met with a low level of compliance. A possible solution could be to change the form 
in which the fish oil is administered. Fish oil capsules, have some benefits over fresh fish, in 
terms of purity and exclusion of contaminants such as mercury or pesticides (Saldeen et a l,
1998). A recent study found 17 out of 18 UK. fresh fish samples were found to be contaminated 
(Jacobs and Johnston, 1995). However, the administration of fish oil capsules is also not without 
problems (Grundy and Denke, 1990; Mantzioris et a l, 2000), principally due to poorer 
bioavailability compared to fresh fish or to insufficient amounts of antioxidants (Higgins et a l,
1999). Fish oil is generally considered very unstable and several studies (Lovegrove et a l, 1997; 
Mantzioris et a l, 2000), have tried to incorporate fish oils in other forms of food such as 
milkshakes. However, it is important to be cautious with regard to the addition of other 
ingredients to n-3 PUFA. They can adversely affect bioavailability, notably in the case of other 
fats such as linoleic acid, which may affect n-3 PUFA incorporation into platelet PL.
There is evidence to suggest that the TAG-lowering effect of fish oil is dose-dependent, 
demonstrating a linear dose-response relationship with intake levels (Schmidt et a l, 1990; 
Wallingford and Yetlet, 1991) that is reversible (Goodnight et a l, 1982). Blonk et a l (1990) 
gave 1,3,5, and 6 g/d of marine fatty acids EPA and DHA, over 12 weeks to 45 healthy men and 
found 3 g/d n-3 PUFA appeared to be the appropriate supplementation dose in humans with 
regard to effects on lipid profiles and incorporation into plasma PL. From 3-6 g/d there was only 
a relatively small additional increase in PL incorporation after doubling the amounts of EPA and 
DHA. Further evidence was provided by Roche and Gibney (1996) who gave 1.05 g/d for 16 
weeks and found a 15 % reduction in plasma TAG, whilst Blonk et a l (1990) gave 3 g/d of EPA 
and DHA for 6 weeks and recorded a 25 % reduction in fasting plasma TAG. However, Sanders 
et a l (1985), gave 5 g/d (19-20 g of maxEPA) and found no response. Low levels of EPA + 
DHA 0.60 g/d (Davidson and Gold, 1988) and 0.65 g/d (Lervang et a l, 1993) have no 
hypotriacylglycerolaemic effect. There is, however, the possibility that lower levels of n-3 
PUFA may be effective in reducing plasma TAG if supplemented for long periods. Agren et a l 
(1996) found significant differences with 1.05 g/d EPA+DHA after 9 weeks of n-3 PUFA 
supplementation. Others suggest that the ratio of EPA:DHA is critical to the
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hypotriacylglycerolaemic effect (Childs et a l, 1990). This ratio varies with the source of fish oil. 
Most studies use Max EPA (EPAiDHA, 1.25) but others have used North Sea fish (EPA:DHA, 
1.6) (Mori et a l, 1987), salmon (EPA;DHA, 0.8) (Coleman et a l, 1987), or cod liver oil 
(EPA:DHA, 0.6) (Popp-Snyders et a l, 1984). The effect of fish oil on plasma TAG has been 
suggested to be due primarily to EPA rather than DHA (Rambjor et a l, 1996; Hamazaki et a l, 
1996). Conversely, Childs et a l (1990) gave 1.5 g/d DHA and claimed that DHA was equally 
effective. Other more recent evidence indicates that DHA is more effective in reducing TAG 
levels than EPA, and criticised Rambjor et a l (1996) for being too short and using too few 
subjects (Davidson e ta l, 1997).
The length of supplementation period is also important in considering whether the effects are 
sustainable or just transient. Agren et a l (1990) found that platelet EPA levels reached a 
maximum concentration within 5 weeks of supplementation, whilst DHA levels continued to rise 
until 12 weeks, which was therefore postulated to be the optimal time to re-establish an 
equilibrium post-supplementation. Saynor and Gillbott (1992) provided 3 g/d of n-3 PUFA for 4 
years and Schmidt et a l (1992) 4 g of n-3 PUFA per day for 9 months and found time-related 
reductions in plasma TAG concentrations. The largest n-3 PUFA fish oil trial conducted to date, 
the GISSI trial (GISSI-Prevenzione Investigators, 1999) involved 11,324 myocardial infarction 
patients who were given 1 g/d of PUFA over a period of two years and still found TAG 
reductions. Schectman et a l (1989) examined the ability of n-3 fatty acid supplementation to 
affect reductions in serum TAG, by administering 10 g/d for 3 months then 4 g/d for 3 months 
and found that plasma TAG reverted back to baseline (habitual) levels. Whilst Durrington et a l, 
(2001) found that 2 g x 2/d over 48 weeks decreased plasma TAG by 30 %. The length of 
supplementation has also proved to be an important determinant of the plasma lipid response to 
n-3 PUFA. While the present study used 12 weeks, effects have been noted in only 4 weeks 
(Saldeen e ta l, 1998; Mantzioris e ta l, 2000).
Problems in interpretation o f study results and additional measurements 
The present study encountered problems of poor compliance in the second cohort. The only way 
to reduce poor compliance would be to bring the subjects into the University and place them into 
a controlled environment, where all food consumed was monitored. This however would be 
invasive, impractical, too expensive for a 12 week dietary intervention, and defeat the object of 
assessing the applicability of incorporating the dietary constituents into a ‘real’-life environment.
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In addition, some researchers such as Bailor et a l (1988) have questioned the use of n-6 PUFA as 
a ‘control’ and found n-6 to produce a reduction in cholesterol, LDL-C and apo B when 
consumed in place of SFA. Target intakes for EPA and DHA were assessed by a 5 day food 
diary which also has limitations. In order to accurately measure the fatty acid content of their 
diet, an individual would be required to undertake a weighed food record for a period of 15-30 
days (Nelson et a l, 1989). However, this is either not practical or is too restricting for 
volunteers. It is also well documented that adherence to dietary recording is adversely affected if 
the period of recording is too long so that volunteers alter their normal eating habits to simplify 
the task (Bingham and Cummings, 1985).
Measurements that could have been made to provide additional information on mechanisms 
include; 1) VLDL-C levels are proposed to decline after n-3 PUFA supplements (Simons et a l, 
1985) and could account for any possible changes in total cholesterol (Connor et a l, 1998); 2) 
Measurements of apo B-48 in TGRL fractions would have enabled further differentiation of 
‘light-TGRL’ of intestinal and hepatic origin, ‘light’ and ‘dense’-VLDL; 3) It has been suggested 
that n-3 PUFA lowers postprandial plasma insulin levels (Zampelas et a l, 1995) and insulin is 
said to be a regulatory hormone controlling hepatic VLDL production, a measure of plasma 
insulin would have been informative (Gibbons, 1990); 4) LPL, providing information on 
catabolism, as LPL activity has been shown to be decreased by n-3 PUFA (Harris et a l, 1997; 
Zampelas et a l, 1994; Levy et a l, 1993; Rambjor et a l, 1996); 5) CETP, as Bagdade et a l 
(1996) proposed that a reduction in CETP activity would limit the transfer of TAG between 
HDL2 and TGRL and could provide further evidence as to how n-3 PUFA affect cholesterol 
metabolism; 6) NEFA, as an indication of lipolysis in the adipose tissue and as a possible 
substrate for TAG synthesis in the liver (Nenseter et a l, 1992; Delzenne et a l, 1998); 7) Since 
PUFA has been shown to attenuate the lipaemic response and to increase the size of CM 
particles, a postprandial test would have enabled the observation of the TGRL in the postprandial 
state (Weintraub et a l, 1988; Zampelas et a l, 1994b); 8) The measurement of the susceptibility 
of LDL and VLDL to oxidation, as it is proposed to be increased after n-3 PUFA, especially in 
HTG individuals (Hau et a l, 1995); 9) Extended intervention studies of more than 2-3 years are 
also needed to examine the duration of the TAG lowering effect (Harris, 1996).
Conclusion
In the present study we found that a diet enriched with long chain n-3 PUFA for 12 weeks
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produced a hypotriacylglycerolaemic effect, that was largely mediated through a reduction in 
‘dense’-rather than ‘light’-VLDL, whilst having no effects on total cholesterol, LDL-C, HDL-C 
or on glucose levels.
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CHAPTER?:
GENERAL DISCUSSION AND CONCLUSION
CHD has become one of the major causes of morbidity and mortality in the Western World, with 
recent research placing great emphasis on the contribution of diet towards this disease. While 
research into those predisposed to atherogenesis, through possession of an ALP, has largely 
concentrated on the involvement of TAG, LDL, HDL, little research has focused on the role of 
TGRL subclasses as potential determinants of the structure and function of LDL and HDL. This 
is despite the well known involvement of TGRL in CHD in those who exhibit HTG (Zilversmit, 
1979). It is clear that the composition of an acute test meal and the fat in the habitual diet 
influences the magnitude of the postprandial lipaemic response, and that the extent of the latter is 
a determinant of the ALP. Whether this is an acute or long term phenomenon is unknown, but 
important questions arise regarding the long term efficacy of promoting the consumption of diets 
low in fat. Existing government recommendations promote the consumption of a high- 
CHO/low-fat diet, whilst a significant amount of recent research effort has concentrated on the 
health benefits of UFA, n-3 PUPA and MUFA.
Influence of CHO-, n-3 FUFA- dietary interventions on fasting values (Table 33)
The findings from the carbohydrate study suggest that the increase in plasma TAG was largely a 
result of an increase in Tight’-VLDL- rather than ‘ dense’-VLDL-TAG, which was supported by 
TGRL-protein data, suggesting an increase in VLDL particle number. The increase in VLDL 
was not due to increased availability of FFA as NEFA levels were not significantly changed. 
There was also an increase in the amount of TAG carried by CM-R and in the number of CM-R 
particles, according to increased levels of protein and CM-Rj-apo B-48. A significant reduction 
in HDL-C suggests that there was a fall in CE and TAG exchange, but unfortunately data on LPL 
activity was not available to provide evidence of reduced clearance. The high, simple-CHO diet, 
surprisingly appeared to have no detrimental effect on glucose or insulin homeostasis, but as 
mentioned previously there were problems with the sensitivity of the insulin assay. Therefore 
with regard to modulation of an ALP, acute, simple CHO supplementation resulted in an increase 
in TAG, VLDL, and a reduction in HDL-C suggesting an increased risk of ALP development, 
which together constitute an exacerbation of this high risk phenotype.
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The n-3 PUFA diet presented the opposite effect to the CHO diet, in that plasma TAG levels 
were reduced, due to a decrease in the amount of TAG carried by Tight’ and ‘dense’-VLDL, and, 
according to TGRL-protein through a decrease in the number of VLDL particles. Ideally, NEFA 
as a substrate for TAG synthesis and LPL as a rate limiting determinant of TAG catabolism, 
should have been measured as possible sources of the reduced VLDL-TAG There was also an 
unexpected decrease in the concentration of endogenous TAG carriers, CM and CM-R, (ideally 
apo B-48 would have been measured to accurately determine this) possibly because of poor 
compliance, in that subjects were not completely fasted before providing baseline blood samples. 
There was no change in HDL-C, LDL-C or total cholesterol, implying that n-3 PUFA targets 
TAG over cholesterol metabolism, and in addition had minimal affects on glucose metabolism. 
With regard to modulating an ALP, the effects of the n-3 PUFA diet on TGRL subclasses were 
consistent with the induction of beneficial changes in LDL and HDL subclasses, though the latter 
were not assessed in present study.
The influence of MUFA intervention on fasting and postprandial TGRL metabolism 
The impact of the MUFA diet on TGRL was examined in the fasting (Table 33) and postprandial 
state (Table 34), and at the height of PPL, at 360 min. While plasma TAG showed similar 
reductions in both states, there were no significant changes in the TAG concentrations of the 
various TGRL pool-fractions. The MUFA diet appeared to have a greater impact on total 
cholesterol and LDL-C in the fasting state.
Influence of ethanol on postprandial TGRL metabolism (Table 34)
Ethanol’s impact to the postprandial increase in plasma TAG was contributed to primarily by an 
increase in VLDL-TAG, but there were also increases in CM-R, TRL-apo B-48 and RE 
containing particles. A significant reduction in HL and a possible decrease in LPL activity 
suggests a reduction in clearance as the primary mechanism, reduced lipolysis being backed up 
by diminished NEFA levels. The impact of acute ethanol administration to the ALP is proposed 
to have a detrimental effect through increased TAG and VLDL levels.
Overall, both ethanol and CHO diets fuelled TAG changes by an increase in both VLDL and 
CM, with the CHO TGRL increase principally in ‘ light’ -VLDL-TAG, both studies providing 
especially mechanistic information on the ALP. Whilst the MUFA diet had a more pronounced 
effect on fasting and PPL cholesterol metabolism, PPL-CM having a greater impact to TAG
204
changes than VLDL and the TAG-lowering n-3 PUFA diet was more likely due to changes in 
VLDL over CM. Both studies suggesting a beneficial outcome for the ALP.
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D iscu ssion
Knowledge of the metabolism of the TGRL is fundamental to the understanding of the 
relationship between TAG and the predisposition to CHD in individuals expressing an ALP. 
Both dietary and environmental factors play a key role in the development of this disease. 
However, controversy exists as to the best dietary approach to prevent CHD. Through the study 
of dietary factors that modulate blood lipids, in both NTG and HTG individuals, existing 
knowledge on TGRL metabolism can be strengthened. The acute intake of ethanol with a fat 
containing meal has been shown to increase serum TAG and to accentuate the postprandial 
response. However, when consumed in moderate amounts (30 g/d) (Rimm et a/., 1999) ethanol 
may confer health benefits by increasing plasma HDL-C, and decreasing LDL-C and NEFA 
effects which may outweigh the negative effects of increased plasma TAG, VLDL, TRL-apo B- 
48 and decrease in LPL found at higher levels of consumption in acute studies. With regard to 
dietary advice, the present Government regulations stipulate that a diet high in CHO is beneficial 
to maintaining a healthy diet. However, there now exists a wealth of evidence that would 
advocate against a high-CHO diet of simple or complex CHO, principally because the former 
may increase VLDL, plasma TAG and reduce HDL-C levels, as found in the present study.
High-MUFA diets have been found to reduce plasma TAG as well as lowering plasma 
cholesterol whilst having minimal effects on glucose metabolism (Mensink et a l, 1989). In 
comparison, the n-3 PUFA diet in addition to minimal effects on glucose metabolism produced 
potent TAG-lowering effects (Williams et a l, 1992). A recent study has shown that both CHO 
and PUFA diets offer metabolic benefits with few adverse effects as compared with SFA 
(Brunner et a l, 2001). The main concern is how to implement this dietary advice, in 
recommending a shift from SFA to UFA consumption to the general public, who lack knowledge 
about dietary sources of n-3 PUFA/MUFA, and as a result are unlikely to be able to self-regulate 
and accurately substitute UFA for SFA in their diet. Changing the general public’s habitual diet 
is very difficult, individuals tend to consume foods that they like rather than one that is ‘good’ 
for them. This inability to self-regulate, gives rise to a tendency to gain weight, which in itself is 
associated with many negative health effects such as obesity and associated disorders including 
diabetes, insulin resistance and CHD. Dietary studies which have incorporated weekly 
nutritional meetings with subjects to ensure compliance, maintain morale and to answer any 
dietary queries in already motivated individuals, have still encountered problems in subjects not 
accurately substituting SFA for UFA and gaining weight (Lovegrove et a l, 1997). This presents
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further problems when transferring dietary advice to the majority of the population who are 
unlikely to be as motivated as subjects used in the present studies into changing their habitual 
diet, unless they have already had a health scare, as they do not have access to dietetic support. 
An invariable outcome is the tendency to gain weight on a high-fat diet, in a population where 
obesity is already a problem. A possible future dietary approach could include the introduction 
of functional foods, which minimise the need for calculation of the type of fat to consume by 
providing UFA-rich foods in a identifiable form and, in addition, recommending a calorie 
controlled diet, and the adoption of regular exercise.
Limitations to the interpretation of the experimental findings
There are several limitations to the present set of studies, firstly the volunteers were 
predominantly normal and healthy, so the outcomes are not largely applicable to high risk HTG 
groups. Secondly, the investigations largely took advantage of existing trials, introducing 
inconsistency in study designs between the various dietary interventions. This also meant that 
the postprandial response, the optimal test, where the TGRL metabolism is under challenge, was 
not able to be addressed in all trials. Also the CHO diet should be repeated, replacing simple 
CHO with complex CHO, or more specifically high glycaemic index CHO with low glycaemic 
index CHO, to investigate the effect of complex CHO on TGRL metabolism. Additional study 
measurements would include: VLDL-C, apo B-48, LPL, NEFA and insulin in all studies, and 
ideally apo B-lOO or VLDL-labelling data would have been available, providing more specific 
information on endogenous lipoprotein metabolism. With regard to the iodixanol method, the 
fact that levels of CM-, CM-R-TAG and protein did not always correspond with apo B-48 data, 
reflects remaining problems in the accurate separation of endogenous from exogenous 
lipoproteins. The data would suggest that the gradient is indeed isolating lipoproteins of 
endogenous and exogenous origin of the same density in the same TGRL-fraction.
Recommendations for further research
The present series of experiments were set up to firstly develop and secondly apply this method 
to study the impact of different diets on Tight’-TGRL, Tight’- and ‘dense’-VLDL metabolism. 
The iodixanol TGRL gradient was used to explore the effect of two hyperlipidaemic diets; CHO 
and ethanol and two hypolipidaemic diets; n-3 PUFA and MUFA, in both NTG and HTG 
subjects. Future TGRL research needs to incorporate the use of apo B-48 data as a routine 
procedure to characterise the separation achieved by the iodixanol gradient. Whilst the existing
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method could be improved by the introduction of automation, incorporating the use of a gradient 
maker, and through a reduction in gradient volume and sedimentation path length, the latter to 
reduce the ‘edge-effect’ or loss of TGRL particles to the sides of the centrifugation tube, all of 
which would contribute to improving the reproducibility of the assay procedure.
In  conclusion
In conclusion, the results from this thesis have provided important information on the effect of 
dietary factors on the metabolism of the TGRL. One of the most important findings from this 
study is that dietary constituents which influence postprandial lipid metabolism do so by exerting 
differential effects on TGRL subclasses. The iodixanol self-forming gradient will provide a 
useful tool in the future differentiation of the relative roles of endogenous and exogenous 
lipoproteins, and ultimately in our understanding of the ALP, the metabolic basis of CHD.
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Acute effects of alcohol on postprandial lipid metabolism. By ANNE J. HAWDON, 
NORHAIZAN MOHD ESA, JOHN W. WRIGHT, BARRY J. GOULD and BRUCE A. GRIFFIN, 
Centrée fo r  Nutrition and Food Safety, School o f Biological Sciences, University o f Surrey, Guildford 
GU2 5XH
Enhanced postprandial lipaemia provides an important metabolic stimulus for the production of abnormalities 
in serum lipoproteins which increase the risk of CHD (Griffin, 1997). Alcohol elevates the postprandial rise 
in serum triacylglycerol (TAG) following the ingestion of dietary &t by promoting the production of TAG in 
the liver which is synthesized and secreted into the circulation as VLDL (Liitiamaa et al. 1997). In contrast, 
very little is known about the effects of alcohol on TAG associated with dietary chylomicrons. A study was 
designed to examine the acute effect of alcohol on postprandial TAG-rich lipoproteins of intestinal and 
hepatic origin, and the activity of lipoprotein lipase (EC 3.1.1.34; LPL), the rate limiting determinant of TAG 
removal. Five healthy, male subjects (25-40 years), were given a test meal on two separate occasions with 
and without alcohol (0.6 g/kg body weight about 5 units). The meal contained 80 g mixed fet, and retinyl 
palmitate (RP) (170 000 lU), as a tracer of dietary chylomicrons. Blood samples were taken over 8 h for the 
détermination of total plasma TAG, RP and the separation of ‘TAG-rich’ (TRL) and ‘TAG-poor’(TPL) 
lipoprotein fractions. Post-heparin (7500 U) LPL activity (PHLA) was measured at 8 h. Apo B-48, as a 
marker of intestinally derived lipoproteins was measured by ELISA using a novel antiseium (Lovegrove et al. 
1996).
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All subjects showed an increase in the incremental area under the curve (lAUC) of TAG (366 (SD 
161) V. 623 (SD 367) mmol/l.min, RP 716 [SD 566 (?<0.05)] v. 158 (SD 51) mmol/Lmin), TRL-TAG 
(389 (SD 282) V. 877 (SD 460) mmol/l.min), and a decreased PHLA (281 (SD 63) v. 212 (SD 57) pmol 
fatty acids/min per ml) (P<0.05) after alcohol. Apo B-48 showed a biphasic response peaking at 3 and 
5 h (control). On alcohol the peaks were delayed and prolonged peaking at between 2-4 h and 6-7 h. 
Alcohol also enhanced the TAG response in the late postprandial phase (>4 h) which is consistent with 
either an increase in the secretion or residence time of VLDL. Moreover, the significant elevation in RP 
(5 h) suggest that chylomicron remnants and intestinally derived lipoproteins respectively contributed to 
the alcohol-induced hypertriacylglycerolaemia. Although alcohol is not generally believed to influence 
LPL, an impaired removal of TAG by LPL may be implicated in this case. The overall impact of this 
phenomenon on lipid-mediated CHD risk is not clear but warrants further investigation, especially since 
the moderate consumption of alcohol confers protection against CHD.
Griffin BA (1997) Proceedings of the Nutrition Society 56,693-702. 263
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Triacyglycerol-rich lipoproteins in postprandial plasma. By ANNE J. HAWDON, BARRY J. 
GOULD and BRUCE A. GRIFFIN. Centre fo r  Nutrition and Food Safety, School o f Biological Sciences, 
University o f Surrey, Guildford GU2 5XH
Structural heterogeneity in triacylglycerol-rich lipoproteins (TAG-RL) has been implicated in the 
generation of a high-risk atherogenic lipoprotein phenotype (ALP). An increase in the residence time of 
the large VLDL species in postprandial plasma may be of particular relevance in this respect. To examine 
the distribution of TAG-RL in the postprandial phase, a rapid, self-forming, iodixanol density gradient 
was developed from the original method of Graham et al. 1996. This proceduie involved the initial 
isolation of chylomicrons (CM, density<1.006g/ml) into a saline overlay (10,000 rpm, 30min, 15 ®). The 
infranatant was then made up to a 10% iodixanol and overlayed with a continuous gradient o f iodixanol 
(0-6%). After centrifiigation in a SW40-Ti rotor (35,000 rpm, 76min, 16 °) the separated lipoproteins 
were eluted into sixty fractions and analysed for TAG to obtain a TAG-RL profile. Light and heavy 
VLDL subfractions prepared by cumulative flotation density gradient centrifugation (VLDLi, Sf 60-400 
and VLDL2, S f20-60) were co-isolated on the iodixanol gradient. The sixty fractions were collected into 
four pools on the basis of the VLDL subclass profiles (Fig.l) such that Pools ‘3’ and ‘4’ were 
representative of VLDL 1 and VLDL] respectively. To examine the effects of postprandial lipaemia on the 
distribution of these TGRL ‘Pools’, eight normal, healthy subjects (n 8) underwent a constant routine 
during which they consumed a fat-containing drink, ‘Fortisip,’. every hour for 20 h (total 70g fat). The 
distribution of TAG between TAG-RL Pools showed considerable variation between individuals.
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Baseline serum TAG correlated with postprandial TAG (r = 0.89, p<0.05). Stepwise regression analysis 
of postprandial serum TAG against the five TAG-RL ‘Pools’ as predictors, showed that 83% of the 
variation in postprandial serum TAG was explained by variation in ‘Pool 3’ (P3 = light, laige VLDLi. r =
0.92, p<0.05). Whilst the subjects under investigation had baseline serum TAG below 1.5mmol/l and 
would thus not be expected to produce large amounts of light TAG-rich VLDLi, this subfraction still 
featured as a significant determinant of postprandial lipaemia. Further resolution of this gradient with 
specific anti-sera to apo B-48 and B-lOO should reveal the relative contributions of TAG-RL of intestinal 
and hepatic origin respectively.
Graham JM, Higgins JA, Gillot T, Taylor T, Wilkinson J, Ford T, & Billington D (1996) Atherosclerosis 124, 125-135.
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The acute effects of ethanol on postprandial lipid metabolism: a follow-up study. By ANNE J. 
HAWDON, NORHAIZAN MOHD ESA, EMMANOUIL MALOUTAS, JOHN W. WRIGHT, 
BARRY J. GOULD and BRUCE A. GRIFFIN. Centre fo r Nutrition and Food Safety, School o f 
Biological Sciences, University o f Surrey, Guildford GU2 7XH
In a previous study by Hawdon et al (1999), the consumption of ethanol with food was shown to 
augment postprandial lipaemia, decrease lipoprotein lipase (LPL) activity and elevate maikers of 
intestinally derived lipoproteins (retinyl palmitate and apo B-48) in the late postprandial phase (>6h). 
Whilst these effects are consistent with a delayed clearance of chylomicron remnants (CMR), very low 
density lipoproteins (VLDL) are likely to contribute to this ethanol-induced lipaemia, since ethanol 
promotes the synthesis of triacyglycerol (TAG) and VLDL in the liver. The present study was designed 
to confirm these previous findings in a larger cohort of subjects and to establish the relative 
contributions of CMRs and VLDL to this phenomenon. In a cross-over design, 8 normal, healthy males 
aged 22-56 years were given a test meal on two separate occasions with and without ethanol (0.6 g / k g  
body weight -5-6 units). The meal contained 80 g of mixed fat, and retinyl palmitate (RP) (170000 
lU). Blood samples were taken over 8 h for the determination of total plasma TAG, RP and apo B-48 
by ELISA. Post-heparin (7500 U) LPL activity (EC 3.1.1.34) was measured at 8 h by a new 
fluorometric method (Progen). After the initial separation of CMs, the remaining TAG-rich lipoproteins 
(TRL) where separated on a self-generating iodixanol gradient and collected into pools representative 
of CM remnants (Pi & P]) and two VLDL pools (P3 & P4) as previously described (Hawdon et aU 
2000).
All subjects showed an increase in postprandial lipaemia in response to ethanol (incremental area under 
the TAG curve (295 (SD 90) v. 933 mmol/1 (SD 316.24), RP (1047 (SD 73) v. 1553 (SD 1047) 
mmol/1), TRL (225 (SD 39) v. 295 (SD 157) mmol/1. Ethanol was associated with a decrease iu the 
activity of LPL in 7 out of 8 subjects and a significant increase in postprandial TAG from 6 horns 
onwards (p<0,05). At 6 hours (time at which the control and ethanol postprandial TAG curves 
diverge), the VLDL pools (P3 & P4) made a significant contribution to the increased lipaemia (see 
table). The increase in plasma TAG at 6h was strongly associated with the decrease in LPL activity (r 
= - 0.89, p<0.03). As shown in the table below, at 6 h the latter correlated significantly with TRL 
pools containing CM remnants and lai'ger, less dense VLDL (CM, P1-P3).
Treatment CM Pi P2 P3 P4
Control 1.04 0.34 0.49 0.57 0.36
Ethanol 1.00 0.28 0.57 0.66 0.63
P value n.s. n.s. n.s. 0.04 0.01
A LPL ACM A P i APz AP3 AP4
r 0.71 0.86 0,74 0.83 0.29
P value 0.05 0.01 0.04 0.01 n.s.
Data shows medians (mmol/1 plasma) and changes in TAG values for TRL pools (r = Spearman correlation coefficient; n.s. = non- 
significance p>0.05)
These results indicate that VLDL contributes to the ethanol-induced lipaemia in the late postprandial 
phase. The reciprocal relationship between LPL activity and TRLs at either end of the density spectrum 
may be explained by competition between TRLs for this common lipolytic pathway and LPL showing 
greater substrate specificity for larger TRLs. The potentially unfavourable effects of ethanol-induced 
lipaemia on cardiovascular health warrants further study. 265
Hawdon AJ, Mohd EsaN, Wright JW, Gould BJ and Griffin B A  (1999). Proceedings of the Nutrition Society, 58 32A  
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Summary of Project & Volunteer Information Sheet
EFFECT OF ETHANOL ON POSTPRANDIAL LIPID METABOLISM IN MAN
The aim of this study is to determine tlie source of the additional lipaemia, seen as excess ‘fat particles’ in the blood, 
which is caused by having alcohol with food. This will lead to a better understanding of how the metabolism of fat and 
alcohol are related and what role(s) are played by the liver and the gastrointestinal tract.
Prior to the study you will be asked about your general health and details of any previous illnesses and medication.
The volunteers will be non-smoking, male subjects with fasting triacylglycerol < 2.5 mmol/L and aged between 23 and 
65 years. Other exclusion parameters will be an alcohol intake of > 30 units/week (a pint of beer is ~2 units, a glass of 
wine ~1 unit) obesity (BMI > 30 kg/m^) and any medication or illness known to affect glucose or triacylglycerol 
metabolism. In addition, no volunteers will be recruited who have participated in a similar trial or who have donated 
blood in the previous 3 montlis. A blood sample will be taken for routine haematology and biochemistry testing. We 
will inform volunteers and their general practitioner of any abnormal results.
The study will involve two visits to the University of Surrey Clinical Investigation Unit, 17AY17, at least one week 
apart. We would like you to arrive at 8 a.m. having fasted (that is to have nothing to eat or drink except water) from 
10 p.m. the previous day. We wUl also ask you not to exercise vigorously or drink alcohol for 24 hours prior to the test 
days. When you arrive at the Unit we will measure your height and weight. Then a cannula (a small needle) will be 
placed in your arm under local anaesthetic through which small amounts of blood will be taken both before and after 
you have eaten the standard breakfast provided. This will consist of milk shake made up with milk and double cream, 
jam sandwiches and orange juice which wiU contain a small amount of vitamin A. You will also be given three 
paracetamol tablets before eating the standard breakfast which allows us to determine your gastric emptying time. On 
one occasion you will be given about 5-6 units of alcohol in orange juice with the breakfast. After the breakfast further 
blood samples will be taken at 30 min, and at 1 ,2 ,3 ,4 ,5 ,6 ,7  & 8 hours. Two further 5 ml blood samples will be 
taken at 5 and 15 minutes after an intravenous injection of heparin to release lipoprotein lipase, which is the main 
enzyme involved in the metabolism of fat particles. The cannula will cause minimal discomfort and prevent the need 
for frequent venepunctures for blood collection. The amount of blood taken over the 2 visits will be about 490 ml, i.e. 
less than 1 pint of blood, and will not cause any ill-effects.
Each visit will involve spending 9-10 hours in the Unit During this time volunteers will remain in the Unit. They 
will be able to academic work, read, play cards and watch videos or television.
All information collected during tliis study will be treated in strict confidence and will not be disclosed in any way that 
will allow identification of yourself.
Participation in this study is entirely voluntary. We will ask you to sign a consent form to take part in the study but 
you should understand that you may withdraw from the study at any time without the need to justify your decision. On 
completion of tlie study volunteers will be paid £50.
Furtlier information about this study is available from; 266
Anne Hawdon, School of Biological Sciences, University of Surrey; Phone Ext; 9716 or Guildford 259716 &/or 
Barry Gould, School of Biological Sciences, University of Surrey: Phone Ext; 6432 or Guildford 876432.
Summary of Project & Volunteer Information Sheet
‘EFFECT OF CARBOHYDRATE LOADING ON LIPID METABOLISM IN 
MAN’
The aim o f this study is to examine the source o f the additional lipid in the blood, which is 
caused by eating large amounts o f  carbohydrate. This will lead to a better understanding o f  
how the metabolism o f fat is affected by carbohydrate and will also provide a model system 
o f check the performance o f a novel technique used to separate lipoprotein particles.
Prior to the study you will be asked about your general health and details o f  any previous 
illnesses and medication. The volunteers will be non-smoking, male subjects with fasting 
triacyglycerol < 2.5  mmol/L and aged between 23-45 years. Other exclusion parameters will 
be an alcohol intake o f  > 30 units/week (a pint o f beer/ is ~  2 units, a glass o f wine ~  1 unit), 
obesity (BMI > 3 0  kg/m2) and any medication or illness known to affect glucose or 
triacylglycerol metabolism. A  blood sample will be taken for routine haematology and 
biochemistry testing. We will also measure you height and weight. We will inform 
volunteers and their general practitioner o f any abnormal results. We will also require 
volunteers to complete a 5 day food diary so that we can assess the relative percentage o f  
energy derived from fat, carbohydrate and protein. We will also need to weigh and measure 
your height.
The study will involve two visits to the University o f  Surrey Clinical Investigation, 17AY17. 
For the first visit we would like you to arrive at 8 and 9 am having fasted (that is to have 
nothing to eat or drink except water) from 10 p.m. the previous day. When you arrive at the 
Unit we will weigh you. Then we will take a 30 ml blood sample. You will be given 
instructions as to how to reduce your fat intake and a drink to increase your carbohydrate 
intake. The flavoured drink will contain high levels o f  sugar and other carbohydrates. You  
will be required to take a specified number o f these drinks per day for 5 days. During this 
time a daily food diary must be completed and your weight needs to be checked each 
morning. For the second visit we would like you to arrive at 8 and 9 am having fasted. You 
will be weighed and another 30 ml blood sample will be taken. The amount o f blood take 
over the 2 visits will be approximately 60 ml.
Each visit should take no more than 30 -  60 min.
All information collected during this study will be treated in strict confidence and will not be 
disclosed in any way that will allow identification o f  you.
Participation in this study is entirely voluntary. W e will ask you to sign a consent form to 
take part in the study but you should understand that you may withdraw from he study at any 
time without need to justify your decision. On completion o f the study volunteers will be 
paid £50.
PLEASE NOTE THAT THIS PROTOCOL IS STILL WITH THE ETHICS COMMITTEE 
AND THEREFORE DETAILS MAY BE SUBJECT TO CHANGE
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m I VOLUNTEER INFORMATION SHEET
Study Title and Summary
The Importance o f a-Unolenic Acid (a~LA) (flaxseed oil) as a Source of Long-^Chain n-3 
Polyunsaturated Fatty A cids (fish oils) and its Influence on Risk Factors o f Cardiovascular 
^Disease.
Ydu have been  asked  to volunteer for a  dietary intervention trial run jointly through the University of 
Surrey and the Royal Surrey County Hospital (RSCH) in Guildford. The study will look at the effects of 
(d ie tary  fats on risk factors for coronary heart d isease  in 54 male volunteers. It will involve changing your 
diet in your own hom e for 12 w eeks by eating a  range of specially m anufactured foods in place of som e of 
thé foods which you normally e a t . . You may also be asked  to take fish-oil supplem ents in the form of 
capsules. W e will supply you with all of the foods and fish-oil supplem ents and provide regular dietary 
^advice and guidance throughout the trial. It is important that you do not lose or gain weight on this diet 
% n d  your calorie intake will be carefully controlled to ensu re  this does not happen. The supplied foods, 
wfiich have been m anufactured by well known food com panies, have been m ade with different types of fat 
wfiich w hen eaten  will modify the fat in your blood in a  way that should reduce your risk of heart d isease. 
#W e will monitor the effects of th ese  dietary fats on risk factors for heart d isease  by taking small blood 
sam ples a t regular intervals (a total of 160ml '~1/4 of a  pint over 12 weeks), by making m easurem ents of 
blood flow by ultrasound (a procedure similar to having your blood pressure  taken), and by giving selected  
volunteers som e fat in the form of an oil capsule labelled with a  harm less tracer so  that w e can follow the 
Àway the fat is handled within the body. You will be paid for the inconvenience of taking part in the trial and 
*foi’ your travel expenses.
I Background information on the study
j ^ a a r t  d isease  rem ains the g rea test c au se  of prem ature death  in middle aged m en in the U.K. The risk of 
Fdying from heart d isease  is largely determ ined by genetic factors (family history) but also  by lifestyle 
factors such a s  diet. W e know that raised levels of cholesterol in the blood increases the  risk of heart 
j d isease  but this is not the whole story. Cholesterol is transported in the blood circulation in different 
\ fractions som e of which deposit in the walls of coronary arteries. This eventually blocks the flow of blood 
mo  the heart which cau se s  an often fatal heart attack. In contrast, other cholesterol fractions actively 
! re nove  cholesterol from artery walls and prevent heart attacks. Fish oils a re  very effective in modifying 
XhB balance of th e se  different cholesterol fractions in the blood in favour of the ‘good’ cholesterol. They 
(a lc o  prevent blood from clotting in ‘clogged’ arteries and protect the walls of coronary arteries from 
^dsim age caused  by fat and physical s tre ss  (high blood pressure). This is how fish-oils a re  thought to 
provide protection against heart d isease, and why we a re  currently being encouraged to e a t  more oily fish 
SL ch a s  herring, mackerel and sardines. However, there is a  problem in that oily fish a re  not ea ten  in a 
quantity sufficient to provide the necessa ry  protection against d isease. An alternative way of acquiring 
• t h  is protection is by getting our own bodies to m ake the oils found naturally in fish. W e can do this by 
supplying the building blocks for the biologically active constituents of fish oils in the form of an oil from 
flsixseed known a s  a-LA. Unlike fish-oil, a-LA can be  easily incorporated into a  wide range of food 
^p roducts  and can be eaten  in quantities which, w e predict, will reduce the risk of developing heart 
di sease. It should be em phasised that fish oils and a-LA are  perfectly safe  to ea t and have been used In 
num erous hum an dietary intervention studies in the past.
W hat do we hope to achieve in this study?
Bw^e aim to show  that dietary a-LA, a  product of flaxseed oil, can be converted in the body into the active 
constituents found in fish oil, and when incorporated into foods and consum ed can produce ‘fish-oil’ like 
cfianges in the blood that will reduce the risk of heart d isease.
®W hy have you been selected?
Y  DU have been  chosen  primarily b ecau se  you are male and middle aged  (35-60 years) and  represent the 
group m ost likely to benefit from the experim ental diets. To be suitable for our study you m ust also be a 
hoalthy non-sm oker who is not taking any drug medication or dietary supplem ents which may adversely 
at feet our results. 268r
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^ h a t  will happen once you have agreed to take part in the trial?
'If the level of fat in your blood is suitable you will be asked  to participate in the study. Before starting you 
will be  asked  to provide written consent of your willingness to participate. This consent does not in any 
way infringe your right to discontinue the trial a t any stage. Before you en ter the trial w e need  to obtain 
information on your normal background diet. To do this you will be given full instructions and  guidance on 
|h o w  to com plete a  7-day food diary. This diary will provide information on the fat content of your normal 
diet and daily calorie intake and help us to design the experimental diets. It Is vitally Important that you  
do hôt châhgë yôUt diet Of any ôfhéf liféàtylé habits ffoih this point Until the staff of  thé âiétàfy 
in terven tion  period.
When and where will the dietary Intervention trial take place and what support will be provided?
The timing of the dietary intervention period will be arranged a t your own convenience but should take 
place within 3-4 months of being recruited. This period allows us time to study your background diet and 
R ecru it more volunteers for the dietary study. You will be notified well in advance of the start date. 
Immediately before the trial com m ences you will be asked  to attend the University to provide a  blood 
sam ple (35ml -3 .5  d e sse rt spoon full). This will also allow you to collect your food supplies I fish-oil 
^supplem ents and to receive dietary advice and information before starting your diet. You will also be 
" a sk e d  if you a re  able to attend the RSCH to undergo a  ‘non-invasive’ a sse ssm en t of blood flow. This 
involves placing à  blood pressure cuff around the upper arm and m easuring blobd flow by m eans of ah 
ultrasound probe placed on the skin. This m easurem ent will be m ade before and after a  tablet of glyceryl 
trinitrate (GTN), a  harm less substance  used  to dilate blood vessels. The 12 w eek intervention period will 
É take place in your own home. A nutritionist will be on call at the University to provide dietary advice and 
f counselling throughout the  12 w eek period. The principal scientific investigators will a lso  b e  available at 
jth (3 University to deal with your enquiries on any asp ec t of the trial (Telephone: G eneral and Dietary 
^Enquiries 01483-879735).
What types of food will you be expected to eat?
W e are aiming to replace approximately 50% of your dietary fat by supplying you with cooking oils, 
sp reads and sach e ts  of oil. The su ccess  of the trial will ultimately depend on the quality of the foods that 
|WD supply. All of our food products will have been m ade by well known food com panies and m ust be 
- a i ceptable and palatable to our volunteers if we are to maintain their interest and dietary compliance 
th "oughout the trial. For this reason w e will endeavour to keep the diet a s  close to your normal diet a s  
possible. If there is evidence of non-com pliance to the diet a t any stage, the volunteer’s  participation in 
3 trial may be terminated.
I Interim blood sample and dietary check
, You will be asked  to provide an interim blood sam ple after 6 w eeks on the diet. This will enab le  us to 
I check on your dietary compliance and to m easure  your blood fat level. It will also provide an opportunity 
# fo r further food collection, though foods will be delivered directly to our volunteers throughout the trial on 
request.rW hat will happen at the end of the 12 week intervention?À1: the end of the 12 w eeks you will be asked  to attend the University to provide a  final blood sam ple. If you had a  blood flow m easurem ent a t the beginning this will also be repeated. Som e volunteers will be asked  to take  part In an additional study which involves swallowing a  small capsule of oil (a-LA) that haskboen labelled with a  harm less tracer substance. This allows us to study the rate a t which a-LA from liriseed is converted inside the body into the types of oils found in fish. W e do this by taking a  small num ber of blood sam ples over 9 hours whilst in the hospital by m eans of fine tube or cannula in your arm; 
j the  cannula prevents the repeated use  of a  needle and syringe. After this you can go hom e and a  nurse m w  11 visit you the next day (24 hours later) to take a  final blood sam ple, th is  com pletes your involvement in 
the  study.
P articipation in this trial is voluntary and subjects may withdraw at any time. All subjects who successfully 
com plete the study will receive £150. In the c ase  of subjects who withdraw prior to the end of the study, 
^ th e  level of rem uneration may be reduced. 269
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APPENDIX I
To ensure sufficient ‘g-force’ was accumulated using a SW 40Ti rotor, a relative centrifugal 
force (RCF) value had to be calculated from those suggested for a SW 55Ti rotor by Graham 
(unpublished) for use with a SW40Ti rotor.
SWSSTi rotor
RCF = (1.12 X  r__ X  RPM l^ x t
1000
1.12 = fixed value
RPM = revolutions per minute 
fmax == rotor radius
t = spinning time (min)
For a calculated 50,000 rpm for 20 min (prespin)
RCF = (1.12 x 108.5 X 50.000Y x 20 min
1000
6.07 X  10^
Plus an additional 35,000 rpm for 70 min
RCF = 1.12 X 108.5 X 35.000f  x 70 min
1000
1.04x10’
Total g-force accumulated = 1.04 x 10’+ 6.07 x 10®
-  1.65x10’ g min
Therefore o n  a  SW40ti rotor  spin  tim e a t  35.000 rpm  is
RCF
SW55Ti
SW40ti
1.12x 158.8x35,000 
2.17x10®
1.65x10’
2.17x10®
76 min
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APPENDIX n
Equation to calculate the amount of KBr to add to plasma samples to adjust density ;
Mass KBr (g) = Volume of plasma or VLDL used (mil x (final density - initial density!
1 - (final density x 0.312)
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APPENDIX m
The discontinuous density gradient method (Mackness and Durrington 1992) gave spinning times 
appropriate for a Beckman LM8, however the centrifuge available was a Beckman XL 100 
ultracentrifuge with a slower ‘come-down’ time. Therefore to ensure sufficient ‘g-force’ was 
accumulated in a Beckman XL 100 ultracentrifuge the m^T value was calculated and used to 
adjust spin times.
LM8
spin 39.000 rpm for Ihr 38 at 23”C = 9.8.101
LM8 ®"T
Start_____ Finish
2.00^09 - 1.31^10= - I . H e IO
XLIOO (d^ T 
Start_____ Finish
3.66^10 - 5.96g 10= -2.30^10
LM8 ®^ T - XLIOO
-l. llglO - -2.30g 10= 1.20g 10
Therefore the new time is:
9.80gl0 - 1.20g 10 = 8.60gl0 which when entered into the XLIOO ultracentrifuge gave a
spin time of 86 min.
• The first spin is therefore for 39,000 rpm for 1 hr 26 at 23°C.
2"** spin 18.500 rpm for 15 hr 41 23”C (®^ T = 2.12^111 
LM8
Start_____ Finish
2.52g08 - 1.80g 09= -1.50g09
272
XLIOO ®^ T
Start Finish
1.4709 - 4.46, 09 = -2.90^ 09
LM8®^T-XLIOO ®^ T
-1.50g09 - -2.90g 09 = 1.40^09
Therefore the new time is:
LM8©^T-XLIOO ®"T
2.12gll - 1.40g 09 = 2.10g 11 or when entered into the XLIOO ultracentrifuge 15 hr and
32 min.
• The second spin is therefore for 18,500 rpm, for 15hr 32 at 23®C.
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APPENDIX IV
Conversion between g-force and RPM
= g  © =0,10472 X  RPM
9800 V == rotor radius (r
Calculation of g.min
©^v X spin time (min) = g.min
9800
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APPENDIX V
Percentage recovery calculation, expression as mmol/1 of TAG corrected to plasma:
1. Allowance for the dilution factor of fraction with a volume of 0.15 ml when TAG value 
expressed as mmol/1
Dilution factor = IL = 6666.66 x fraction TAG value
fraction volume (0.15 ml)
2. Sum of all gradient fraction-TAG values = ( A )
3. Allowance for dilution factor of subject plasma TAG (1.5 mmol/1) in 2.5 ml of plasma
mmol = Plasma TAG value (mmol/H 1.5 = 0.00375
dilution factor of 2.5 ml of plasma in IL 400
4. Percentage recovery
0.00375 / ( A ) X 100 = percentage recovery
275
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APPENDIX V n
Nutritional composition of food products and supplements
Nutrient (lOOg) Rapeseed oil Sunflower oil MÜFA spread Pikasol
Energy (KJ) 3764.1 3768.3 2826.2 3764.1
Fat (g) 100 99 9 75 100
SFA(g) 6.67 12 11.5 -
MÜFA (g) 60 20.5 35 -
PUFA(g) 30 63.3 14.7 -
Total n-6 (g) 9.6 63.2 - nil
Total n-3 (g) 19.6 .1 - 60.3
C20:5 (EPA) (g) - - - 27.9
C22:6 (DBA) (g) - nil - 22.3
O F  S U n r i E V  L # '
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